***I
REPORT


Committee on the Environment, Public Health and Food Safety

Rapporteur: Dagmar Roth-Behrendt
Symbols for procedures

* Consultation procedure
*** Consent procedure
***I Ordinary legislative procedure (first reading)
***II Ordinary legislative procedure (second reading)
***III Ordinary legislative procedure (third reading)

(The type of procedure depends on the legal basis proposed by the draft act.)

Amendments to a draft act

In amendments by Parliament, amendments to draft acts are highlighted in **bold italics**. Highlighting in *normal italics* is an indication for the relevant departments showing parts of the draft act which may require correction when the final text is prepared – for instance, obvious errors or omissions in a language version. Suggested corrections of this kind are subject to the agreement of the departments concerned.

The heading for any amendment to an existing act that the draft act seeks to amend includes a third line identifying the existing act and a fourth line identifying the provision in that act that Parliament wishes to amend. Passages in an existing act that Parliament wishes to amend, but that the draft act has left unchanged, are highlighted in **bold**. Any deletions that Parliament wishes to make in such passages are indicated thus: [...].
CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRAFT EUROPEAN PARLIAMENT LEGISLATIVE RESOLUTION</td>
<td>4</td>
</tr>
<tr>
<td>EXPLANATORY STATEMENT</td>
<td>229</td>
</tr>
<tr>
<td>OPINION OF THE COMMITTEE ON EMPLOYMENT AND SOCIAL AFFAIRS</td>
<td>234</td>
</tr>
<tr>
<td>OPINION OF THE COMMITTEE ON THE INTERNAL MARKET AND CONSUMER PROTECTION</td>
<td>255</td>
</tr>
<tr>
<td>PROCEDURE</td>
<td>336</td>
</tr>
</tbody>
</table>
DRAFT EUROPEAN PARLIAMENT LEGISLATIVE RESOLUTION


(Ordinary legislative procedure: first reading)

The European Parliament,

– having regard to the Commission proposal to Parliament and the Council (COM(2012)0542),

– having regard to Article 294(2) and Articles 114 and 168(4)(c) of the Treaty on the Functioning of the European Union, pursuant to which the Commission submitted the proposal to Parliament (C7-0318/2012),

– having regard to Article 294(3) of the Treaty on the Functioning of the European Union,

– having regard to the opinion of the European Economic and Social Committee of 14 February 2013¹,

– after consulting the Committee of the Regions,

– having regard to Rule 55 of its Rules of Procedure,

– having regard to the report of the Committee on the Environment, Public Health and Food Safety and the opinions of the Committee on Employment and Social Affairs and the Committee on the Internal Market and Consumer Protection (A7-0324/2013),

1. Adopts its position at first reading hereinafter set out;

2. Calls on the Commission to refer the matter to Parliament again if it intends to amend its proposal substantially or replace it with another text;

3. Instructs its President to forward its position to the Council, the Commission and the national parliaments.

¹ OJ C 0, 0.0.0000, p. 0. .
Amendment 1
Proposal for a regulation
Recital 1 a (new)

Text proposed by the Commission

(1a) The desire to provide swift access to new medical devices for patients should never take precedence over the need to ensure patient safety.

Justification

As stated in the European Parliament resolution on defective silicone gel breast implants made by French company PIP (2012/2621(RSP)), and as a reference to the first Hippocrates principle inviting the healthcare professional in first place not to harm.

Amendment 2
Proposal for a regulation
Recital 2

Text proposed by the Commission

(2) This Regulation aims to ensure the functioning of the internal market as regards medical devices, taking as a base a high level of protection of health. At the same time, this Regulation sets high standards of quality and safety for medical devices to meet common safety concerns as regards these products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market which may then benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for those medical devices by ensuring, among

Amendment

(2) This Regulation aims to ensure the functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients, users and operators. At the same time, this Regulation sets high standards of quality and safety for medical devices to meet common safety concerns as regards these products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market which may then benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for
other things, that data generated in clinical investigations is reliable and robust and that the safety of the subjects participating in a clinical investigation is protected.

Amendment 3
Proposal for a regulation
Recital 2 a (new) – sentence 1 (new)

Text proposed by the Commission


Amendment 4
Proposal for a regulation
Recital 2 a (new) – sentence 2 (new)

Text proposed by the Commission

Directive 2010/63/EU of the European Parliament and of the Council1 states that tests on vertebrate animals must be replaced, restricted or refined.

Justification

Article 4(1) of this Directive states that: Member States shall ensure that, wherever possible, a scientifically satisfactory method or testing strategy, not entailing the use of live animals, shall be used instead of a procedure.

Amendment 5

Proposal for a regulation
Recital 3

Text proposed by the Commission

(3) Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding devices should be introduced, to improve health and safety.

Amendment

(3) Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding devices should be introduced, to improve health and safety for health professionals, patients, users and operators, including in the waste disposal chain.

Amendment 6

Proposal for a regulation
Recital 3 a (new)

Text proposed by the Commission

(3a) In the area of medical devices many SMEs are active. This should be taken into account when regulating the sector without compromising the safety and health aspects.

Amendment 7
Proposal for a regulation

Recital 7

Text proposed by the Commission

(7) The scope of application of this Regulation should be clearly delimited from other Union harmonisation legislation concerning products, such as in vitro diagnostic medical devices, medicinal products, cosmetics and food. Therefore, Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety should be amended to exclude medical devices from its scope.

Amendment


Amendment 8

Proposal for a regulation
Recital 7 a (new)

Text proposed by the Commission

(7a) A multidisciplinary Medical Device Advisory Committee (MDAC) composed of experts and representatives of the relevant stakeholders should be set up to provide scientific advice to the Commission, the Medical Device Coordination Group (MDCG) and Member States on issues of medical technology, regulatory status of devices and other aspects of implementation of this Regulation as necessary.

Amendment 9

Proposal for a regulation
Recital 8

Text proposed by the Commission

(8) It should be the responsibility of the Member States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. If necessary, the Commission may decide, on a case-by-case basis, whether or not a product falls within the definition of a medical device or of an accessory to a medical device. Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility to take an EU-wide decision regarding the regulatory status of a product should also be introduced in Regulation No 1223/2009 of the European Parliament and of the Council of 30 November 2009

Amendment

(8) In order to ensure consistent classification across all Member States, particularly with regards to borderline cases, it should be the responsibility of the Commission, having consulted the MDCG and the MDAC, to decide on a case-by-case basis whether or not a product or groups of products fall within the scope of this Regulation. Member States should also have the possibility to request the Commission to take a decision on the appropriate regulatory status of a product, or category or group of products.
on cosmetic products.

Amendment 10
Proposal for a regulation
Recital 11 a (new)

Text proposed by the Commission

(11a) Unregulated non-intrusive devices, such as non-corrective contact lenses for cosmetic purposes, can cause health complications - such as Microbial Keratitis - when manufactured or used incorrectly. Appropriate safety standards must be in place to protect the safety of consumers who decide to use such products.

Amendment 11
Proposal for a regulation
Recital 12

Text proposed by the Commission

(12) Like for products that contain viable tissues or cells of human or animal origin, that are explicitly excluded from Directives 90/385/EEC and 93/42/EEC and hence from this Regulation, it should be clarified that products that contain living biological substances of other origin are also not covered by this Regulation.

Justification

Currently, medical devices consisting of viable biological substances are covered by Directive 93/42/EEC. A general exclusion of biological substances would result in a loss of safe and efficient medical devices existing on the market at present which will not be approved as medicinal products as they have no pharmacological, immunological or metabolic mode of action.
Amendment 12
Proposal for a regulation
Recital 12 a (new)

Text proposed by the Commission


Justification

Medical devices authorised and used in this field are subject to the provisions of five further EU legal texts. Many of the standards required under these texts are higher than those provided for in this Regulation. Those standards should not be lowered.

Amendment 13
Proposal for a regulation
Recital 12 b (new)

Text proposed by the Commission

(12b) The advertising of cosmetic surgery should be better regulated, in order to ensure that patients are fully aware of the risks as well as the benefits.
Justification

The advertising of cosmetic surgery, such as breast implants, risks trivialising these interventions. Some Member States have banned the advertising of cosmetic surgery, and there is already a ban on the advertising of prescription medicines within the EU.

Amendment 14

Proposal for a regulation

Recital 13

Text proposed by the Commission

(13) There is scientific uncertainty about the risks and benefits of nanomaterials used for medical devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, with the necessary flexibility to adapt this definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of medical devices, the manufacturers should take special care when using nanoparticles that can be released to the human body and those devices should be subject to the most severe conformity assessment procedure.

Amendment

(13) There is scientific uncertainty about the risks and benefits of nanomaterials used for medical devices. In order to ensure a high level of health and safety protection for health professionals, operators and patients, as well as free movement of goods, legal certainty for manufacturers and responsibility on their part, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, with the necessary flexibility to adapt this definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of medical devices, the manufacturers should take special care when using nanoparticles which are intended to be intentionally released in the human body should be subject to the most severe conformity assessment procedure.

Justification

The risk of the use of nanomaterials shall be taken into account in the risk assessment process. However, too many products with no serious concern for health may fall under this rule. Therefore, the up-classification in Class III shall be made only when the use of nanomaterials is intentional and part of the intended use of the product.
Amendment 15
Proposal for a regulation
Recital 13 a (new)

Text proposed by the Commission

Amendment

(13a) Medical devices used in the
donation of substances of human origin
and their subsequent use for treatment
must conform to Union public health
legislation ensuring minimum standards
for quality and safety, including Directive
2002/98/EC on minimum standards of
quality and safety for the collection,
testing, processing, storage and
distribution of human blood and blood
components and its additional directives.

Justification

Medical devices involved in the collection, storage, testing and processing of blood, such as
those used for aphaeresis must already conform to six additional EU public health
legislations. Existing legislation ensures that the blood and blood components output by the
devices are of a certain high standard; as such the devices themselves are already subject to
the highest patient safety standards and controls.

Amendment 16
Proposal for a regulation
Recital 15 a (new)

Text proposed by the Commission

Amendment

(15a) This Regulation includes
requirements regarding the design, safety
and performance characteristics of
medical devices intended to prevent
occupational injuries as laid down in
Directive 2010/32/EU.

Amendment 17
Proposal for a regulation
Recital 19

Text proposed by the Commission

(19) To recognise the important role of standardisation in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No […] on European standardisation should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as quality and risk management.

Amendment

(19) To recognise the important role of standardisation and traceability in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No 1025/2012 of the European Parliament and of the Council\(^1\) should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as quality and risk management.


Amendment 18

Proposal for a regulation

Recital 19 a (new)

Text proposed by the Commission

(19a) With devices that consist of more than one implantable part, such as hip implants, compatibility of the parts of different manufacturers should be ensured in order to avoid the replacement of the functional part of the device and thus unnecessary risks and inconvenience...
for patients. The Commission should investigate the need for further measures to ensure the compatibility of the equivalent parts of hip implants from different manufacturers, bearing in mind that the hip operations are most often made on older people for whom the health risks of operations are higher.

**Amendment 19**

Proposal for a regulation
Recital 21 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(21a) Directive 2013/35/EU of the European Parliament and of the Council should be the reference text for ensuring that people working in the vicinity of magnetic resonance imaging equipment when it is functioning are properly protected.</td>
<td></td>
</tr>
</tbody>
</table>


**Amendment 20**

Proposal for a regulation
Recital 24

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(24) It is appropriate to set out clearly the</td>
<td></td>
</tr>
<tr>
<td>(24) It is appropriate to set out clearly the</td>
<td></td>
</tr>
</tbody>
</table>

RR\1005935EN.doc 15/336 PE507.972v04-00
general obligations of the different economic operators, including importers and distributors as laid down in the New Legislative Framework for the Marketing of Products, without prejudice to the specific obligations laid down in the different parts of this Regulation, to enhance understanding of the legal requirements and thus to improve regulatory compliance by the relevant operators.

Amendment 21
Proposal for a regulation
Recital 25 a (new)

Text proposed by the Commission

(25a) To ensure that patients harmed are compensated for any damage and associated treatment as a result of a faulty medical device, that the risk of damage as well as the risk of the manufacturer's insolvency are not shifted to patients harmed by a faulty medical device, manufacturers should be obliged to take liability insurance with sufficient minimum coverage.

Amendment 22
Proposal for a regulation
Recital 27

Text proposed by the Commission

(27) It should be ensured that supervision and control of the manufacture of medical devices is carried out within the manufacturer's organisation by a person who fulfils minimum conditions of qualification.

In addition to regulatory compliance, that person could also be
responsible for compliance in other fields such as manufacturing processes and quality assessment. The required qualifications of the person responsible for the regulatory compliance should be without prejudice to national provisions regarding professional qualifications, in particular for manufacturers of custom-made devices where such requirements could be met through different educational and professional training systems at national level.

Amendment 23
Proposal for a regulation
Recital 31

Text proposed by the Commission

(31) The findings of the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), established by Commission Decision 2008/721/EC of 5 August 2008 setting up an advisory structure of Scientific Committees and experts in the field of consumer safety, public health and the environment and repealing Decision 2004/210/EC, in its scientific opinion of 15 April 2010 on the safety of reprocessed medical devices marketed for single-use, and of the Commission in its report of 27 August 2010 to the European Parliament and the Council on the issue of reprocessing of medical devices in the European Union, in accordance with Article 12a of Directive 93/42/EEC, call for regulation of the reprocessing of single-use devices in order to ensure a high level of protection of health and safety whilst allowing this practice to further develop under clear conditions. By reprocessing a single-use device its intended purpose is modified and the reprocessor should therefore be considered the manufacturer of the
reprocessed device.

Amendment 24
Proposal for a regulation
Recital 31 a (new)

_text proposed by the Commission_

(31a) The current possibility to reprocess medical devices labelled as single-use is not acceptable from a safety point of view. Only devices labelled as reusable should therefore be reprocessed. Consequently, medical devices labelled as single-use should be real single-use and there should be only two possibilities: single-use or reusable. In order to avoid any systematic labelling of devices as single-use, all devices should be reusable as a rule, except if they are included in a list established by the Commission, after consultation of the MDAC, of categories and groups of medical devices which are unsuitable for reprocessing. The reprocessing of devices encompasses various activities to ensure that a medical device can be safely reused, ranging from decontamination, sterilisation, cleaning, disassembly, repair, component replacement and packaging. These activities should be subject to comparable and transparent standards.

Amendment 25
Proposal for a regulation
Recital 32

_text proposed by the Commission_

(32) Patients who are implanted with a device should be given essential information related to the implanted device allowing it to be identified and containing any necessary warnings or precautions to

(32) Patients who are implanted with a device should be given clear and easily accessible essential information related to the implanted device allowing it to be identified and containing information
be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.

**Amendment 26**

**Proposal for a regulation**

**Recital 33**

*Text proposed by the Commission*

(33) Medical devices should, as a general rule, bear the CE marking to indicate their conformity with this Regulation so that they can move freely within the Union and be put into service in accordance with their intended purpose. Member States should not create obstacles to their placing on the market or putting into service for reasons related to the requirements laid down in this Regulation.

*Amendment*

(33) Medical devices should, as a general rule, bear the CE marking to indicate their conformity with this Regulation so that they can move freely within the Union and be put into service in accordance with their intended purpose. Member States should not create obstacles to their placing on the market or putting into service for reasons related to the requirements laid down in this Regulation. *However Member States should be allowed to decide whether to restrict the use of any specific type of medical device in relation to aspects that are not covered by this Regulation.*

**Amendment 27**

**Proposal for a regulation**

**Recital 34**

*Text proposed by the Commission*

(34) The traceability of medical devices by means of a Unique Device Identification (UDI) system based on international guidance should significantly enhance the effectiveness of the post-market safety of medical devices due to improved incident reporting, targeted field safety corrective

*Amendment*

(34) The traceability of medical devices by means of a Unique Device Identification (UDI) system based on international guidance should significantly enhance the effectiveness of the post-market safety of medical devices due to improved incident reporting, targeted field safety corrective
actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against counterfeit devices. Use of the UDI system should also improve purchase-policy and stock-management by hospitals.

wholesalers and pharmacists and be compatible with the safety features as referred to in Directive 2011/62/EU of the European Parliament and of the Council and other authentication systems already in place in those settings.


Justification

It is likely an electronic medicine authentication system will be put in place pursuant to Falsified Medicines Directive. It is important that the systems for medical devices and medicines are compatible. Otherwise this will bring a significant and possible unmanageable burden for the agents of the supply chain working with both kinds of products

Amendment 28

Proposal for a regulation

Recital 35

Text proposed by the Commission

(35) Transparency and better information are essential to empower patients and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system.

Amendment

(35) Transparency and adequate access to information, appropriately presented for the intended user, are essential to empower patients, users and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system.
Amendment 29

Proposal for a regulation
Recital 36

Text proposed by the Commission

(36) One key aspect is the creation of a central database that should integrate different electronic systems, with the UDI as an integral part of it, to collate and process information regarding medical devices on the market and the relevant economic operators, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency, to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member States as well as between Member States among themselves and with the Commission, to avoid multiple reporting requirements and to enhance the coordination between Member States. Within an internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices (Eudamed) set up by Commission Decision 2010/227/EU of 19 April 2010 on the European Databank for Medical Devices.

Amendment

(36) One key aspect is the creation of a central database that should integrate different electronic systems, with the UDI as an integral part of it, to collate and process information regarding medical devices on the market and the relevant economic operators, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency through better access to information for the public and healthcare professionals, to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member States as well as between Member States among themselves and with the Commission, to avoid multiple reporting requirements and to enhance the coordination between Member States. Within an internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices (Eudamed) set up by Commission Decision 2010/227/EU of 19 April 2010 on the European Databank for Medical Devices.

Amendment 30

Proposal for a regulation
Recital 37

Text proposed by the Commission

(37) Eudamed's electronic systems regarding devices on the market, the relevant economic operators and certificates should enable the public to be

Amendment

(37) Eudamed's electronic systems should enable the public and healthcare professionals to be adequately informed about devices on the Union market.
adequately informed about devices on the Union market. The electronic system on clinical investigations should serve as tool for the cooperation between Member States and for enabling sponsors to submit, on a voluntary basis, a single application for several Member States and, in this case, to report serious adverse events. The electronic system on vigilance should enable manufacturers to report serious incidents and other reportable events and to support the coordination of their assessment by national competent authorities. The electronic system regarding market surveillance should be a tool for the exchange of information between competent authorities.

Adequate levels of access for the public and healthcare professionals to those parts of Eudamed's electronic systems which provide key information on medical devices that may pose a risk to public health and safety is essential. Where such access is limited, it should be possible, upon a reasoned request, to disclose the existing information on medical devices, unless the limitation of access is justified on grounds of confidentiality. The electronic system on clinical investigations should serve as tool for the cooperation between Member States and for enabling sponsors to submit, on a voluntary basis, a single application for several Member States and, in this case, to report serious adverse events. The electronic system on vigilance should enable manufacturers to report serious incidents and other reportable events and to support the coordination of their assessment by national competent authorities. The electronic system regarding market surveillance should be a tool for the exchange of information between competent authorities. A regular overview of vigilance and market surveillance information should be made available to healthcare professionals and the public.

Amendment 31
Proposal for a regulation
Recital 39

Text proposed by the Commission

(39) For high-risk medical devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available.

Amendment

(39) For high-risk medical devices, in the interests of increased transparency, manufacturers should draw up a report of the safety and performance aspects of the device and the outcome of the clinical evaluation. A summary of the safety and performance report should be publicly available via Eudamed.
### Amendment 32
Proposal for a regulation
Recital 39a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(39a) According to the policy of the European Medicines Agency (EMA) on access to documents, the EMA releases documents submitted as part of applications for marketing authorisation for medicinal products, including clinical trial reports, on request once the decision-making process for the medicinal product in question has been completed. Corresponding standards on transparency and access to documents should be upheld and reinforced for high-risk medical devices, in particular as they are not subject to pre-market approval. For the purposes of this Regulation, in general the data included in clinical investigations should not be considered commercially sensitive once compliance of a device with the applicable requirements has been demonstrated following the applicable conformity assessment procedure. This should be without prejudice to intellectual property rights concerning the data in clinical investigations by the manufacturer with regard to the use of these data by other manufacturers.</td>
<td></td>
</tr>
</tbody>
</table>

### Amendment 33
Proposal for a regulation
Recital 39 b (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(39b) As regards invasive devices with a diagnostic and measuring function, Member States should take all necessary</td>
<td></td>
</tr>
</tbody>
</table>
measures to prevent the risk of infection and microbial contamination between patients. To this end, the Member States should eliminate the known or foreseeable risks to patient safety by advocating inter alia the safest levels of and guidelines for disinfection and ensure their effective implementation by users and health establishments. In accordance with this Regulation, the Commission should ensure that these preventive health protection measures are appropriate.

Justification

Recent clinical assessments show a significant risk of patient-to-patient transmission of pathogens that are vectors of STI-type diseases (papilloma virus, herpes, hepatitis, etc.). The difference between practice and the patient safety guidelines for these devices has led to patient infection and sometimes deaths.

Amendment 34

Proposal for a regulation
Recital 40

Text proposed by the Commission

(40) The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection and citizens' confidence in the system. Designation and monitoring of notified bodies by the Member States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.

Amendment

(40) The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection for health professionals, users and operators, including in the waste disposal chain, and for ensuring citizens’ confidence in the system. Designation and monitoring of notified bodies by the Member States, and where applicable by the EMA, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.
Amendment 35

Proposal for a regulation
Recital 42

Text proposed by the Commission

(42) For high risk medical devices, authorities should be informed at an early stage about devices which are subject to conformity assessment and be given the right, on scientifically valid grounds, to scrutinise the preliminary assessment conducted by notified bodies, in particular regarding novel devices, devices for which a novel technology is being used, devices belonging to a category of devices with increased serious incident rates, or devices for which significant discrepancies in the conformity assessments by different notified bodies have been identified in respect of substantially similar devices. The process foreseen in this Regulation does not prevent a manufacturer from informing voluntarily a competent authority of his intention to file an application for conformity assessment for a high risk medical device before submitting the application to the notified body.

Amendment 36

Proposal for a regulation
Recital 42 a (new)

Text proposed by the Commission

(42a) For high risk medical devices, such as devices in class III, implantable devices and devices incorporating medicinal products, the conformity assessment should be the responsibility of special notified bodies. Those special notified bodies should be designated by the EMA on the basis of the reinforced
requirements on staff qualification and training as referred to in Section 3.5a of Annex VI. These special notified bodies should meet in a Network in order in particular to exchange good practice and ensure convergence in their work. The Assessment Committee for Medical Devices (ACMD) should decide to provide, on a case-by-case basis, and taking into account for instance cases of novel devices or of devices for which a novel technology is being used, an opinion on the summary of the preliminary conformity assessment and more specifically on the robustness of the clinical data.

Amendment 37
Proposal for a regulation
Recital 42 b (new)

_Text proposed by the Commission__

(42b) The ACMD should be composed of sub-groups of experts in the main medical fields. It should be headed by a coordination group, composed of the chairs of each sub-group, which, should ensure the overall coordination of the sub-groups and correct assignment of work. The coordination group should meet on request from the Commission and its meetings should be chaired by a Commission representative. The Commission should provide logistic support to the secretariat and operations of this Committee.

Amendment 38
Proposal for a regulation
Recital 45
Amendment 39

Proposal for a regulation
Recital 47

Text proposed by the Commission

(47) The rules on clinical investigations should be in line with major international guidance in this field, such as the international standard ISO 14155:2011 or any subsequent version of it on good clinical practice for clinical investigations of medical devices for human subjects and the most recent (2008) version of the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects to ensure that clinical investigations conducted in the Union are accepted elsewhere and that clinical investigations conducted outside the Union in accordance with international guidelines can be accepted under this Regulation.

Amendment

(47) The rules on clinical investigations should be in line with major international guidance in this field, such as the international standard ISO 14155:2011 or any subsequent version of it on good clinical practice for clinical investigations of medical devices for human subjects and the most recent version of the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects to ensure that clinical investigations conducted in the Union are accepted elsewhere and that clinical investigations conducted outside the Union in accordance with international guidelines can be accepted under this Regulation.

Amendment 40

Proposal for a regulation
Recital 47 a (new)

Text proposed by the Commission

(47a) The Declaration of Helsinki of the World Medical Association states in Article 15 that "the research protocol
must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins". Clinical investigations involving risk for the subject should only be allowed after assessment and approval by an ethics committee. The reporting Member State and the other concerned Member States need to organise themselves in a way that the competent authority concerned receives approval by an ethics committee on the clinical performance study protocol.

1 WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and lastly amended by the 59th WMA General Assembly, Seoul, Korea, October 2008


Amendment 41
Proposal for a regulation
Recital 48 a (new)

Text proposed by the Commission  Amendment

(48a) For the sake of transparency, sponsors should submit the results of a clinical investigation together with a layperson summary within the deadlines specified by the regulation. The Commission should be empowered to adopt delegated acts on the preparation of the layperson's summary and the communication of the clinical investigation report. The Commission should provide guidelines for managing and facilitating the sharing of raw data from all clinical investigations.
Amendment 42

Proposal for a regulation
Recital 49

Text proposed by the Commission

(49) Sponsors of clinical investigations to be conducted in more than one Member State should be given the possibility to submit a single application in order to reduce administrative burden. In order to allow for resource-sharing and to ensure consistency regarding the assessment of the health and safety related aspects of the investigational device and of the scientific design of the clinical investigation to be conducted in several Member States, such single application should facilitate the coordination between the Member States under the direction of a coordinating Member State. The coordinated assessment should not include the assessment of intrinsically national, local and ethical aspects of a clinical investigation, including informed consent. Each Member State should retain the ultimate responsibility for deciding whether the clinical investigation may be conducted on its territory.

Amendment

(49) Sponsors of clinical investigations to be conducted in more than one Member State should be given the possibility to submit a single application in order to reduce administrative burden. In order to allow for resource-sharing and to ensure consistency regarding the assessment of the health and safety related aspects of the investigational device and of the scientific design of the clinical investigation to be conducted in several Member States, such single application should facilitate the coordination between the Member States under the direction of a coordinating Member State. Each Member State should retain the ultimate responsibility for deciding whether the clinical investigation may be conducted on its territory.

Amendment 43

Proposal for a regulation
Recital 50

Text proposed by the Commission

(50) Sponsors should report certain adverse events occurring during clinical investigations to the Member States concerned, which should have the possibility to terminate or suspend the investigations if considered necessary to ensure a high level of protection of the

Amendment

(50) Sponsors should report adverse events occurring during clinical investigations to the Member States concerned, which shall have the possibility to terminate or suspend the investigations if considered necessary to ensure a high level of protection of the
ensure a high level of protection of the subjects enrolled in a clinical investigation. Such information should be communicated to the other Member States.

Amendment 44
Proposal for a regulation
Recital 51 a (new)

Text proposed by the Commission

(51a) Strict rules for persons unable to give informed consent such as children and incapacitated persons should be established at the same level as in Directive 2001/20/EC of the European Parliament and of the Council\(^1\).

---


Amendment 45
Proposal for a regulation
Recital 52

Text proposed by the Commission

(52) In order to better protect the health and safety of health professionals, patients, users and operators, including in the waste disposal chain, regarding devices on the market, the vigilance system for medical devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions.
and field safety corrective actions.

Amendment 46

Proposal for a regulation
Recital 53

Text proposed by the Commission

(53) Healthcare professionals and patients should be empowered to report suspected serious incidents at national level using harmonised formats. The national competent authorities should inform manufacturers and share the information with their peers when they confirm that a serious incident has occurred in order to minimise recurrence of those incidents.

Amendment

(53) Member States should take all necessary measures to raise awareness among healthcare professionals, users and patients about the importance of reporting incidents. Healthcare professionals, users and patients should be empowered and enabled to report such incidents at national level using harmonised formats and guaranteeing anonymity, where appropriate. In order to minimise the recurrence of such incidents, the national competent authorities should inform manufacturers, and, if appropriate, their subsidiaries and sub-contractors, and report the information via the respective electronic system in Eudamed when they confirm that an incident has occurred.

Amendment 47

Proposal for a regulation
Recital 54

Text proposed by the Commission

(54) The assessment of reported serious incidents and field safety corrective actions should be conducted at national level but coordination should be ensured where similar incidents have occurred or field safety corrective actions have to be carried out in more than one Member State with the objective of sharing resources and ensuring consistency regarding the

Amendment

(54) The assessment of reported serious incidents and field safety corrective actions should be conducted at national level but where similar incidents have occurred or field safety corrective actions have to be carried out in more than one Member State coordination, with the objective of sharing resources and ensuring consistency regarding the corrective action, and transparency of procedures should be
corrective action. ensured.

Amendment 48
Proposal for a regulation
Recital 54 a (new)

Text proposed by the Commission

(54a) Manufacturers should report periodically on medical devices classified as class III as regards the data relevant to the risk benefit ratio and the exposition of the population in order to evaluate whether any action concerning the medical device concerned is necessary.

Amendment 49
Proposal for a regulation
Recital 56

Text proposed by the Commission

(56) Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures.

Amendment

(56) Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures. The Commission should clearly define the way these inspections should be conducted in order to ensure a full and harmonised implementation within the Union.
Amendment 50

Proposal for a regulation
Recital 57

*Text proposed by the Commission*

(57) The Member States shall levy fees for the designation and monitoring of notified bodies to ensure sustainability of the monitoring of those bodies by Member States and to establish a level playing field for notified bodies.

*Amendment*

(57) The Member States should levy fees for the designation and monitoring of notified bodies to ensure sustainability of the monitoring of those bodies by Member States and to establish a level playing field for notified bodies. These fees should be comparable across Member States and should be made public.

Amendment 51

Proposal for a regulation
Recital 57 a (new)

*Text proposed by the Commission*

(57a) Member States are invited to set and enforce serious penalties for manufacturers that commit fraud and cheat with regard to medical devices. Those penalties should be at least as large as the revenue gains from fraud or cheating. Penalties may include imprisonment.

Amendment 52

Proposal for a regulation
Recital 58

*Text proposed by the Commission*

(58) Whilst this Regulation should not affect the right of Member States to levy fees for activities at national level, Member States should inform the Commission and the other Member States before they adopt the level and structure of the fees to ensure transparency.

*Amendment*

(58) Whilst this Regulation should not affect the right of Member States to levy fees for activities at national level, Member States should inform the Commission and the other Member States before they adopt a comparable level and structure of the fees to ensure transparency.
Amendment 53
Proposal for a regulation
Recital 58 a (new)

Text proposed by the Commission

(58a) Member States should adopt provisions on standard fees for notified bodies, which should be comparable across Member States. The Commission should provide guidelines to facilitate the comparability of those fees. Member States should transmit their list of standard fees to the Commission and ensure that the notified bodies registered on their territory make the lists of standard fees for their conformity assessment activities publicly available.

Amendment 54
Proposal for a regulation
Recital 59

Text proposed by the Commission

(59) An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member States based on their role and expertise in the field of medical devices and in vitro diagnostic medical devices should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) […/…] on in vitro diagnostic medical devices, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation.

Amendment

(59) A MDCG, composed of persons designated by the Member States based on their role and expertise in the field of medical devices and in vitro diagnostic medical devices should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) […/…] on in vitro diagnostic medical devices, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation.

Justification

The MDCG is not an expert committee per se but an EU Level coordination group and as it
lacks all the expertise that would be needed to decide on specific topics that will come up, the MDCG would need to be assisted by advisory committee which will provide the narrow expertise as per the needs of a given case etc.

Amendment 55

Proposal for a regulation
Recital 61

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(61) The Commission should provide scientific, technical and corresponding logistic support to the coordinating national authority and ensure that the regulatory system for medical devices is effectively implemented at Union level based on sound scientific evidence.</td>
<td>(61) The Commission should provide scientific, technical and corresponding logistic support to the coordinating national authority and ensure that the regulatory system for medical devices is effectively and uniformly implemented at Union level based on sound scientific evidence.</td>
</tr>
</tbody>
</table>

Amendment 56

Proposal for a regulation
Recital 63

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(63) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and notably human dignity, the integrity of the person, the protection of personal data, the freedom of art and science, the freedom to conduct business and the right to property. This Regulation should be applied by the Member States in accordance with those rights and principles.</td>
<td>(63) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and notably human dignity, the integrity of the person, the principle of free and informed consent, the protection of personal data, the freedom of art and science, the freedom to conduct business and the right to property, as well as the European Convention on Human Rights. This Regulation should be applied by the Member States in accordance with those rights and principles.</td>
</tr>
</tbody>
</table>
Amendment 57

Proposal for a regulation
Recital 64

Text proposed by the Commission

(64) In order to maintain a high level of health and safety, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission in respect of the products subject to this Regulation that are similar to medical devices but do not necessarily have a medical purpose; adaptation of the definition of nanomaterial to technical progress and to developments at Union and international level; adaptation to technical progress of the general safety and performance requirements, of the elements to be addressed in the technical documentation, of the minimum content of the EU declaration of conformity and of the certificates issued by notified bodies, of the minimum requirements to be met by notified bodies, of the classification rules, of the conformity assessment procedures, and of the documentation to be submitted for the approval of clinical investigations; the establishment of the UDI system; the information to be submitted for the registration of medical devices and certain economic operators; the level and structure of fees for the designation and monitoring of notified bodies; the publicly available information in respect of clinical investigations; the adoption of preventive health protection measures at EU level; and the tasks of and criteria for European Union reference laboratories and the level and structure of fees for scientific opinions delivered by them. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. The Commission, when preparing and drawing up delegated acts, should ensure a simultaneous, timely and appropriate

Amendment

(64) In order to maintain a high level of health and safety, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission in respect of the products subject to this Regulation that are similar to medical devices but do not necessarily have a medical purpose; adaptation of the definition of nanomaterial to technical progress and to developments at Union and international level; adaptation to technical progress of the general safety and performance requirements, of the elements to be addressed in the technical documentation, of the minimum content of the EU declaration of conformity and of the certificates issued by notified bodies, of the requirements to be met by notified bodies, of the classification rules, of the conformity assessment procedures, and of the documentation to be submitted for the approval of clinical investigations; the establishment of the UDI system the information to be submitted for the registration of medical devices and certain economic operators; the level and structure of fees for the designation and monitoring of notified bodies; the publicly available information in respect of clinical investigations; the adoption of preventive health protection measures at EU level; and the tasks of and criteria for European Union reference laboratories and the level and structure of fees for scientific opinions delivered by them. However, basic aspects of this Regulation such as general safety and performance requirements, stipulations on technical documentation and the requirements for CE marking certification, as well as any amendments or additions to it, should be provided for...
transmission of relevant documents to the European Parliament and to the Council. only through the ordinary legislative procedure. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. The Commission, when preparing and drawing up delegated acts, should ensure a simultaneous, timely and appropriate transmission of relevant documents to the European Parliament and to the Council.

Justification

In order to standardise the requirements to be met by notified bodies in all the Member States and to ensure a level playing field, it is preferable to refer to the ‘requirements’, rather than the ‘minimum requirements’ to which they are subject. Moreover, this wording is in line with that used in relation to notified bodies in Decision No 768/2008/EC of the European Parliament and of the Council.

Amendment 58

Proposal for a regulation
Recital 68

Text proposed by the Commission

(68) To allow economic operators, notified bodies, Member States and the Commission to adapt to the changes introduced by this Regulation, it is appropriate to provide for a sufficient transitional period for that adaptation and for the organisational arrangements to be taken for its proper application. It is particularly important that by the date of application, a sufficient number of notified bodies are designated in accordance with the new requirements to avoid any shortage of medical devices on the market.

Amendment

(68) To allow economic operators, especially SMEs, to adapt to the changes introduced by this Regulation and to ensure its proper application, it is appropriate to provide for a sufficient transitional period for the organisational arrangements to be taken. However, parts of the Regulation that affect directly Member States and the Commission should be implemented as soon as possible. It is particularly important that by the date of application, a sufficient number of notified bodies are designated in accordance with the new requirements to avoid any shortage of medical devices on the market. Also at the date of application, existing notified bodies that handle class III devices, shall be subject to an application for notification in accordance
This Regulation establishes rules to be complied with by medical devices and accessories to medical devices that are placed on the market or put into service in the Union for human use.

Justification

Devices for aesthetic purposes should also fall within the scope of the regulation.

This Regulation establishes rules to be complied with by medical devices for human use, accessories to medical devices and medical devices for aesthetic purposes that are placed on the market or put into service in the Union.

Justification

Devices for aesthetic purposes should also fall within the scope of the regulation.
Amendment 61

Proposal for a regulation
Article 1 – paragraph 2 – point f

Text proposed by the Commission
(f) products that contain or consist of biological substances or organisms other than those referred to in points (c) and (e) that are viable, including living micro-organisms, bacteria, fungi or virus;

Amendment
(f) all products that contain or consist of biological substances or organisms other than those referred to in points (c) and (e) that are viable and that achieve their intended purpose by pharmacological, immunological or metabolic means, including certain living micro-organisms, bacteria, fungi or virus;

Justification
Currently, medical devices consisting of viable biological substances are covered by Directive 93/42/EEC. A general exclusion of biological substances would result in a loss of safe and efficient medical devices existing on the market at present which will not be approved as medicinal products as they have no pharmacological, immunological or metabolic mode of action.

Amendment 62

Proposal for a regulation
Article 1 – paragraph 4 – subparagraph 1

Text proposed by the Commission
Where a device, when placed on the market or used in accordance with the manufacturer's instructions, incorporates, as an integral part, a substance which, if used separately, would be considered to be a medicinal product as defined in Article 1(2) of Directive 2001/83/EC, including a medicinal product derived from human blood or human plasma as defined in Article 1(10) of that Directive, with action ancillary to that of the device, that device shall be assessed and authorised in accordance with this Regulation.

Amendment
Where a device, when placed on the market or used in accordance with the manufacturer's instructions, incorporates, as an integral part, a substance which, if used separately, would be considered to be a medicinal product as defined in Article 1(2) of Directive 2001/83/EC, including a medicinal product derived from human blood or human plasma as defined in Article 1(10) of that Directive, with action ancillary to that of the device, that device shall be assessed and authorised in accordance with this Regulation following consultation with the national medicine agency or with the EMA.
Amendment 63

Proposal for a regulation
Article 1 – paragraph 5 a (new)

Text proposed by the Commission
5a. This Regulation shall not impede the continued application of measures within Directive 2002/98/EC and its five Daughter Directives setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components.

Articles 10 (Personnel), 14 (Traceability), 15 (Notification of serious adverse events and reactions), 19 (Examination of donors) and 29 (Technical requirements and their adaptation to technical and scientific progress) of Directive 2002/98/EC ensure donor and patient safety and as such those existing standards shall be maintained.

Amendment 64

Proposal for a regulation
Article 1 – paragraph 7 a (new)

Text proposed by the Commission
7a. The regulation of medical devices at Union level shall not interfere with the freedom of Member States to decide whether to restrict the use of any specific type of device in relation to aspects that are not covered by this Regulation.
**Amendment 65**

**Proposal for a regulation**

**Article 2 – paragraph 1 – point 1 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) ‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article, intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific medical purposes of:</td>
<td>(1) ‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article, intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific <strong>direct or indirect</strong> medical purposes of:</td>
</tr>
</tbody>
</table>

**Amendment 66**

**Proposal for a regulation**

**Article 2 – paragraph 1 – point 1 – indent 1**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– diagnosis, prevention, monitoring, treatment or alleviation of disease,</td>
<td>– diagnosis, prevention, monitoring, <strong>prediction</strong>, treatment or alleviation of disease,</td>
</tr>
</tbody>
</table>

**Justification**

*Corresponding to amendment 14 IVD regulation*

**Amendment 67**

**Proposal for a regulation**

**Article 2 – paragraph 1 – point 1 – paragraph 2**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The implantable or other invasive products, intended to be used for human beings, which are listed in Annex XV shall be considered medical devices, regardless of whether or not they are intended by the manufacturer to be used for a medical purpose.</td>
<td>The implantable or other invasive products, <strong>as well as products using external physical agents</strong>, intended to be used for human beings, which are listed on a non-exhaustive basis in Annex XV, shall be considered medical devices for the purposes of this Regulation, regardless of</td>
</tr>
</tbody>
</table>

RR\1005935EN.doc 41/336 PE507.972v04-00
whether or not they are intended by the manufacturer to be used for a medical purpose.

**Amendment 68**

Proposal for a regulation
Article 2 – paragraph 1 – point 2

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) ‘accessory to a medical device’ means an article which, whilst not being a medical device, is intended by its manufacturer to be used together with one or several particular medical device(s) to specifically enable <em>or assist</em> the device(s) to be used in accordance with its/their intended purpose(s);</td>
<td>(2) ‘accessory to a medical device’ means an article which, whilst not being a medical device, is intended by its manufacturer to be used together with one or several particular medical device(s) to specifically enable the device(s) to be used in accordance with its/their intended purpose(s); <em>or to specifically assist the medical functionality of the medical device(s) in view of its/their intended purpose(s)</em>;</td>
</tr>
</tbody>
</table>

**Amendment 69**

Proposal for a regulation
Article 2 – paragraph 1 – point 2 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2a) ‘device for aesthetic purposes’ means any instrument, apparatus, appliance, software, implant, material, substance or other article, intended by the manufacturer to be used, alone or in combination, for the purposes of modifying the physical appearance of human beings, without any therapeutic or reconstructive intent, by implanting it in the human body, attaching it to the surface of the eye or using it to induce a tissue or cell reaction on external or non-external parts of the human body.</td>
<td></td>
</tr>
</tbody>
</table>
Tattooing products and piercings shall not be considered devices for aesthetic purposes.

Justification

Devices for aesthetic purposes should also fall within the scope of the regulation.

Amendment 70

Proposal for a regulation
Article 2 – paragraph 1 – point 3 – paragraph 1

Text proposed by the Commission

(3) ‘custom-made device’ means any device specifically made in accordance with a written prescription of a doctor of medicine, of a dental practitioner or of any other person authorised by national law by virtue of this person’s professional qualifications which gives, under his responsibility, specific design characteristics, and is intended for the sole use of a particular patient.

Amendment

(3) ‘custom-made device’ means any device specifically made by an appropriately qualified person exclusively to meet a specific patient’s individual requirements and needs. In particular a ‘custom-made device’ may be produced on the basis of a written prescription of a doctor of medicine, of a dental practitioner or of any other person authorised by national law by virtue of this person’s professional qualifications which gives, under his responsibility, specific design characteristics. However, mass-produced devices which need to be adapted to meet the specific requirements of a doctor of medicine, a dental practitioner or any other professional user and devices which are mass-produced by means of industrial manufacturing processes in accordance with the written prescriptions of doctors of medicine, dental practitioners or any other authorised person shall not be considered to be custom-made devices;

Justification

It is overly restrictive to define ‘custom-made devices’ as devices for which a prescription is required. Providers of hearing aids, for example, regularly make earpieces although there is no requirement for a prescription for an earpiece. The definition should therefore be enlarged accordingly.
### Amendment 71

**Proposal for a regulation**  
**Article 2 – paragraph 1 – point 4 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) ‘active device’ means any device, the operation of which depends on</td>
<td>(4) ‘active device’ means any device, the operation of which depends on</td>
</tr>
<tr>
<td>a source of electrical energy or any source of power other than that</td>
<td>a source of electrical energy or any source of power other than that</td>
</tr>
<tr>
<td>directly generated by gravity and which acts by changing the density</td>
<td>directly generated by the human body or by gravity and which acts by</td>
</tr>
<tr>
<td>of or converting this energy. Devices intended to transmit energy,</td>
<td>changing the density of or converting this energy. Devices intended to</td>
</tr>
<tr>
<td>substances or other elements between an active device and the patient,</td>
<td>transmit energy, substances or other elements between an active device</td>
</tr>
<tr>
<td>without any significant change, shall not be considered to be active</td>
<td>and the patient, without any significant change, shall not be considered</td>
</tr>
<tr>
<td>devices.</td>
<td>to be active devices.</td>
</tr>
</tbody>
</table>

### Amendment 72

**Proposal for a regulation**  
**Article 2 – paragraph 1 – point 4 – paragraph 2**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stand alone software shall be considered an active device;</td>
<td>deleted</td>
</tr>
</tbody>
</table>

### Amendment 73

**Proposal for a regulation**  
**Article 2 – paragraph 1 – point 8 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(8) ‘single-use device’ means a device that is intended to be used on an</td>
<td>(8) ‘single-use device’ means a device that is intended to be used on an</td>
</tr>
<tr>
<td>individual patient during a single procedure.</td>
<td>individual patient during a single procedure and which has been tested</td>
</tr>
<tr>
<td></td>
<td>and demonstrated to be impossible to reuse.</td>
</tr>
</tbody>
</table>
Amendment 74

Proposal for a regulation
Article 2 – paragraph 1 – point 8 a (new)

Text proposed by the Commission

(8a) ‘Reusable device’ means a device that is intended to be used on multiple patients or during multiple procedures, and after reprocessing where required.

Amendment

Amendment 75

Proposal for a regulation
Article 2 – paragraph 1 – point 9

Text proposed by the Commission

(9) ‘single-use device for critical use’ means a single-use device intended to be used for surgically invasive medical procedures;

Amendment
deleted

Amendment 76

Proposal for a regulation
Article 2 – paragraph 1 – point 16

Text proposed by the Commission

(16) ‘making available on the market’ means any supply of a device, other than an investigational device, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge;

(16) ‘making available on the market’ means any supply of a device, other than an investigational device, for distribution, consumption or use on the Union market, whether in return for payment or free of charge;

Amendment

Amendment 77

Proposal for a regulation
Article 2 – paragraph 1 – point 24
**Text proposed by the Commission**

| Amendment | (24) ‘health institution’ means an organisation whose primary purpose is the care or treatment of patients or the promotion of public health; |

**Justification**

*It is too unclear what could fall under the category of a organisation who's primary purpose is “the promotion of public health” since it is not defined elsewhere. So to avoid confusion and uncertainties it should be deleted.*

**Amendment 78**

**Proposal for a regulation**

**Article 2 – paragraph 1 – point 27 – introductory part**

| Text proposed by the Commission | Amendment |

| (27) ‘reprocessing’ means the process carried out on a used device in order to allow its safe reuse including cleaning, disinfection, sterilisation and related procedures, as well as testing and restoration of the technical and functional safety of the used device; | (27) ‘reprocessing’ means the process carried out on a used device in order to allow its safe reuse including cleaning, disinfection, sterilisation and related procedures, as well as testing and restoration of the technical and functional safety of the used device; routine device maintenance service activities are not included in this definition; |

**Justification**

*It is important that routine maintenance operations (such a checking lung ventilators in hospitals) do not fall under this category.*

**Amendment 79**

**Proposal for a regulation**

**Article 2 – paragraph 1 – point 31 a (new)**

| Text proposed by the Commission | Amendment |

| (31a) ‘performance’ means any technical characteristics, any effects and any |
benefit of the device when used for the intended purpose and in accordance with the instructions of use;

Amendment 80

Proposal for a regulation
Article 2 – paragraph 1 – point 31 b (new)

Text proposed by the Commission

(31b) ‘benefit’ means the positive health impact of a medical device based on clinical and non-clinical data;

Amendment 81

Proposal for a regulation
Article 2 – paragraph 1 – point 31 c (new)

Text proposed by the Commission

(31c) ‘safety’ means the avoidance of risk or harm caused by the medical device or associated with its use;

Amendment 82

Proposal for a regulation
Article 2 – paragraph 1 – point 32

Text proposed by the Commission

(32) ‘clinical evaluation’ means the assessment and analysis of clinical data pertaining to a device in order to verify the safety and performance of the device when used as intended by the manufacturer;

Amendment

(32) ‘clinical evaluation’ means the assessment and analysis of clinical data pertaining to a device in order to verify the safety, performance and clinical benefits of the device when used as intended by the manufacturer;
Amendment 83

Proposal for a regulation
Article 2 – paragraph 1 – point 33 – paragraph 2 (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical investigations for medical devices, where made compulsory in accordance with this Regulation, shall include randomised clinical investigations in the appropriate target population and well-controlled investigations.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 84

Proposal for a regulation
Article 2 – paragraph 1 – point 36 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(36) ‘clinical data’ means the information concerning the safety or performance that is generated from the use of a device and that are sourced from the following:</td>
<td></td>
</tr>
<tr>
<td>(36) ‘clinical data’ means all the information concerning the safety or performance that is generated from the use of a device and that are sourced from the following:</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 85

Proposal for a regulation
Article 2 - paragraph 1 - point 36 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(36a) 'comparator' means the standard reference treatment(s) with another medical device and/or medicinal products;</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 86

Proposal for a regulation
Article 2 – paragraph 1 – point 37
Text proposed by the Commission

(37) ‘sponsor’ means an individual, company, institution or organisation which takes responsibility for the initiation and management of a clinical investigation;

Amendment

(37) ‘sponsor’ means an individual, company, institution or organisation which takes responsibility for the initiation and management, conduct or financing of a clinical investigation;

Amendment 87

Proposal for a regulation
Article 2 – paragraph 1 – point 37 a (new)

Text proposed by the Commission

(37a) ‘conformity assessment’ means, in relation to a clinical study, the checking by the authorities responsible of the relevant official documentation, facilities and records and of the existence of sufficient insurance cover. Such checking may be carried out on the premises of the sponsor and/or the research establishment or wherever the authority responsible may deem checks to be necessary.

Amendment

(37a) ‘conformity assessment’ means, in relation to a clinical study, the checking by the authorities responsible of the relevant official documentation, facilities and records and of the existence of sufficient insurance cover. Such checking may be carried out on the premises of the sponsor and/or the research establishment or wherever the authority responsible may deem checks to be necessary.

Justification

This Regulation, unlike the proposal for a regulation in Commission communication COM(2012)369 final, makes no stipulations on conformity assessment for clinical studies. Certain minimum standards must, however, be met.

Amendment 88

Proposal for a regulation
Article 2 - paragraph 1 - point 37 b (new)

Text proposed by the Commission

(37b) 'ethics committee' means an independent body in a Member State, consisting of health-care professionals and non-medical members including at least one well-experienced, knowledgeable
patient or patient representative. Its responsibility is to protect the rights, safety, physical and mental integrity, dignity and well-being of subjects involved in clinical investigations and to provide public assurance of that protection in full transparency. In cases of such investigations involving minors, the ethics committee shall include at least one healthcare professional with paediatric expertise;

Amendment 89
Proposal for a regulation
Article 2 – paragraph 1 – point 39 – indent 2 – point iii

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(iii) hospitalisation or extending the duration of hospitalisation,</td>
<td>(iii) hospitalisation or prolongation of patient hospitalisation,</td>
</tr>
</tbody>
</table>

Justification

This wording brings the text in line with ISO 14155:2011 Clinical investigation of medical devices for human subjects — Good clinical practice.

Amendment 90
Proposal for a regulation
Article 2 – paragraph 1 – point 39 – indent 3

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– foetal distress, foetal death or a congenital abnormality or birth defect;</td>
<td>– foetal distress, foetal death or a congenital physical or mental impairments or birth defect;</td>
</tr>
</tbody>
</table>

Justification

The term 'congenital abnormality' is viewed by persons with disabilities and their representatives as discrimination. It should therefore be replaced.
Amendment 91
Proposal for a regulation
Article 2 – paragraph 1 – point 40

Text proposed by the Commission

(40) ‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer;

Amendment

(40) ‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of a device, as defined in points 1 to 6 of this paragraph, including malfunction, or inadequacy in the information supplied by the manufacturer;

Justification

Correction of an error in referencing.

Amendment 92
Proposal for a regulation
Article 2 – paragraph 1 – point 48 a (new)

Text proposed by the Commission

(48a) 'unannounced inspection' means an inspection conducted without advance notice;

Amendment

(48a) 'unannounced inspection' means an inspection conducted without advance notice;

Amendment 93
Proposal for a regulation
Article 3

Text proposed by the Commission

1. The Commission may, at the request of a Member State or on its own initiative, by means of implementing acts, determine whether or not a specific product, or category or group of products, falls within the definitions of 'medical device' or 'accessory to a medical device'. Those implementing acts shall be adopted in accordance with the examination procedure

Amendment

1. The Commission may on its own initiative or shall at the request of a Member State, by means of implementing acts on the basis of the opinions of the MDCG and the MDAC referred to in Articles 78 and 78a respectively, determine whether or not a specific product, or category or group of products, including borderline products, falls within
referred to in Article 88(3).

2. The Commission shall ensure the sharing of expertise between Member States in the fields of medical devices, in vitro diagnostic medical devices, medicinal products, human tissues and cells, cosmetics, biocides, food and, if necessary, other products in order to determine the appropriate regulatory status of a product, or category or group of products.

Amendment 94

Proposal for a regulation
Article 4 – paragraph 4

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Devices that are manufactured and used within a single health institution shall be considered as being put into service. The provisions regarding CE marking referred to in Article 18 and the obligations laid down in Articles 23 to 27 shall not apply to those devices, provided that manufacture and use of those devices occur under the health institution's single quality management system.</td>
<td>4. Devices that are manufactured and used within a single health institution shall be considered as being put into service. The provisions regarding CE marking referred to in Article 18 and the obligations laid down in Articles 23, 26 and 27 shall not apply to those devices, provided that manufacture and use of those devices occur under the health institution's single quality management system.</td>
</tr>
</tbody>
</table>

Justification

In order to increase patient safety, it is important that full traceability and transparency of products used by single health institutions is ensured. Therefore Articles 24 (on Unique Device Identification) and Article 25 (on electronic registration of devices) should also fully apply to these devices, just as it does for any other devices used outside a single health institution.
Amendment 95
Proposal for a regulation
Article 4 – paragraph 5

Text proposed by the Commission

5. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress and considering the intended users or patients, the general safety and performance requirements set out in Annex I, including the information supplied by the manufacturer.

Amendment

deleted

Amendment 96
Proposal for a regulation
Article 5 – paragraph 1

Text proposed by the Commission

1. A device offered by means of information society services as defined in Article 1(2) of Directive 98/34/EC to a natural or legal person established in the Union shall comply with this Regulation at the latest when the device is placed on the market.

Amendment

1. A device offered by means of information society services as defined in Article 1(2) of Directive 98/34/EC to a natural or legal person established in the Union shall comply with this Regulation at the latest by the day on which the device is placed on the market.

Justification

EU directives use various definitions of the terms ‘placing on the market’ and ‘making available on the market’. Devices should comply with the regulation immediately they are placed on the market (irrespective of whether for an end user or for stocks in storage).

Amendment 97
Proposal for a regulation
Article 5 – paragraph 2 a (new)

Text proposed by the Commission

2a. Service providers providing means of
distance communication shall be obliged, upon receiving a request from the competent authority, to disclose the details of entities engaging in distance selling.

Justification

Zapisy, które zostały zaproponowane przez Komisję w projektach rozporządzeń nie są wystarczające i tym samym nie zabezpieczają w przedmiotowym zakresie interesów państw członkowskich. Utrzymanie propozycji komisjnej, która została już ugruntowana w praktyce organów komentnych spowoduje, że w internecie będą obecne reklamy wprowadzające w błąd potencjalnego nabywcę wyrobów, gdyż będzie można oferować produkty, dla których nie przeprowadzono procedury oceny zgodności, a dopiero w momencie ich sprzedaży, będzie trzeba zapewnić, że taki wyrób spełnia wymagania. Jest to niepokojące i dlatego należy umożliwić organom komentnym, możliwość zdobycia wiedzy, kto zamieszkał takie ogłoszenia w przypadku otrzymania sygnału z rynku, że właśnie wyrób niespełniający wymagań, w tym nawet niebezpieczny dla zdrowia lub życia użytkownika, został w taki sposób sprzedany i aby dostarczyciele usług internetowych udostępniali dane o podmiotach zamieszczających reklamy wyrobów w internecie.

Amendment 98

Proposal for a regulation
Article 5 – paragraph 2 b (new)

Text proposed by the Commission

2b. There shall be a prohibition on the marketing, placing in use, distribution, delivery and making available of products whose names, labelling or instructions for use may mislead with regard to the product’s characteristics and effects by:

(a) ascribing characteristics, functions and effects to the product which the product does not have;

(b) creating the false impression that treatment or diagnosis using the product is sure to be successful, or failing to inform of a likely risk associated with the use of the product in line with its intended use or for a longer-than-anticipated period;

(c) suggesting uses or characteristics of the product other than those declared
when the conformity assessment was carried out.

Promotional materials, presentations and information about the products may not mislead in the manner referred to in the first subparagraph.

Justification

Kwestie podnoszone w powyższej poprawce, w ogóle nie znalazły się w propozycjach nowych przepisów. Należy wprowadzić zakaz reklamy wprowadzającej w błąd, co do właściwości i przeznaczenia wyrobów, gdyż wpłynie to pozytywnie na ochronę europejczyków przed nieetycznym postępowaniem, które może doprowadzić nawet do zaniechania właściwego leczenia medycznego przy zastosowaniu wyrobu, który obiecywał dużo, ale w zasadzie nie leczy lub nie udowodniono wskazania zawartego w instrukcjach o dane kliniczne. W obszarze produktów leczniczych regulacja idzie nawet dalej, gdyż każda reklama, powinna być zaopatrzona w stosowne zdanie informujące, że przed skorzystaniem z leku należy skorzystać z konsultacji lekarza lub farmaceuty, jednakże dla wyrobów medycznych wydaje się na razie wystarczające, aby zawrzeć zaproponowane powyżej przepisy.

Amendment 99

Proposal for a regulation
Article 7

Text proposed by the Commission

1. Where no harmonised standards exist or where relevant harmonised standards are not sufficient, the Commission shall be empowered to adopt common technical specifications (CTS) in respect of the general safety and performance requirements set out in Annex I, the technical documentation set out in Annex II or the clinical evaluation and post-market clinical follow-up set out in Annex XIII. The CTS shall be adopted by means of implementing acts in accordance with the examination procedure referred to in Article 88(3).

Amendment

1. Where no harmonised standards exist or where there is a need to address public health concerns, the Commission, after having consulted the MDCG and the MDAC, shall be empowered to adopt common technical specifications (CTS) in respect of the general safety and performance requirements set out in Annex I, the technical documentation set out in Annex II or the clinical evaluation and post-market clinical follow-up set out in Annex XIII. The CTS shall be adopted by means of implementing acts in accordance with the examination procedure referred to in Article 88(3).

1a. Before adopting CTS referred to in paragraph 1, the Commission shall ensure that the CTS have been developed with the appropriate support of the relevant stakeholders and that they are
coherent with the European and international standardisation system. CTS are coherent if they do not conflict with European standards, meaning they cover areas where no harmonised standards exist, the adoption of new European standards is not envisaged within a reasonable period, where existing standards have not gained market uptake or where those standards have become obsolete or have been demonstrated as clearly insufficient according to vigilance or surveillance data, and where the transposition of the technical specifications into European standardisation deliverables is not envisaged within a reasonable period.

Amendment 100

Proposal for a regulation
Article 8 – paragraph 2 – subparagraph 2

Text proposed by the Commission

The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress, the elements in the technical documentation set out in Annex II.

Amendment

deleted

Amendment 101

Proposal for a regulation
Article 8 – paragraph 6 – subparagraph 2

Text proposed by the Commission

If in the course of the post-market surveillance a need for corrective action is identified, the manufacturer shall implement the appropriate measures.

Amendment

If in the course of the post-market surveillance a need for corrective action is identified, the manufacturer shall implement the appropriate measures, including immediate notification to
Amendment 102

Proposal for a regulation
Article 8 – paragraph 8

_**Text proposed by the Commission**_

8. Manufacturers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately take the necessary corrective action to bring that product into conformity, withdraw it or recall it, as appropriate. They shall inform the distributors and, where applicable, the authorised representative accordingly.

_**Amendment**_

8. Manufacturers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately take the necessary corrective action to bring that product into conformity, withdraw it or recall it, as appropriate. They shall inform the distributors, the importers and, where applicable, the authorised representative accordingly.

Amendment 103

Proposal for a regulation
Article 8 – paragraph 9 – subparagraph 2 (new)

_**Text proposed by the Commission**_

If a competent authority considers or has reason to believe that a device has caused damages, it shall ensure, where this is not already foreseen by national litigation or judicial proceedings, that the potentially harmed user, the user's successor in title, the user's health insurance company or other third parties affected by the damage caused to the user may request the information referred to in the first subparagraph from the manufacturer or his authorised representative while ensuring due respect to the intellectual property rights.

_**Amendment**_

If a competent authority considers or has reason to believe that a device has caused damages, it shall ensure, where this is not already foreseen by national litigation or judicial proceedings, that the potentially harmed user, the user's successor in title, the user's health insurance company or other third parties affected by the damage caused to the user may request the information referred to in the first subparagraph from the manufacturer or his authorised representative while ensuring due respect to the intellectual property rights.
Amendment 104
Proposal for a regulation
Article 8 – paragraph 10 a (new)

Text proposed by the Commission

10a. Before placing a medical device on the market, manufacturers shall ensure they are covered by an appropriate liability insurance covering the risk of insolvency and any damages to patients or users that can be directly attributed to a manufacturing defect of the same medical device, with a level of coverage proportionate to the potential risk associated with the medical device produced, and in accordance with Council Directive 85/374/EEC¹.


Amendment 105
Proposal for a regulation
Article 11 – paragraph 2 – subparagraph 1 – point -a (new)

Text proposed by the Commission

(-a) that the manufacturer is identifiable and has the technical, scientific and financial capacity to produce a medical device compliant with this Regulation, and that importers make available to the national authorities and on their website a report on the investigation procedures attesting to the expertise of the manufacturer.
Amendment 106
Proposal for a regulation
Article 11 – paragraph 2 – subparagraph 1 – point f a (new)

Text proposed by the Commission

(proposed by the Commission)

Amendment

(fa) that the manufacturer has taken out appropriate liability insurance coverage pursuant to Article 8(10a), unless the importer himself ensures sufficient coverage that meets the requirements of that paragraph.

Amendment 107
Proposal for a regulation
Article 11 – paragraph 7

Text proposed by the Commission

7. Importers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately inform the manufacturer and his authorised representative and, if appropriate, take the necessary corrective action to bring that device into conformity, withdraw or recall it. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available and, if applicable, the notified body that issued a certificate in accordance with Article 45 for the device in question, giving details, in particular, of the non-compliance and of any corrective action taken.

Amendment

7. Importers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately inform the manufacturer and his authorised representative and, if appropriate, ensure that the necessary corrective action to bring that device into conformity, withdraw or recall it, is taken and, implement that action. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available and, if applicable, the notified body that issued a certificate in accordance with Article 45 for the device in question, giving details, in particular, of the non-compliance and of any corrective action they have implemented.

Amendment 108
Proposal for a regulation
Article 12 – paragraph 2 – subparagraph 1 – point c

Text proposed by the Commission

(c) the manufacturer and, where applicable, the importer have complied with the requirements set out in Article 24 and Article 11(3) respectively.

Amendment

(c) the manufacturer and, where applicable, the importer have complied with the requirements set out in Article 11(3).

Justification

It will not be possible for most distributors (like pharmacists) to ensure that manufacturers have complied with their traceability obligations. To take one example, Article 24 (5) requires manufacturers to store device identifiers. Pharmacists could not ensure compliance with this without access to the manufacturer’s database.

Amendment 109

Proposal for a regulation

Article 12 – paragraph 4

Text proposed by the Commission

4. Distributors who consider or have reason to believe that a device which they have made available on the market is not in conformity with this Regulation shall immediately inform the manufacturer and, where applicable, his authorised representative and the importer and make sure that the necessary corrective action to bring that device into conformity, withdraw or recall it, if appropriate, is taken. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available, giving details, in particular, of the non-compliance and of any corrective action taken.

Amendment

4. Distributors who consider or have reason to believe that a device which they have made available on the market is not in conformity with this Regulation shall immediately inform the manufacturer and, where applicable, his authorised representative and the importer and make sure, within the scope of their respective activities, that the necessary corrective action to bring that device into conformity, withdraw or recall it, if appropriate, is taken. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available, giving details, in particular, of the non-compliance and of any corrective action taken.

Justification

The proposal does not distinguish between the different roles and responsibilities of actors in the supply chain for medical devices. Under the Commission text, all distributors would have
the same obligations, some of which could be difficult to fulfil. This amendment has been
tabled in order to forge meaningful links between the obligation and the activity carried out
by the distributor, in line with the approach adopted in Article 19(2) of Regulation (EC) No
178/2002 on food security.

Amendment 110

Proposal for a regulation
Article 13

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person responsible for regulatory compliance</td>
<td>Person responsible for regulatory compliance</td>
</tr>
<tr>
<td>1. Manufacturers shall have available within their organisation at least one qualified person who possesses expert knowledge in the field of medical devices. The expert knowledge shall be demonstrated by either of the following qualifications:</td>
<td></td>
</tr>
<tr>
<td>(a) a diploma, certificate or other evidence of formal qualification awarded on completion of a university degree or of an equivalent course of study, in natural sciences, medicine, pharmacy, engineering or another relevant discipline, and at least two years of professional experience in regulatory affairs or in quality management systems relating to medical devices;</td>
<td></td>
</tr>
<tr>
<td>(b) five years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</td>
<td></td>
</tr>
<tr>
<td>Without prejudice to national provisions regarding professional qualifications, manufacturers of custom-made devices may demonstrate their expert knowledge referred to in the first subparagraph by at least two years of professional experience within the relevant field of manufacture.</td>
<td></td>
</tr>
<tr>
<td>This paragraph shall not apply to manufacturers of custom-made devices</td>
<td></td>
</tr>
<tr>
<td>(a) a diploma, certificate or other evidence of formal qualification awarded on completion of a university degree or of an equivalent course of study, in law, natural sciences, medicine, pharmacy, engineering or another relevant discipline;</td>
<td></td>
</tr>
<tr>
<td>(b) three years of professional experience in regulatory affairs or in quality management systems relating to medical devices.</td>
<td></td>
</tr>
<tr>
<td>Without prejudice to national provisions regarding professional qualifications, manufacturers of custom-made devices may demonstrate their expert knowledge referred to in the first subparagraph by at least two years of professional experience within the relevant field of manufacture.</td>
<td></td>
</tr>
<tr>
<td>This paragraph shall not apply to manufacturers of custom-made devices</td>
<td></td>
</tr>
</tbody>
</table>
who are micro-enterprises as defined by Commission Recommendation 2003/361/EC.

2. The **qualified** person shall at least be responsible for ensuring the following matters:

(a) that the conformity of the devices is appropriately assessed before a batch is released;

(b) that the technical documentation and the declaration of conformity are drawn up and kept up-to-date;

(c) that the reporting obligations in accordance with Articles 61 to 66 are fulfilled;

(d) in the case of investigational devices, that the statement referred to in point 4.1 of Chapter II of Annex XIV is issued.

3. The **qualified** person shall suffer no disadvantage within the manufacturer's organisation in relation to the proper fulfilment of his duties.

4. Authorised representatives shall have available within their organisation at least one **qualified** person who possesses **expert knowledge** regarding the regulatory requirements for medical devices in the Union. The **expert knowledge** shall be demonstrated by either of the following qualifications:

(a) a diploma, certificate or other evidence of formal qualification awarded on completion of a university degree or of an equivalent course of study, in law, natural sciences, medicine, pharmacy, engineering or another relevant discipline, and at least two years of professional experience in

who are micro-enterprises as defined by Commission Recommendation 2003/361/EC.

2. The person **responsible for regulatory compliance** shall at least be responsible for ensuring the following matters:

(a) that the conformity of the devices is appropriately assessed before a batch is released;

(b) that the technical documentation and the declaration of conformity are drawn up and kept up-to-date;

(c) that the reporting obligations in accordance with Articles 61 to 66 are fulfilled;

(d) in the case of investigational devices, that the statement referred to in point 4.1 of Chapter II of Annex XIV is issued.

**If a number of persons are jointly responsible for regulatory compliance in accordance with paragraphs 1 and 2, their respective areas of responsibility shall be stipulated in writing.**

3. The person **responsible for regulatory compliance** shall suffer no disadvantage within the manufacturer's organisation in relation to the proper fulfilment of his duties.

4. Authorised representatives shall have available within their organisation at least one person **responsible for regulatory compliance** who possesses the **requisite expertise** regarding the regulatory requirements for medical devices in the Union. The **requisite expertise** shall be demonstrated by either of the following qualifications:

(a) a diploma, certificate or other evidence of formal qualification awarded on completion of a university degree or of an equivalent course of study, in law, natural sciences, medicine, pharmacy, engineering or another relevant discipline;
regulatory affairs or in quality management systems relating to medical devices;

(b) **five** years of professional experience in regulatory affairs or in quality management systems relating to medical devices.

(b) **three** years of professional experience in regulatory affairs or in quality management systems relating to medical devices.

Amendment 111

Proposal for a regulation
Article 14 – paragraph 1 – subparagraph 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A distributor, importer or other natural or legal person shall assume the obligations incumbent on the manufacturer under paragraph 1(a) only if the device in question was manufactured outside the Union. In the case of devices manufactured within the Union, the manufacturer’s proof of compliance with this Regulation shall suffice.</td>
<td></td>
</tr>
</tbody>
</table>

Justification

Article 14(1)(a) concerns firms which engage in own-branding – buying hearing aids or spectacles from the manufacturers and then placing them on the market under their own name. Under the Commission’s proposal, these firms would have the same obligations as the actual manufacturers. In the case of devices that originate in the EU, this is disproportionate because manufacturers here already have a comprehensive set of obligations.

Amendment 112

Proposal for a regulation
Article 14 – paragraph 4

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Prior to making the relabelled or repackaged device available, the distributor or importer referred to in paragraph 3 shall inform the manufacturer and the competent</td>
<td></td>
</tr>
</tbody>
</table>

4. **At least 28 calendar days** prior to making the relabelled or repackaged device available, the distributor or importer referred to in paragraph 3 shall inform the
authority of the Member State where he plans to make the device available and, upon request, shall provide them with a sample or a mock-up of the relabelled or repackaged device, including any translated label and instructions for use. He shall submit to the competent authority a certificate, issued by a notified body referred to in Article 29, designated for the type of devices that are subject to activities mentioned in points (a) and (b) of paragraph 2, attesting that the quality management system complies with the requirements laid down in paragraph 3. Within the same period of 28 calendar days, he shall submit to the competent authority a certificate, issued by a notified body referred to in Article 29, designated for the type of devices that are subject to activities mentioned in points (a) and (b) of paragraph 2, attesting that the quality management system complies with the requirements laid down in paragraph 3.

Amendment 113
Proposal for a regulation
Article 15

Text proposed by the Commission

Article 15

Single-use devices and their reprocessing

1. Any natural or legal person who reprocesses a single-use device to make it suitable for further use within the Union shall be considered to be the manufacturer of the reprocessed device and shall assume the obligations incumbent on manufacturers laid down in this Regulation.

2. Only single-use devices that have been placed on the Union market in accordance with this Regulation, or prior to [date of application of this Regulation] in accordance with Directive 90/385/EEC or Directive 93/42/EEC may be reprocessed.

3. In the case of reprocessing of single-use devices for critical use, only reprocessing that is considered safe according to the latest scientific evidence
may be carried out.

4. The Commission, by means of implementing acts, shall establish and regularly update a list of categories or groups of single-use devices for critical use which may be reprocessed in accordance with paragraph 3. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

5. The name and address of the legal or natural person referred to in paragraph 1 and the other relevant information in accordance with Section 19 of Annex I shall be indicated on the label and, where applicable, in the instructions for use of the reprocessed device.

The name and address of the manufacturer of the original single-use device shall no longer appear on the label, but shall be mentioned in the instructions for use of the reprocessed device.

6. A Member State may maintain or introduce national provisions prohibiting, within its territory, on grounds of protection of public health specific to that Member State the following:

(a) the reprocessing of single-use devices and the transfer of single-use devices to another Member State or to a third country with a view to their reprocessing;

(b) the making available of reprocessed single-use devices.

Member States shall notify the Commission and the other Member States of the national provisions and the grounds for introducing them. The Commission shall keep the information publicly available.
Amendment 114

Proposal for a regulation
Article 15 a (new)

Text proposed by the Commission

Amendment

Article 15a

General principles on single-use devices and reprocessing of reusable devices

1. All medical devices shall be treated as reusable devices unless they are placed on the list of single-use devices referred to in Article 15b.

2. Devices labelled as ‘single-use’ shall not be reprocessed.

3. Any natural or legal person, including health institutions as specified in Article 4(4), who wishes to reprocess a single-use device to make it suitable for further use within the Union, and who can provide evidence that such a device could be safely reprocessed shall be considered to be the manufacturer of its reprocessed device and be held liable for its reprocessing activities. The natural or legal person shall ensure the traceability of the reprocessed device and shall assume the obligations incumbent on manufacturers laid down in this Regulation, with the exception of obligations linked to the conformity assessment procedure.

4. Only reusable devices that have been placed on the Union market in accordance with this Regulation, or prior to [date of application of this Regulation] in accordance with Directive 90/385/EEC or Directive 93/42/EEC may be reprocessed.
Amendment 115

Proposal for a regulation
Article 15 b (new)

Text proposed by the Commission

Amendment

Article 15b

List of single-use devices unsuitable for reprocessing

1. In accordance with the first indent of Article 15a(1), the Commission, after the mandatory consultation of the MDAC shall establish, by means of delegated acts, and regularly update, including by adding or removing, a list of medical devices or types of medical devices which are unsuitable for reprocessing.

2. The decision to include or remove any device or type of device from the list shall be done owing in particular to:

- their intended use in or on the human body and the body parts they will be in contact with;
- the conditions of their use;
- their intended purpose;
- the material which they are composed of;
- the severity of the disease that is being treated;
- a genuine safety risk; and
- the latest scientific and technological advancements in the relevant fields and disciplines.

3. The delegated acts referred to in paragraph 1 shall be adopted in accordance with Article 89.
Amendment 116

Proposal for a regulation
Article 15 c (new)

Text proposed by the Commission

Amendment

Article 15c

Removal of a single-use device from the list of single-use devices unsuitable for reprocessing

1. Any natural or legal person who wishes to reprocess device placed on the list of single-use devices referred to in Article 15b to make it suitable for further use within the Union shall inform the Commission, the members of the MDAC and the manufacturer of the intention to do so and submit the requisite evidence shall be submitted to one of the EU reference laboratories, as referred to in Article 81.

2. Opinion of the EU reference laboratory: The EU reference laboratory shall adopt an opinion within 60 days and inform the Commission, the manufacturer and the natural or legal person accordingly.

3. Final opinion: The EU reference laboratory shall consider the original information from the manufacturer and the further evidence provided and adopt a final opinion within 90 days, and inform the natural or legal person requesting to reprocess the single-use device, the manufacturer and the Commission.

4. In the event of the EU reference laboratory agreeing with the natural or legal person that the device can be safely reprocessed, the Commission shall remove the single-use device from the list referred to in Article 15b and the manufacturer shall as soon as possible and, in any case, within 120 days following the adoption of the opinion of the EU reference laboratory, re-label any newly produced
item of the respective medical device as ‘reusable’ in accordance with Article 15c.

5. Appeal procedure for the natural or legal person requesting to reprocess a single-use device: In the event of the EU reference laboratory issuing a negative opinion and that the natural or legal person disagrees with it, the latter may, within 60 days following the adoption of the opinion, provide the concerned EU reference laboratory with further evidence that reprocessing the device will not put patient safety at risk. It shall also inform the Commission.

6. Final opinion: The EU reference laboratory shall then immediately consider that further evidence and adopt a final opinion within 90 days, and inform the natural or legal person requesting to reprocess the single-use device, its manufacturer and the Commission.

   In the event of the EU reference laboratory confirming its first opinion according to which the concerned device may not be safely reprocessed, the natural or legal person shall not reprocess the concerned single-use device.

7. Where a positive opinion on the safe reprocessing of a single-use device has been issued by the EU reference laboratory and, as a consequence, the single-use device removed by the Commission from the list referred to in Article 15b, that opinion shall include the following information which, in accordance with Section 19.3. point (k) of Annex I, shall appear on the label:

   - the appropriate processes to allow reuse, including cleaning, disinfection, decontamination, packaging and, where appropriate, the validated method of re-sterilisation;

   - the maximum number of times the reusable device can be reprocessed and used on patients; and
- the circumstances under which the device shall no longer be used, for example signs of material degradation.

Amendment 117
Proposal for a regulation
Article 15 d (new)

Text proposed by the Commission

Amendment

Article 15d
Labelling of medical devices as ‘reusable’ or ‘single-use’

1. All reusable medical devices shall be labelled as following: ‘This device can be reprocessed for reuse. Reprocessing is done in accordance with the EU safety and quality standards’. The label to be used on such devices shall be consistent across the Union.

In case of a reprocessed device, its label shall include information that allows the user and/or patient to be informed of any warnings, precautions, measures to be taken and limitations of use regarding the device.

2. All single-use medical devices shall be labelled as following: ‘This is a single-use device which shall not be reprocessed’. The single-use label to be used on such devices shall be consistent across the Union.

Amendment 118
Proposal for a regulation
Article 15 e (new)

Text proposed by the Commission

Amendment

Article 15e
Reprocessing of medical devices labelled
as reusable

1. Any natural or legal person, including health institutions as specified in Article 4(4), who reprocesses a device labelled as ‘reusable’ shall:

- comply with the EU standards referred to in paragraph 2;

- ensure that, where a single-use device is removed from the list referred to in Article 15b, the reusable device is reprocessed in accordance with the opinion of the EU reference laboratory, as referred to in Article 15c(2);

- ensure that the reusable device is not reprocessed beyond the maximum number of times specified for that device;

2. The Commission shall, by means of implementing acts, and in collaboration with the International Medical Devices Regulatory Forum and international standardisation bodies, define a clear set of high quality and safety standards for reprocessing of single use devices, including specific requirements for the manufacturers of reprocessed devices.

3. In drawing up these quality and safety standards, the Commission shall notably include:

- cleaning, disinfection and sterilisation processes in line with the risk assessment for the respective devices,

- requirements in relation to systems for hygiene, infection-prevention, quality management and documentation applicable to the natural or legal persons reprocessing the medical devices,

- functionality testing of the devices after reprocessing.

These standards shall be consistent with the latest scientific evidence and guarantee the highest level of quality and safety, in accordance with the severity of the condition, as reflected in European
standards from the European standardisation organisations, where the latter take into account the provisions of relevant international standards, in particular those of ISO and IEC, or any other international technical standards able to guarantee, at the very least, a higher level of quality, safety and performance than ISO and IEC standards.

3. The natural or legal person referred to in paragraph 1 shall comply with EU standards referred to in paragraph 1 to ensure the quality of the reprocessing of medical devices labelled as ‘reusable’ and the safety of reprocessed devices.

4. Where no harmonised standards exist or where relevant harmonised standards are not sufficient, the Commission shall be empowered to adopt CTS, as referred to in Article 7(1).

Amendment 119

Proposal for a regulation
Article 15 f (new)

Text proposed by the Commission

Amendment

Article 15f

Report on the functioning of the system referred to in Articles 15a to 15e

No later than four years after the date of application of this Regulation, the Commission shall assess the application of Articles 15a to 15e and draw up an evaluation report. The report shall be submitted to the European Parliament and the Council. Where appropriate, the report shall be accompanied by a legislative proposal.
**Amendment 120**

**Proposal for a regulation**

**Article 16**

*Text proposed by the Commission*

**Implant card**

1. The manufacturer of an implantable device shall provide together with the device an implant card which shall be made available to the **particular patient who has been implanted with the device.**

2. This card shall contain the following:

   (a) the information allowing identification of the device, including the Unique Device Identification;

   (b) any warnings, precautions or measures to be taken by the patient or a healthcare professional with regard to reciprocal interference with reasonably foreseeable external influences or environmental conditions;

   (ba) description of potential adverse

*Amendment*

**Implant card and information about implantable devices**

1. The manufacturer of an implantable device shall provide together with the device an implant card which shall be made available to the **healthcare professional implanting the device who shall be responsible for:**

   - submitting the implant card to the patient, and

   - recording all the information contained on the implant card in the patient's medical records;

   *The implant card shall also be made available by the manufacturer in an electronic format and Member States shall ensure that hospitals and clinics keep an electronic version on record.*

   *The following implants shall be exempted from this obligation: sutures, staples, dentals implants, screws and plates.*

   *The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing this list of exempted implants.*

2. This card shall contain the following:

   (a) the information allowing identification of the device, including the Unique Device Identification;

   (b) any warnings, precautions or measures to be taken by the patient or a healthcare professional with regard to reciprocal interference with reasonably foreseeable external influences or environmental conditions;

   (ba) description of potential adverse
(c) any information about the expected lifetime of the device and any necessary follow-up.

The information shall be written in a way that is readily understood by a lay person.

Amendment 121

Proposal for a regulation
Article 21 – paragraph 1

Text proposed by the Commission

1. Any natural or legal person who makes available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without significantly changing its performance or safety characteristics, shall ensure that the article does not adversely affect the safety and performance of the device. Substantiating evidence shall be kept available to the competent authorities of the Member States.

Amendment

1. Any natural or legal person who makes available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without changing its performance or safety characteristics, shall ensure that the article does not adversely affect the safety and performance of the device. When the article is a part of an implantable device, the natural or legal person who makes it available on the market shall cooperate with the manufacturer of the device to ensure its compatibility with the functioning part of the device in order to avoid the replacement of the whole device and its consequences for patient safety. Substantiating evidence shall be kept available to the competent authorities of the Member States.
### Amendment 122

**Proposal for a regulation**  
**Article 21 – paragraph 2**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. An article that is intended specifically to replace a part or component of a device and that significantly changes the performance or safety characteristics of the device shall be considered a device.</td>
<td>2. An article that is intended specifically to replace a part or component of a device and that changes the performance or safety characteristics of the device shall be considered as a device and shall meet the requirements laid down in this Regulation.</td>
</tr>
</tbody>
</table>

**Justification**

*The term ‘significant’ can lead to differing interpretations of the facts and, because of its indeterminacy, to incoherent implementation of the requirements. Changes to or in the performance and security features should under all circumstances lead to a classification of the article as a new medical device.*

### Amendment 123

**Proposal for a regulation**  
**Article 24 – paragraph 1 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. For devices, other than custom-made and investigational devices, a system for Unique Device Identification shall be put in place in the Union. The UDI system shall allow the identification and traceability of devices and shall consist of the following:</td>
<td>1. For devices, other than custom-made and investigational devices, a single system for Unique Device Identification (UDI) shall be put in place in the Union. The UDI system shall allow the identification and traceability of devices, be coherent if possible with the global regulatory approach for UDI in medical devices, and shall consist of the following:</td>
</tr>
</tbody>
</table>

**Justification**

*The word “single” needs to be inserted to ensure that we have a unique and harmonised approach to UDI in Europe and where possible globally.*
Amendment 124
Proposal for a regulation
Article 24 – paragraph 1 a (new)

Text proposed by the Commission

Amendment

1a. The UDI system shall be updated with the results of the post-market clinical follow-up evaluation report referred to in Section 3 of Part B of Annex XIII.

Amendment 125
Proposal for a regulation
Article 24 – paragraph 2 – point e – point i

Text proposed by the Commission

Amendment

(i) to operate its system for the assignment of UDIs for the period to be determined in the designation which shall at least be three years after its designation;

(i) to operate its system for the assignment of UDIs for the period to be determined in the designation which shall at least be five years after its designation;

Justification

The UDI System is a vital component of the new Regulatory system, and providers of UDIs should ensure a greater degree of permanence to their role

Amendment 126
Proposal for a regulation
Article 24 – paragraph 8 – point b

Text proposed by the Commission

Amendment

(b) the legitimate interest in protecting commercially sensitive information;

(b) the legitimate interest in protecting commercially sensitive information, providing that it does not conflict with public health protection;
Amendment 127
Proposal for a regulation
Article 24 – paragraph 8 – point e a (new)

Text proposed by the Commission
Amendment

(ea) compatibility with other traceability systems used by the stakeholders involved with medical devices

Justification

It is likely an electronic medicine authentication system will be out in place pursuant to Falsified Medicines Directive. It is important that the systems for medical devices and medicines are compatible, otherwise this will bring a significant and possibly unmanageable burden for the agents in the supply chain working with both kinds of products.

Amendment 128
Proposal for a regulation
Article 24 – paragraph 8 – point e b (new)

Text proposed by the Commission
Amendment

(eb) the compatibility of the UDI systems with the safety features established under Directive 2011/62/EU.

Amendment 129
Proposal for a regulation
Article 25 – paragraph 2 – subparagraph 2

Text proposed by the Commission
Amendment

Steps shall be taken to ensure that no additional national registration procedures are necessary.
Amendment 130

Proposal for a regulation
Article 26

Text proposed by the Commission

Summary of safety and clinical performance

1. In the case of devices classified as class III and implantable devices, other than custom-made or investigational devices, the manufacturer shall draw up a summary of safety and clinical performance. It shall be written in a way that is clear to the intended user. The draft of this summary shall be part of the documentation to be submitted to the notified body involved in the conformity assessment in accordance with Article 42 and shall be validated by that body.

2. The Commission may, by means of implementing acts, set out the form and the presentation of the data elements to be included in the summary of safety and clinical performance. Those implementing acts shall be adopted in accordance with the advisory procedure referred to in Article 88(2).

Amendment

Safety and clinical performance report

1. In the case of devices classified as class III and implantable devices, other than custom-made or investigational devices, the manufacturer shall draw up a report on the safety and clinical performance of the device based on the full information collected during the clinical investigation. The manufacturer shall also draw up a summary of that report which shall be written in a way that is easy for a lay person to understand in the official language(s) of the country where the medical device is made available on the market. The draft report shall be part of the documentation to be submitted to and validated by the special notified body involved in the conformity assessment in accordance with Article 43a as well as to the EMA.

1a. The summary referred to in paragraph 1 shall be made available to the public through Eudamed in accordance with provisions under point (b) of Article 27(2) and point 18 of Annex V Part A.

2. The Commission may, by means of implementing acts, set out the form of the presentation of the data elements to be included in both the report and the summary referred to in paragraph 1. Those implementing acts shall be adopted in accordance with the advisory procedure referred to in Article 88(2).
Amendment 131

Proposal for a regulation
Article 27

Text proposed by the Commission

1. The Commission shall develop and manage the European databank on medical devices (Eudamed) for the following purposes:

(a) to enable the public to be adequately informed about devices placed on the market, about the corresponding certificates issued by notified bodies and about the relevant economic operators;

(b) to enable traceability of devices within the internal market;

(c) to enable the public to be adequately informed about clinical investigations and to enable sponsors of clinical investigations to be conducted in more than one Member State to comply with information obligations under Articles 50 to 60;

(d) to enable manufacturers to comply with information obligations under Articles 61 to 66;

(e) to enable the competent authorities of the Member States and the Commission to carry out their tasks relating to this Regulation on a well informed basis and to enhance the cooperation between them.

2. Eudamed shall include the following as integral parts:

(a) the electronic system on UDI referred to in Article 24;

(b) the electronic system on registration of...

Amendment

1. The Commission shall develop, and manage the European databank on medical devices (Eudamed) for the following purposes:

(a) to enable the public to be adequately informed about devices placed on or removed from the market, about the corresponding certificates issued by notified bodies and about the relevant economic operators, with due regard to commercial confidentiality where justified;

(b) to enable traceability of devices within the internal market;

(c) to enable the public to be adequately informed about clinical investigations, and to have an overview of vigilance data and market surveillance activities as well as to enable healthcare professionals to have adequate access to the results of clinical investigations, and to enable sponsors of clinical investigations to be conducted in more than one Member State to comply with information obligations under Articles 50 to 60;

(d) to enable manufacturers to comply with information obligations under Articles 61 to 66;

(e) to enable the competent authorities of the Member States and the Commission to carry out their tasks relating to this Regulation on a well informed basis and to enhance the cooperation between them.

2. Eudamed shall include the following as integral parts:

(a) the electronic system on UDI referred to in Article 24;

(b) the electronic system on registration of...
devices and economic operators referred to in Article 25;
(c) the electronic system on information on certificates referred to in Article 45(4);
(d) the electronic system on clinical investigations referred to in Article 53,
(e) the electronic system on vigilance referred to in Article 62;
(f) the electronic system on market surveillance referred to in Article 68.

3. The data shall be entered into Eudamed by the Member States, notified bodies, economic operators and sponsors as specified in the provisions concerning the electronic systems referred to in paragraph 2.

4. All the information collated and processed by Eudamed shall be accessible to the Member States and to the Commission. The information shall be accessible to notified bodies, economic operators, sponsors and the public to the extent defined in the provisions referred to in paragraph 2.

5. Eudamed shall contain personal data only insofar as this is necessary for the electronic systems referred to in paragraph 2 to collate and process the information in accordance with this Regulation. Personal data shall be kept in a form which permits identification of the data subjects for no longer than the periods referred to in Article 8(4).

6. The Commission and the Member States shall ensure that the data subjects may effectively exercise their rights to
information, to access, to rectify and to object in accordance with Regulation (EC) No 45/2001 and Directive 95/46/EC, respectively. They shall ensure that the data subjects may effectively exercise the right of access to data relating to them, and the right to have inaccurate or incomplete data corrected and erased. Within their respective responsibilities, the Commission and the Member States shall ensure that inaccurate and unlawfully processed data is deleted, in accordance with the applicable legislation. Corrections and deletions shall be carried out as soon as possible, but no later than within 60 days after a request is made by a data subject.

7. The Commission shall, by means of implementing acts, lay down the modalities necessary for the development and management of Eudamed. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

8. In relation to its responsibilities under this Article and the processing of personal data involved therein, the Commission shall be considered controller of Eudamed and its electronic systems.

7a. The information contained in the European Databank shall be robust, transparent and user-friendly, enabling the public and healthcare professionals to compare information on registered devices, economic operators, clinical investigations, vigilance data and market-surveillance activities.

When developing and managing Eudamed, the Commission shall, in consultation with relevant stakeholders including patient and consumer organisations, ensure that all publicly accessible parts of Eudamed are presented in a user-friendly format.

8. In relation to its responsibilities under this Article and the processing of personal data involved therein, the Commission shall be considered controller of Eudamed and its electronic systems.
Amendment 132

Proposal for a regulation
Article 28 - paragraphs 5 to 8

Text proposed by the Commission

5. The national authority responsible for notified bodies shall safeguard the confidentiality of the information it obtains. However, it shall exchange information on a notified body with other Member States and the Commission.

6. The national authority responsible for notified bodies shall have a sufficient number of competent personnel at its disposal for the proper performance of its tasks.

Amendment

5. The national authority responsible for notified bodies shall safeguard the confidential aspects of the information it obtains. However, it shall exchange information on a notified body with other Member States and the Commission.

6. The national authority responsible for notified bodies shall have a sufficient number of permanent and competent personnel "in house", for the proper performance of its tasks. Compliance with that requirement shall be assessed in the peer-review referred to in paragraph 8.

In particular, the personnel of the national authority responsible for auditing the work of personnel of notified bodies in charge of carrying out product related reviews shall have proven qualifications equivalent to those of the personnel of the notified bodies as laid down in point 3.2.5. of Annex VI.

Similarly, the personnel of the national authority responsible for auditing the work of personnel of notified bodies in charge of carrying out audits of the manufacturer's quality management system shall have proven qualifications equivalent to those of the personnel of the notified bodies as laid down in point 3.2.6. of Annex VI.

Without prejudice to Article 33(3), where a national authority is responsible for the designation of notified bodies in the field of products other than medical devices, the competent authority for medical devices shall be consulted on all aspects specifically related to medical devices.

7. Member States shall provide the Commission and the other Member States

Without prejudice to Article 33(3), where a national authority is responsible for the designation of notified bodies in the field of products other than medical devices, the competent authority for medical devices shall be consulted on all aspects specifically related to medical devices.

7. The ultimate responsibility for the notified bodies and the national authority
with information on their procedures for the assessment, designation and notification of conformity assessment bodies and for the monitoring of notified bodies, and of any changes thereto. 

responsible for notified bodies lies with the Member State in which they are located. The Member State is required to check that the designated national authority responsible for notified bodies performs its work on the assessment, designation and notification of conformity assessment bodies and for the monitoring of the notified bodies properly and that the designated national authority responsible for notified bodies works impartially and objectively. Member States shall provide the Commission and the other Member States with all information they request on their procedures for the assessment, designation and notification of conformity assessment bodies and for the monitoring of notified bodies, and of any changes thereto. Such information shall be publicly available subject to provisions under Article 84.

8. The national authority responsible for notified bodies shall be peer-reviewed every second year. The peer-review shall include an on-site visit to a conformity assessment body or a notified body under the responsibility of the reviewed authority. In the case referred to in the second subparagraph of paragraph 6, the competent authority for medical devices shall participate in the peer-review.

The Member States shall draw up the annual plan for the peer-review, ensuring an appropriate rotation in respect of reviewing and reviewed authorities, and submit it to the Commission. The Commission may participate in the review. The outcome of the peer-review shall be communicated to all Member States and to the Commission and a summary of the outcome shall be made publicly available.

Amendment 133

Proposal for a regulation
Article 29 – paragraph 1

The national authority responsible for notified bodies shall be peer-reviewed every second year. The peer-review shall include an on-site visit to a conformity assessment body or a notified body under the responsibility of the reviewed authority. In the case referred to in the second subparagraph of paragraph 6, the competent authority for medical devices shall participate in the peer-review.

The Member States shall draw up the annual plan for the peer-review, ensuring an appropriate rotation in respect of reviewing and reviewed authorities, and submit it to the Commission. The Commission shall participate in the review. The outcome of the peer-review shall be communicated to all Member States and a summary of the outcome shall be made publicly available.
1. Notified bodies shall satisfy the organisational and general requirements and the quality management, resource and process requirements that are necessary to fulfil their tasks for which they are designated in accordance with this Regulation. Minimum requirements to be met by notified bodies are set out in Annex VI.

1. Notified bodies shall satisfy the organisational and general requirements and the quality management, resource and process requirements that are necessary to fulfil their tasks for which they are designated in accordance with this Regulation. In this respect, permanent in house administrative, technical and scientific personnel, with medical, technical and where needed pharmacological knowledge shall be ensured. Permanent in house personnel shall be used, but notified bodies may hire external experts on an ad hoc and temporary basis as and when needed. Minimum requirements to be met by notified bodies are set out in Annex VI. In particular, in accordance with point 1.2. of Annex VI, the notified body shall be organised and operated so as to safeguard the independence, objectivity and impartiality of its activities and avoid conflict of interests.

The notified body shall publish a list of its staff responsible for the conformity assessment and certification of medical devices. This list shall at least contain the qualifications, curriculum vitae and declaration of interests for each member of staff. The list shall be sent to the national authority responsible for notified bodies which shall check that the staff satisfies the requirements of this Regulation. The list shall also be sent to the Commission.
Text proposed by the Commission

1. Where a notified body subcontracts specific tasks connected with conformity assessment or has recourse to a subsidiary for specific tasks connected with conformity assessment, it shall verify that the subcontractor or the subsidiary meets the relevant requirements set out in Annex VI and shall inform the national authority responsible for notified bodies accordingly.

2. Notified bodies shall take full responsibility for the tasks performed on their behalf by subcontractors or subsidiaries.

3. Conformity assessment activities may be subcontracted or carried out by a subsidiary only with the agreement of the legal or natural person that applied for conformity assessment.

4. Notified bodies shall keep at the disposal of the national authority responsible for notified bodies the relevant documents concerning the verification of the qualifications of the subcontractor or the subsidiary and the work carried out by them under this Regulation.

Amendment

-1. Notified bodies shall have permanent in house competent personnel and expertise, both in technical fields linked with the assessment of the performance of the devices, and in the medical field. They shall have the capacity to evaluate in house the quality of subcontractors.

Contracts may be awarded to external experts for the assessment of medical devices or technologies in particular where clinical expertise is limited.

1. Where a notified body subcontracts specific tasks connected with conformity assessment or has recourse to a subsidiary for specific tasks connected with conformity assessment, it shall verify that the subcontractor or the subsidiary meets the relevant requirements set out in Annex VI and shall inform the national authority responsible for notified bodies accordingly.

2. Notified bodies shall take full responsibility for the tasks performed on their behalf by subcontractors or subsidiaries.

2a. Notified bodies shall make publicly available the list of subcontractors or subsidiaries, the specific tasks for which they are responsible and the declarations of interest of their personnel.

3. Conformity assessment activities may be subcontracted or carried out by a subsidiary only with the explicit agreement of the legal or natural person that applied for conformity assessment.

4. At least once a year, notified bodies shall submit to the national authority responsible for notified bodies the relevant documents concerning the verification of the qualifications of the subcontractor or the subsidiary and the work carried out by them under this Regulation.
4a. The annual assessment of notified bodies as provided for in Article 35(3) shall include verification of the compliance of the subcontractor(s) or the subsidiary(ies) of notified bodies with the requirements set out in Annex VI.

Amendment 135

Proposal for a regulation
Article 30 a (new)

Text proposed by the Commission

Amendment

Article 30a

Electronic system on registration of subsidiaries and subcontractors

1. The Commission, in collaboration with the Member States, shall set up and manage an electronic system to collate and process information on subcontractors and subsidiaries, as well as on the specific tasks for which they are responsible.

2. Before subcontracting can effectively take place, the notified body which intends to subcontract specific tasks connected with conformity assessment or has recourse to a subsidiary for specific tasks connected with conformity assessment, shall register their name(s) together with their specific tasks.

3. Within one week of any change occurring in relation to the information referred to in paragraph 1, the relevant economic operator shall update the data in the electronic system.

4. The data contained in the electronic system shall be accessible to the public.
Amendment 136
Proposal for a regulation
Article 31

Text proposed by the Commission

1. A conformity assessment body shall submit an application for notification to the national authority responsible for notified bodies of the Member State in which it is established.

In case a conformity assessment body wants to be notified for devices referred to in Article 43a(1), it shall indicate so and submit an application for notification to the EMA in accordance with Article 43a.

Amendment 137
Proposal for a regulation
Article 32

Text proposed by the Commission

3. Within 14 days of the submission referred to in paragraph 2, the Commission shall designate a joint assessment team made up of at least two experts chosen from a list of experts who are qualified in the assessment of conformity assessment bodies. The list shall be drawn up by the Commission in cooperation with the MDCG. At least one of these experts shall be a representative of the Commission who shall lead the joint assessment team.

Amendment

3. Within 14 days of the submission referred to in paragraph 2, the Commission shall designate a joint assessment team made up of at least three experts chosen from a list of experts who are qualified in the assessment of conformity assessment bodies and free of conflicts of interest with the applicant conformity assessment body. The list shall be drawn up by the Commission in cooperation with the MDCG. At least one of these experts shall be a representative of the Commission, and at least one other shall come from a Member State other than the one in which the applicant conformity assessment body is established. The Commission representative shall lead the joint assessment team. In case the conformity assessment body has asked to be notified for devices referred to in Article 43a(1), the EMA shall also be part of the joint
4. Within 90 days after designation of the joint assessment team, the national authority responsible for notified bodies and the joint assessment team shall review the documentation submitted with the application in accordance with Article 31 and conduct an on-site assessment of the applicant conformity assessment body and, where relevant, of any subsidiary or subcontractor, located inside or outside the Union, to be involved in the conformity assessment process. Such on-site assessment shall not cover requirements for which the applicant conformity assessment body has received a certificate delivered by the national accreditation body as referred to in Article 31(2), unless the Commission representative mentioned in Article 32(3) requests the on-site assessment.

Findings regarding non-compliance of a body with the requirements set out in Annex VI shall be raised during the assessment process and discussed between the national authority responsible for notified bodies and the joint assessment team with a view to finding common agreement with respect to the assessment of the application. Divergent opinions shall be identified in the assessment report of the national authority responsible.

5. The national authority responsible for notified bodies shall submit its assessment report and its draft notification to the Commission which shall immediately transmit those documents to the MDCG and to the members of the joint assessment team. Upon request by the Commission, those documents shall be submitted by the authority in up to three official Union

assessment team.

4. Within 90 days after designation of the joint assessment team, the national authority responsible for notified bodies and the joint assessment team shall review the documentation submitted with the application in accordance with Article 31 and conduct an on-site assessment of the applicant conformity assessment body and, where relevant, of any subsidiary or subcontractor, located inside or outside the Union, to be involved in the conformity assessment process. Such on-site assessment shall not cover requirements for which the applicant conformity assessment body has received a certificate delivered by the national accreditation body as referred to in Article 31(2), unless the Commission representative mentioned in Article 32(3) requests the on-site assessment.

Findings regarding non-compliance of an applicant conformity assessment body with the requirements set out in Annex VI shall be raised during the assessment process and discussed between the national authority responsible for notified bodies and the joint assessment team. The national authority shall set out in the assessment report the measures that the notify body shall take to ensure compliance of that applicant conformity assessment body with the requirements set out in Annex VI. In the event of a disagreement, a separate opinion drawn up by the assessment team setting out its reservations regarding notification shall be appended to the assessment report of the national authority responsible.

5. The national authority responsible for notified bodies shall submit its assessment report and its draft notification to the Commission which shall immediately transmit those documents to the MDCG and to the members of the joint assessment team. If the assessment team draws up a separate opinion, this too shall be submitted to the Commission for
languages.

6. The joint assessment team shall provide its opinion regarding the assessment report and the draft notification within 21 days of receipt of those documents and the Commission shall immediately submit this opinion to the MDCG. Within 21 days after receipt of the opinion of the joint assessment team, the MDCG shall issue a recommendation with regard to the draft notification which the relevant national authority shall duly take into consideration for its decision on the designation of the notified body.

6. The joint assessment team shall provide its final opinion regarding the assessment report, the draft notification and, where appropriate, the separate opinion drawn up by the assessment team, within 21 days of receipt of those documents and the Commission shall immediately submit this opinion to the MDCG. Within 21 days after receipt of the opinion of the joint assessment team, the MDCG shall issue a recommendation with regard to the draft notification. The relevant national authority shall base its decision on the designation of the notified body on the recommendation by the MDCG. In case where its decision differs from the MDCG recommendation, the relevant national authority shall provide the MDCG in writing with all the necessary justification for its decision.

Amendment 138

Proposal for a regulation
Article 33

Text proposed by the Commission

2. Member States may notify only conformity assessment bodies which satisfy the requirements set out in Annex VI.

Amendment

2. Member States shall notify only conformity assessment bodies which satisfy the requirements set out in Annex VI and for which the application assessment procedure has been completed in accordance with Article 32.

3. Where a national authority responsible for notified bodies is responsible for designation of notified bodies in the field of products other than medical devices, the competent authority for medical devices shall provide, prior to the notification, a positive opinion on the forwarding to the MDCG.
notification and its scope.

4. The notification shall clearly specify the scope of the designation indicating the conformity assessment activities, the conformity assessment procedures and the type of devices which the notified body is authorised to assess.

The Commission may, by means of implementing acts, set up a list of codes and the corresponding types of devices to define the scope of the designation of notified bodies which the Member States shall indicate in their notification. Those implementing acts shall be adopted in accordance with the advisory procedure referred to in Article 88(2).

8. When a Member State or the Commission raises objections in accordance with paragraph 7, the effect of the notification shall be suspended. In this case, the Commission shall bring the matter before the MDCG within 15 days after expiry of the period referred to in paragraph 7. After consulting the parties involved, the MDCG shall give its opinion at the latest within 28 days after the matter has been brought before it. If the notifying Member State does not agree with the opinion of the MDCG, it may request the Commission to give its opinion.

9. Where no objection is raised in accordance with paragraph 7 or where the MDCG or the Commission, after having been consulted in accordance with paragraph 8, is of the opinion that the notification may be accepted fully or partially, the Commission shall publish the notification accordingly.

The Commission shall also enter information on the notification of the notified body into the electronic system referred to in Article 27(2). That information shall be accompanied by the final assessment report of the national authority responsible for notified bodies, the opinion of the joint assessment team.
and the recommendation of the MDCG, as referred to in this article.

The full details of the notification, including the class and the typology of devices, as well as the annexes, shall be made publicly available.

Amendment 139

Proposal for a regulation
Article 34 – paragraph 1

Text proposed by the Commission
1. The Commission shall assign an identification number to each notified body for which the notification is accepted in accordance with Article 33. It shall assign a single identification number even when the body is notified under several Union acts.

Amendment
1. The Commission shall assign an identification number to each notified body for which the notification is accepted in accordance with Article 33. It shall assign a single identification number even when the body is notified under several Union acts. If they are successfully renotified, bodies notified pursuant to Directives 90/385/EEC and 93/42/EEC shall retain the identification number assigned to them.

Justification

If they are renotified, existing notified bodies should retain the identification number assigned to them. Unnecessary administrative formalities, such as the inputting of the new identification numbers into various European databases, and the costly process of changing product labels would thus be avoided.

Amendment 140

Proposal for a regulation
Article 34 – paragraph 2

Text proposed by the Commission
2. The Commission shall make the list of the bodies notified under this Regulation, including the identification numbers that have been assigned to them and the activities for which they have been

Amendment
2. The Commission shall make the list of the bodies notified under this Regulation, including the identification numbers that have been assigned to them and the activities for which they have been
notified, accessible to the public. The Commission shall ensure that the list is kept up to date.

Amendment 141

Proposal for a regulation

Article 35

Text proposed by the Commission

1. The national authority responsible for notified bodies shall continuously monitor the notified bodies to ensure ongoing compliance with the requirements set out in Annex VI. The notified bodies shall, on request, supply all relevant information and documents, required to enable the authority to verify compliance with those criteria.

Notified bodies shall, without delay, inform the national authority responsible for notified bodies of any changes, in particular regarding their personnel, facilities, subsidiaries or subcontractors, which may affect compliance with the requirements set out in Annex VI or their ability to conduct the conformity assessment procedures relating to the devices for which they have been designated.

2. Notified bodies shall respond without delay to requests relating to conformity assessments they have carried out, submitted by their or another Member State's authority or by the Commission. The national authority responsible for notified bodies of the Member State in which the body is established shall enforce requests submitted by authorities of any other Member State or by the Commission unless there is a legitimate reason for not doing so in which case both sides may consult the MDCG. The notified body or their national authority responsible for notified bodies may request that any notified bodies

Amendment

1. The national authority responsible for notified bodies, and where applicable the EMA, shall continuously monitor the notified bodies to ensure ongoing compliance with the requirements set out in Annex VI. The notified bodies shall, on request, supply all relevant information and documents, required to enable the authority to verify compliance with those criteria.

Notified bodies shall, without delay, and within 15 days at the latest, inform the national authority responsible for notified bodies of any changes, in particular regarding their personnel, facilities, subsidiaries or subcontractors, which may affect compliance with the requirements set out in Annex VI or their ability to conduct the conformity assessment procedures relating to the devices for which they have been designated.

2. Notified bodies shall respond without delay, and within 15 days at the latest, to requests relating to conformity assessments they have carried out, submitted by their or another Member State's authority or by the Commission. The national authority responsible for notified bodies of the Member State in which the body is established shall enforce requests submitted by authorities of any other Member State or by the Commission. Where there is a legitimate reason for not doing so, the notified bodies shall explain these reasons in writing and shall consult the MDCG, which shall then issue a
3. At least once a year, the national authority responsible for notified bodies shall assess whether each notified body under its responsibility still satisfies the requirements set out in Annex VI. This assessment shall include an on-site visit to each notified body.

4. Three years after notification of a notified body, and again every third year thereafter, the assessment to determine whether the notified body still satisfies the requirements set out in Annex VI shall be conducted by the national authority responsible for notified bodies of the Member State in which the body is established and a joint assessment team designated in accordance with the procedure described in Article 32(3) and (4). At the request of the Commission or of a Member State, the MDCG may initiate the assessment process described in this paragraph at any time when there is reasonable concern about the ongoing compliance of a notified body with the requirements set out in Annex VI.

3. At least once a year, the national authority responsible for notified bodies shall assess whether each notified body under its responsibility still satisfies the requirements set out in Annex VI, including an assessment of whether its subcontractor(s) and subsidiary/-ies satisfy these requirements. This assessment shall include an unannounced inspection through an on-site visit to each notified body, and to each subsidiary or subcontractor within or outside the Union, if relevant.

The assessment shall also include a review of samples of the design dossier assessments carried out by the notified body to determine the ongoing competence of the notified body and quality of its assessments, in particular the notified body's ability to evaluate and assess clinical evidence.

4. Two years after notification of a notified body, and again every second year thereafter, the assessment to determine whether the notified body and its subsidiaries and subcontractors still satisfy the requirements set out in Annex VI shall be conducted by the national authority responsible for notified bodies of the Member State in which the body is established and a joint assessment team designated in accordance with the procedure described in Article 32(3) and (4). At the request of the Commission or of a Member State, the MDCG may initiate the assessment process described in this paragraph at any time when there is reasonable concern about the ongoing compliance of a notified body, or a subsidiary or subcontractor of a notified body, with the requirements set out in Annex VI.
For special notified bodies under Article 43a, the assessment referred to in this paragraph shall be performed every year.

The comprehensive results of the assessments shall be published.

5. The Member States shall report to the Commission and to the other Member States, at least once a year, on their monitoring activities. This report shall contain a summary which shall be made publicly available.

5a. Every year, the notified bodies shall forward an annual activity report setting out the information referred to in Annex VI, point 5 to the competent authority and to the Commission, which shall forward it to the MDCG.

Amendment 142

Proposal for a regulation
Article 35 a (new)

Text proposed by the Commission

Penalties

Member States shall ensure they have a system of penalties in place in case notified bodies do not fulfil the minimum requirements. This system should be transparent and proportionate to the nature and level of the non-compliance.

Amendment 143

Proposal for a regulation
Article 36

Text proposed by the Commission

1. The Commission and the other Member States shall be notified of any subsequent
relevant changes to the notification. The procedures described in Article 32(2) to (6) and in Article 33 shall apply to changes where they entail an extension of the scope of the notification. In all other cases, the Commission shall immediately publish the amended notification in the electronic notification tool referred to in Article 33(10).

2. Where a national authority responsible for notified bodies has ascertained that a notified body no longer meets the requirements set out in Annex VI, or that it is failing to fulfil its obligations, the authority shall suspend, restrict, or fully or partially withdraw the notification, depending on the seriousness of the failure to meet those requirements or fulfil those obligations. A suspension shall not exceed a period of one year, renewable once for the same period. Where the notified body has ceased its activity, the national authority responsible for notified bodies shall withdraw the notification.

The national authority responsible for notified bodies shall immediately inform the Commission and the other Member States of any suspension, restriction or withdrawal of a notification.

3. In the event of restriction, suspension or withdrawal of a notification, the Member State shall take appropriate steps to ensure that the files of the notified body concerned are either processed by another notified body or kept available for the national authorities responsible for notified bodies and for market surveillance at their request.

4. The national authority responsible for notified bodies shall assess whether the

relevant changes to the notification. The procedures described in Article 32(2) to (6) and in Article 33 shall apply to changes where they entail an extension of the scope of the notification. In all other cases, the Commission shall immediately publish the amended notification in the electronic notification tool referred to in Article 33(10).

2. Where a national authority responsible for notified bodies has ascertained that a notified body no longer meets the requirements set out in Annex VI, or that it is failing to fulfil its obligations, the authority shall suspend, restrict, or fully or partially withdraw the notification, depending on the seriousness of the failure to meet those requirements or fulfil those obligations. Suspension shall apply until a decision to annul the suspension has been reached by the MDCG, which shall follow an assessment by a joint assessment team designated in accordance with the procedure described in Article 32(3). Where the notified body has ceased its activity, the national authority responsible for notified bodies shall withdraw the notification.

The national authority responsible for notified bodies shall immediately and within 10 days at the latest, inform the Commission, the other Member States and the relevant manufacturers and health professionals of any suspension, restriction or withdrawal of a notification.

3. In the event of restriction, suspension or withdrawal of a notification, the Member State shall inform the Commission and shall take appropriate steps to ensure that the files of the notified body concerned are either processed by another notified body or kept available for the national authorities responsible for notified bodies and for market surveillance at their request.

4. The national authority responsible for notified bodies shall assess whether the
reasons which gave rise to the change to the notification have an impact on the certificates issued by the notified body and, within three months after having notified the changes to the notification, shall submit a report on its findings to the Commission and the other Member States. Where necessary to ensure the safety of devices on the market, that authority shall instruct the notified body to suspend or withdraw, within a reasonable period of time determined by the authority, any certificates which were unduly issued. If the notified body fails to do so within the determined period of time, or has ceased its activity, the national authority responsible for notified bodies itself shall suspend or withdraw the certificates unduly issued.

5. The certificates, other than those unduly issued, which were issued by the notified body for which the notification has been suspended, restricted or withdrawn shall remain valid in the following circumstances:

(a) in the case of suspension of a notification: on condition that, within three months of the suspension, either the competent authority for medical devices of the Member State in which the manufacturer of the device covered by the certificate is established, or another notified body confirm in writing that it is assuming the functions of the notified body during the period of suspension;

reasons which gave rise to the suspension, restriction or withdrawal of the notification have an impact on the certificates issued by the notified body and, within three months after having notified the changes to the notification, shall submit a report on its findings to the Commission and the other Member States. Where necessary to ensure the safety of devices on the market, that authority shall instruct the notified body to suspend or withdraw, within a reasonable period of time determined by the authority, and at the latest 30 days after the publication of the report, any certificates which were unduly issued. If the notified body fails to do so within the determined period of time, or has ceased its activity, the national authority responsible for notified bodies itself shall suspend or withdraw the certificates unduly issued.

With a view to verifying whether the reasons for the suspension, restriction or withdrawal of the notification have implications for the certificates issued, the national authority responsible shall ask the relevant manufacturers to supply evidence of conformity at notification, and the manufacturers shall have 30 days in which to respond to that request.

5. The certificates, other than those unduly issued, which were issued by the notified body for which the notification has been suspended, restricted or withdrawn shall remain valid in the following circumstances:

(a) in the case of suspension of a notification: on condition that, within three months of the suspension another notified body confirm in writing that it is assuming the functions of the notified body during the period of suspension;
(b) in the case of restriction or withdrawal of a notification: for a period of three months after the restriction or withdrawal. The competent authority for medical devices of the Member State in which the manufacturer of the device covered by the certificate is established may extend the validity of the certificates for further periods of three months, which altogether may not exceed twelve months, provided it is assuming the functions of the notified body during this period.

The authority or the notified body assuming the functions of the notified body affected by the change of notification shall immediately inform the Commission, the other Member States and the other notified bodies thereof.

Amendment 144

Proposal for a regulation

Article 37 – paragraph 3 – subparagraph 1

Where the Commission ascertains that a notified body no longer meets the requirements for its notification, it shall inform the notifying Member State accordingly and request it to take the necessary corrective measures, including the suspension, restriction or withdrawal of the notification if necessary.

The Commission shall make a report with the opinions of Member States publicly available after the assessment.
### Amendment 145

**Proposal for a regulation**
**Article 39 – paragraph 1**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Commission shall ensure that appropriate coordination and cooperation between notified bodies is put in place and operated in the form of a coordination group of notified bodies in the field of medical devices, including <em>in vitro</em> diagnostic medical devices.</td>
<td>The Commission, <em>in consultation with the MDCG</em>, shall ensure that appropriate coordination and cooperation between notified bodies is put in place and operated in the form of a coordination group of notified bodies in the field of medical devices, including <em>in vitro</em> diagnostic medical devices. <em>This group shall meet on a regular basis and at least twice a year.</em></td>
</tr>
</tbody>
</table>

*Justification*

The coordination group should be an effective forum for discussion, and should allow experience-sharing between Notified Bodies, but also between Notified Bodies and competent authorities.

### Amendment 146

**Proposal for a regulation**
**Article 39 – paragraph 2 a (new)**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>The Commission or the MDCG may request the participation of any notified body.</em></td>
<td></td>
</tr>
</tbody>
</table>

*Justification*

The coordination group should be an effective forum for discussion, and should allow scrutiny by the Commission and competent authorities. It should be made clear that attendance is compulsory if requested by the Commission or MDCG.
Amendment 147

Proposal for a regulation
Article 39 – paragraph 2 b (new)

Text proposed by the Commission

The Commission may, by means of implementing acts, adopt measures setting out the modalities for the functioning of the coordination group of notified bodies as set out in this Article. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 84(3).

Justification

The coordination group should be an effective forum for discussion, and should allow experience-sharing between Notified Bodies, but also between Notified Bodies and competent authorities. The modalities for the functioning of the coordination group should be further developed through implementing acts

Amendment 148

Proposal for a regulation
Article 40

Text proposed by the Commission

Fees

1. The Member State where the bodies are established shall levy fees on applicant conformity assessment bodies and on notified bodies. These fees shall, wholly or partly, cover the costs relating to the activities exercised by the national authorities responsible for notified bodies in accordance with this Regulation.

2. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 setting out the structure and the level of the fees referred to in paragraph 1, taking into account the objectives of protection of human health and safety,

Amendment

Fees for the activities of national authorities

1. The Member State where the bodies are established shall levy fees on applicant conformity assessment bodies and on notified bodies. These fees shall, wholly or partly, cover the costs relating to the activities exercised by the national authorities responsible for notified bodies in accordance with this Regulation.

2. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 setting out the structure and the level of the fees referred to in paragraph 1, taking into account the objectives of protection of human health and safety,
support of innovation and cost-effectiveness. Particular attention shall be paid to the interests of notified bodies that submitted a valid certificate delivered by the national accreditation body as referred to in Article 31(2) and notified bodies that are small and medium-sized enterprises as defined by Commission Recommendation 2003/361/EC.

support of innovation, cost-effectiveness and the need to create a level-playing field across Member States. Particular attention shall be paid to the interests of notified bodies that submitted a valid certificate delivered by the national accreditation body as referred to in Article 31(2) and notified bodies that are small and medium-sized enterprises as defined by Commission Recommendation 2003/361/EC.

These fees shall be proportionate and consistent with national standards of living. The level of fees shall be made public.

Amendment 149

Proposal for a regulation
Article 40 a (new)

Text proposed by the Commission

Amendment

Article 40 a

Transparency on fees charged by notified bodies for conformity assessment activities

1. Member States shall adopt provisions on standard fees for notified bodies.

2. Fees shall be comparable across Member States. The Commission shall provide guidelines to facilitate comparability of those fees within 24 months from the date of entry into force of this Regulation.

3. Member States shall transmit their list of standard fees to the Commission.

4. The national authority shall ensure that the notified bodies make the lists of standard fees for the conformity assessment activities publicly available.
Amendment 150
Proposal for a regulation
Article 41 – paragraph 2 – subparagraph 2

**Text proposed by the Commission**

At least 14 days prior to any decision, the competent authority shall notify the MDCG and the Commission of its envisaged decision.

**Amendment**

At least 14 days prior to any decision, the competent authority shall notify the MDCG and the Commission of its envisaged decision. The final decision shall be made publically available in the Eudamed.

Amendment 151
Proposal for a regulation
Article 41 – paragraph 3 – subparagraph 1

**Text proposed by the Commission**

The Commission may, at the request of a Member State or on its own initiative, by means of implementing acts, decide on the application of the classification criteria set out in Annex VII to a given device, or category or group of devices, with a view to determining their classification.

**Amendment**

The Commission may, at the request of a Member State or on its own initiative, by means of implementing acts, decide on the application of the classification criteria set out in Annex VII to a given device, or category or group of devices, with a view to determining their classification. Such decision should in particular be taken in order to resolve diverging decisions between Member States.

Amendment 152
Proposal for a regulation
Article 41 – paragraph 3 – subparagraph 2

**Text proposed by the Commission**

Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

**Amendment**

Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3). Before adopting implementing acts, the Commission shall consult with relevant
stakeholders and take into account their suggestions.

**Justification**

To improve transparency of the process leading to implementing and delegated acts, the Commission should consult and take into account the suggestions of relevant stakeholders.

### Amendment 153
Proposal for a regulation
Article 41 – paragraph 4 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. In the light of technical progress and any information which becomes available in the course of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 as regards the following:</td>
<td>4. In the light of technical progress and any information which becomes available in the course of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission, <strong>having consulted relevant stakeholders, including organisations of healthcare professionals</strong>, shall be empowered to adopt delegated acts in accordance with Article 89 as regards the following:</td>
</tr>
</tbody>
</table>

### Amendment 154
Proposal for a regulation
Article 42 – paragraph 4

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Manufacturers of devices classified as class IIa, other than custom-made or investigational devices, shall be subject to a conformity assessment based on full quality assurance as specified in Annex VIII, except for its Chapter II, with assessment of the design documentation within the technical documentation on a representative basis. Alternatively, the manufacturer may choose to draw up the technical documentation set out in Annex II coupled with a conformity assessment</td>
<td>4. Manufacturers of devices classified as class IIa, other than custom-made or investigational devices, shall be subject to a conformity assessment based on full quality assurance as specified in Annex VIII, except for its Chapter II, with assessment of the <strong>prototype and the</strong> design documentation within the technical documentation on a representative basis. Alternatively, the manufacturer may choose to draw up the technical documentation set out in Annex II coupled</td>
</tr>
</tbody>
</table>
based on product conformity verification as specified in Section 7 of Part A or Section 8 of Part B of Annex X.

with a conformity assessment based on product conformity verification as specified in Section 7 of Part A or Section 8 of Part B of Annex X.

---

**Amendment 155**

**Proposal for a regulation**

**Article 42 – paragraph 10 – subparagraph 1 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Commission <em>may</em>, by means of implementing acts, specify the modalities and the procedural aspects with a view to ensuring harmonised application of the conformity assessment procedures by the notified bodies for any of the following aspects:</td>
<td>The Commission <em>shall</em>, by means of implementing acts, specify the modalities and the procedural aspects with a view to ensuring harmonised application of the conformity assessment procedures by the notified bodies for any of the following aspects:</td>
</tr>
</tbody>
</table>

**Justification**

This amendment seeks to make certain that all notified bodies are applying the conformity assessment procedures at the same consistent high level.

---

**Amendment 156**

**Proposal for a regulation**

**Article 42 – paragraph 10 – subparagraph 1 – indent 2**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– the minimum frequency of unannounced factory inspections and sample checks to be conducted by notified bodies in accordance with Section 4.4 of Annex VIII, taking into account the risk-class and the type of device;</td>
<td>deleted</td>
</tr>
</tbody>
</table>

**Justification**

The number of unannounced inspections in section 4.4 of Annex VIII has to be clearly defined in order to strengthen the necessary controls and to guarantee unannounced inspections at the same level and frequency in all Member States. Therefore unannounced inspections
should be performed at least once in a certification cycle and for each manufacturer and
generic device group. Because of the vital importance of this instrument, the scope and
procedures of the unannounced inspections should be stated in the Regulation itself instead of
in down streamed rules such as an implementing act.

Amendment 157

Proposal for a regulation
Article 42 – paragraph 10 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>10a. Unannounced inspections, in terms of their nature and extent, may be counted as regular inspections, with offsetting of economic operators’ costs resulting from unannounced inspections, provided that no significant non-conformities are recorded during unannounced inspections. Account must be taken at all times, when ordering unannounced inspections and carrying them out, of the proportionality principle, with due regard, in particular, for the risk potential of each individual product.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 158

Proposal for a regulation
Article 42 – paragraph 11

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. In the light of technical progress and any information which becomes available in the course of the designation or monitoring of notified bodies set out in Articles 28 to 40, or of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing the conformity assessment procedures set out in Annexes VIII to XI.</td>
<td>deleted</td>
</tr>
</tbody>
</table>
Amendment 159

Proposal for a regulation
Article 43 – paragraph 1

Text proposed by the Commission

Involvement of notified bodies

Where the conformity assessment procedure requires the involvement of a notified body, the manufacturer may apply to a notified body of his choice, provided that the body is notified for the conformity assessment activities, the conformity assessment procedures and the devices concerned. An application may not be lodged in parallel with more than one notified body for the same conformity assessment activity.

Amendment

Involvement of notified bodies in conformity assessment procedures

Where the conformity assessment procedure requires the involvement of a notified body, the manufacturer of devices other than those listed in Article 43a(1) may apply to a notified body of his choice, provided that the body is notified for the conformity assessment activities, the conformity assessment procedures and the devices concerned. Where a manufacturer applies to a notified body located in a Member State other than the one where it is registered, the manufacturer shall inform its national authority responsible for the notified bodies of the application. An application may not be lodged in parallel with more than one notified body for the same conformity assessment activity.

Amendment 160

Proposal for a regulation
Article 43 – paragraph 2

Text proposed by the Commission

2. The notified body concerned shall inform the other notified bodies of any manufacturer who withdraws his application prior to the notified body's decision regarding the conformity assessment.

Amendment

2. The notified body concerned shall inform the other notified bodies of any manufacturer who withdraws his application prior to the notified body's decision regarding the conformity assessment. It shall also inform all of the competent national bodies without delay.
Amendment 161
Proposal for a regulation
Chapter V - Section 2a (new)

Text proposed by the Commission

Amendment

Additional provisions for the conformity assessment of high-risk devices:
Involvement of special notified bodies

Amendment 162
Proposal for a regulation
Article 43 a (new)

Text proposed by the Commission

Amendment

Article 43a
Involvement of the special notified bodies in the conformity assessment procedures of high-risk devices

1. Only special notified bodies shall be entitled to conduct conformity assessments for the following devices:
- implantable devices,
- devices incorporating a substance, as referred to in Article 1(4) and point 6.1. of Annex VII (Rule 13),
- Class IIb devices intended to administer and/or remove a medicinal product, as referred to in Article 1(5) and point 5.3. of Annex VII (Rule 11),
- devices manufactured utilising tissues or cells of human or animal origin, or their derivatives, which are non-viable or are rendered non-viable, or
- all other class III devices.

2. Applicant special notified bodies which consider they fulfil the requirements for special notified bodies referred to in Annex VI, point 3.6, shall submit their application to the EMA.
3. The application shall be accompanied by the fee payable to the EMA to cover the costs relating to the examination of the application.

4. The EMA shall select the special notified bodies among applicants, in accordance with requirements listed in Annex VI, and adopt its opinion on the authorisation to perform conformity assessments for devices listed in paragraph 1 within 90 days and send it to the Commission.

5. The Commission shall then publish the notification accordingly and the names of the special notified bodies.

6. This notification shall become valid the day after its publication in the database of notified bodies developed and managed by the Commission. The published notification shall determine the scope of lawful activity of the special notified body. This notification shall be valid for five years and subject to renewal every five years, following a new application to the EMA.

7. The manufacturer of devices listed in paragraph 1 may apply to a special notified body of his choice, whose name appears in the electronic system of Article 43 b (new).

8. An application may not be lodged in parallel with more than one special notified body for the same conformity assessment activity.

9. The special notified body shall notify the EMA and the Commission of applications for conformity assessments for devices listed in paragraph 1.

10. Article 43, paragraphs 2, 3 and 4 apply to special notified bodies.
Amendment 163
Proposal for a regulation
Article 43 b (new)

Text proposed by the Commission

Amendment

Article 43b
Electronic system on special notified bodies

1. The Commission, in collaboration with the EMA, shall establish and regularly update an electronic registration system for:

- the registration of applications and granted authorisations to perform conformity assessments as special notified bodies under this Section and to collate and process information on the name of the special notified bodies;
- the exchange of information with national authorities;
- and for the publication of assessment reports;

2. The information collated and processed in the electronic system which relates to special notified bodies shall be entered into the electronic registration system by the EMA.

3. The information collated and processed in the electronic system and which relates to special notified bodies shall be accessible to the public.

Amendment 164
Proposal for a regulation
Article 43 c (new)

Text proposed by the Commission

Amendment

Article 43c
Network of special notified bodies
1. The EMA shall establish, host, coordinate and manage the network of special notified bodies.

2. The network shall have the following objectives:
   (a) to help realise the potential of European cooperation regarding highly specialised medical technologies in the area of medical devices;
   (b) to contribute to the pooling of knowledge regarding medical devices;
   (c) to encourage the development of conformity assessment benchmarks and to help develop and spread best practice within and outside the network;
   (d) to help identify the experts in innovative fields;
   (e) to develop and update rules on conflicts of interest; and
   (f) to find common answers to similar challenges concerning the conduct of conformity assessment procedures in innovative technologies.

3. Meetings of the network shall be convened whenever requested by at least two of its members or by the EMA. It shall meet at least twice a year.

Amendment 165

Proposal for a regulation
Article 44

Text proposed by the Commission

Amendment

Article 44

Mechanism for scrutiny of certain conformity assessments

1. Notified bodies shall notify the Commission of applications for conformity assessments for devices
classified as class III, with the exception of applications to supplement or renew existing certificates. The notification shall be accompanied by the draft instructions for use referred to in Section 19.3 of Annex I and the draft summary of safety and clinical performance referred to in Article 26. In its notification the notified body shall indicate the estimated date by which the conformity assessment is to be completed. The Commission shall immediately transmit the notification and the accompanying documents to the MDCG.

2. Within 28 days of receipt of the information referred to in paragraph 1, the MDCG may request the notified body to submit a summary of the preliminary conformity assessment prior to issuing a certificate. Upon suggestion by any of its members or by the Commission, the MDCG shall decide on making such request in accordance with the procedure set out in Article 78(4). In its request the MDCG shall indicate the scientifically valid health reason for having selected the specific file for submission of a summary of the preliminary conformity assessment. When selecting a specific file for submission, the principle of equal treatment shall be duly taken into account.

Within 5 days after receipt of the request by the MDCG, the notified body shall inform the manufacturer thereof.

3. The MDCG may submit comments on the summary of the preliminary conformity assessment at the latest 60 days after submission of this summary. Within that period and at the latest 30 days after submission, the MDCG may request the submission of additional information that for scientifically valid grounds are necessary for the analysis of the notified body's preliminary conformity assessment. This may include a request for samples or an on-site visit to the
manufacturer's premises. Until submission of the additional information requested, the period for comments referred to in the first sentence of this subparagraph shall be suspended. Subsequent requests for additional information from the MDCG shall not suspend the period for the submission of comments.

4. The notified body shall give due consideration to any comments received in accordance with paragraph 3. It shall convey to the Commission an explanation of how they have been taken into consideration, including any due justification for not following the comments received, and its final decision regarding the conformity assessment in question. The Commission shall immediately transmit this information to the MDCG.

5. Where deemed necessary for the protection of patient safety and public health, the Commission, may determine, by means of implementing acts, specific categories or groups of devices, other than devices of class III, to which paragraphs 1 to 4 shall apply during a predefined period of time. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Measures pursuant to this paragraph may be justified only by one or more of the following criteria:

(a) the novelty of the device or of the technology on which it is based and the significant clinical or public health impact thereof;

(b) an adverse change in the risk-benefit profile of a specific category or group of devices due to scientifically valid health concerns in respect of components or source material or in respect of the impact on health in case of failure;
(c) an increased rate of serious incidents reported in accordance with Article 61 in respect of a specific category or group of devices;

(d) significant discrepancies in the conformity assessments carried out by different notified bodies on substantially similar devices;

(e) public health concerns regarding a specific category or group of devices or the technology on which they are based.

6. The Commission shall make a summary of the comments submitted in accordance with paragraph 3 and the outcome of the conformity assessment procedure accessible to the public. It shall not disclose any personal data or information of commercially confidential nature.

7. The Commission shall set up the technical infrastructure for the data-exchange by an electronic means between notified bodies and MDCG for the purposes of this Article.

8. The Commission, by means of implementing acts, may adopt the modalities and the procedural aspects concerning the submission and analysis of the summary of the preliminary conformity assessment in accordance with paragraphs 2 and 3. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment

Proposal for a Regulation
Article 44 a (new)

Text proposed by the Commission

Amendment

Article 44a

Case-by-case assessment procedure for
the conformity assessments of certain high-risk devices

1. Special notified bodies shall notify the Commission of applications for conformity assessments for devices referred in Art 43a(1), with the exception of applications to renew existing certificates. The notification shall be accompanied by the draft instructions for use referred to in Section 19.3 of Annex I and the draft summary of safety and clinical performance referred to in Article 26. In its notification the special notified body shall indicate the estimated date by which the conformity assessment is to be completed. The Commission shall immediately transmit the notification and the accompanying documents to the Coordination Group (CG) of the Assessment Committee for Medical Devices (ACMD), referred to in Article 78b. The CG shall immediately transmit the notification and the accompanying documents to the relevant sub-groups.

2. Within 20 days of receipt of the information referred to in paragraph 1, the CG may decide, upon suggestion by at least three of the members of the relevant sub-groups of the ACMD or by the Commission, to request the special notified body to submit the following documents prior to issuing a certificate:

- the summary of the preliminary conformity assessment,

- the clinical evaluation report as referred to in Annex XIII, including the clinical investigations report as referred to in Annex XIV,

- the post market clinical follow-up plan referred to in Annex XIII, and

- any information regarding the marketing or not of the device in third countries and, where available, the results of evaluation conducted by competent authorities in those countries,
The members of the relevant sub-groups of the ACMD shall decide on making such case-by-case request notably on the basis of the following criteria:

(a) the novelty of the device or of the technology on which it is based and the significant clinical or public health impact thereof;

(b) an adverse change in the risk-benefit profile of a specific category or group of devices due to scientifically valid health concerns in respect of components or source material or in respect of the impact on health in case of failure;

(c) an increased rate of serious incidents reported in accordance with Article 61 in respect of a specific category or group of devices;

(d) significant discrepancies in the conformity assessments carried out by different special notified bodies on substantially similar devices;

In the light of technical progress and any information which becomes available, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing these criteria.

In its request the ACMD shall indicate the scientifically valid health reason for having selected the specific file.

In the absence of request from the ACMD within 20 days of receipt of the information referred to in paragraph 1, the special notified body shall proceed with the conformity assessment procedure.

3. The ACMD, following the consultation of the relevant sub-groups, shall issue an opinion on the documents referred to in paragraph 2 at the latest 60 days after its submission. Within that period and at the latest 30 days after submission, the ACMD may request the submission of
additional information that for scientifically valid grounds are necessary for the analysis of the special notified body's preliminary conformity assessment. This may include a request for samples or an on-site visit to the manufacturer's premises. Until submission of the additional information requested, the period for comments referred to in the first sentence of this paragraph shall be suspended. Subsequent requests for additional information from the ACMD shall not suspend the period for the submission of comments.

4. In its opinion the ACMD may recommend modifications of the documents referred to in paragraph 2.

5. The ACMD shall inform the Commission, the special notified body and the manufacturer of its opinion within 5 days of its adoption.

6. Within 15 days after receipt of the opinion referred to in paragraph 5, the special notified body shall indicate whether or not it agrees with the opinion of the ACMD. In the latter case, it may give written notice to the ACMD that it wishes to request a re-examination of the opinion. In that case, the special notified body shall forward to the ACMD the detailed grounds for the request within 30 days after receipt of the opinion. The ACMD shall immediately transmit this information to the Commission.

Within 30 days following receipt of the grounds for the request, the ACMD shall re-examine its opinion. The reasons for the conclusion reached shall be annexed to the final opinion.

7. Within 15 days after its adoption, the ACMD shall send its final opinion to the Commission, the special notified body and the manufacturer.

8. Within 15 days after receipt of the
opinion referred to in paragraph 6 in case of agreement by the special notified body or of the final opinion as referred to in paragraph 7, the Commission shall prepare, on the basis of the opinion, a draft of the decision to be taken in respect of the examined application for conformity assessment. This draft decision shall include or make reference to the opinion referred to in paragraph 6 and 7 as applicable. Where the draft decision is not in accordance with the ACMD opinion, the Commission shall annex a detailed explanation of the reasons for the differences.

Within 30 days following receipt of the grounds for the request, the ACMD shall re-examine its opinion. The reasons for the conclusion reached shall be annexed to the final opinion.

7. Within 15 days after its adoption, the ACMD shall send its final opinion to the Commission, the special notified body and the manufacturer.

8. Within 15 days after receipt of the opinion referred to in paragraph 6 in case of agreement by the special notified body or of the final opinion as referred to in paragraph 7, the Commission shall prepare, on the basis of the opinion, a draft of the decision to be taken in respect of the examined application for conformity assessment. This draft decision shall include or make reference to the opinion referred to in paragraph 6 and 7, as applicable. Where the draft decision is not in accordance with the ACMD opinion, the Commission shall annex a detailed explanation of the reasons for the differences.

The draft decision shall be forwarded to the Member States, the special notified body and the manufacturer.

The Commission shall take a final decision in accordance with, and within 15 days after the end of, the examination
procedure referred to in Article 88(3).

9. Where deemed necessary for the protection of patient safety and public health, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 to determine, specific categories or groups of devices, other than devices referred to in paragraph 1, to which paragraphs 1 to 8 shall apply during a predefined period of time.

Measures pursuant to this paragraph may be justified only by one or more of the criteria referred to in paragraph 2.

10. The Commission shall make a summary of the opinion referred to in paragraph 6 and 7 accessible to the public. It shall not disclose any personal data or information of commercially confidential nature.

11. The Commission shall set up the technical infrastructure for the data-exchange by electronic means between special notified bodies and the ACMD and between the ACMD and itself for the purposes of this Article.

12. The Commission, by means of implementing acts, may adopt the modalities and the procedural aspects concerning the submission and analysis of the documentation provided in accordance with this Article. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).
1. The certificates issued by the notified bodies in accordance with Annexes VIII, IX and X shall be in an official Union language determined by the Member State in which the notified body is established or otherwise in an official Union language acceptable to the notified body. The minimum content of the certificates is set out in Annex XII.

Amendment 168

Proposal for a regulation
Article 45 – paragraph 3

Text proposed by the Commission

3. Where a notified body finds that requirements of this Regulation are no longer met by the manufacturer, it shall, taking account of the principle of proportionality, suspend or withdraw the certificate issued or impose any restrictions on it unless compliance with such requirements is ensured by appropriate corrective action taken by the manufacturer within an appropriate deadline set by the notified body. The notified body shall give the reasons for its decision.

Amendment

3. Before issuing a certificate, the notified conformity assessment body shall take into account any findings set out in the clinical investigation report referred to in Article 59(4). The certificates issued by the notified bodies in accordance with Annexes VIII, IX and X shall be in an official Union language determined by the Member State in which the notified body is established or otherwise in an official Union language acceptable to the notified body. The minimum content of the certificates is set out in Annex XII.

Amendment 169

Proposal for a regulation

Text proposed by the Commission

The notified body shall give the reasons for its decision and shall notify them to the competent authorities of the Member States in which the medical device is manufactured and placed on the market, the Commission and the MDCG.
Article 46 – paragraph 2 a (new)

Text proposed by the Commission

2a. It shall notify the competent authorities of the Member States affected by the manufacture and placing on the market of the relevant medical device, the Commission and the MDCG.

Amendment

Amendment 170

Proposal for a regulation

Article 47 – paragraph 1

Text proposed by the Commission

1. By way of derogation from Article 42, any competent authority may authorise, on duly justified request, the placing on the market or putting into service within the territory of the Member State concerned, of a specific device for which the procedures referred to in Article 42 have not been carried out and use of which is in the interest of public health or patient safety.

Amendment

1. By way of derogation from Article 42, any competent authority may authorise, on duly justified request, the placing on the market or putting into service within the territory of the Member State concerned, of a specific device for which the procedures referred to in Article 42 have not been carried out and use of which is in the interest of public health or patient safety, provided that the MDCG has authorised it. This derogation shall be possible only if the manufacturer submits the requisite clinical data to the competent authority within the prescribed period.

Amendment 171

Proposal for a regulation

Article 47 – paragraph 2

Text proposed by the Commission

2. The Member State shall inform the Commission and the other Member States of any decision to authorise the placing on the market or putting into service of a device in accordance with paragraph 1

Amendment

2. The Member State shall inform the Commission, the notified body responsible for assessing the relevant medical device, the MDCG and the other Member States of any decision to authorise the placing on the
where such authorisation is granted for use other than for a single patient.

market or putting into service of a device in accordance with paragraph 1 where such authorisation is granted for use other than for a single patient.

Amendment 172

Proposal for a regulation
Article 49 – paragraph 3

Text proposed by the Commission

3. Where demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be given based on the results of the manufacturer’s risk management and on consideration of the specifics of the interaction between the device and the human body, the clinical performances intended and the claims of the manufacturer. The adequacy of demonstration of conformity with the general safety and performance requirements based on the results of non-clinical testing methods alone, including performance evaluation, bench testing and pre-clinical evaluation, has to be duly substantiated in the technical documentation referred to in Annex II.

Amendment

3. **Except for class III devices**, where demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be given based on the results of the manufacturer’s risk management and on consideration of the specifics of the interaction between the device and the human body, the clinical performances intended and the claims of the manufacturer. The adequacy of demonstration of conformity with the general safety and performance requirements based on the results of non-clinical testing methods alone, including performance evaluation, bench testing and pre-clinical evaluation, has to be duly substantiated in the technical documentation referred to in Annex II.

**Exemption from demonstration of conformity with general safety and performance requirements based on clinical data under the first subparagraph shall be subject to prior approval by the competent authority.**

**Justification**

*To avoid a loop hole risking an easy opt-out from clinical evaluations, namely in what concerns high-risk devices.*
Amendment 173
Proposal for a regulation
Article 49 – paragraph 5 – subparagraph 1 a (new)

Text proposed by the Commission

Amendment

For devices classified as class III and implantable devices, the summary of safety and clinical performance referred to in Article 26(1) shall be updated at least annually with clinical evaluation reports.

Amendment 174
Proposal for a regulation
Article 50 – paragraph 1 – point a

(a) to verify that, under normal conditions of use, devices are designed, manufactured and packaged in such a way that they are suitable for one or more of the specific purposes of a medical device referred to in number (1) of Article 2(1), and achieve the performances intended as specified by the manufacturer;

(b) to verify the clinical safety and efficacy of the device, including the intended benefits to the patient, when used for the intended purpose, in the target population and in accordance with the instructions of use;

Amendment 175
Proposal for a regulation
Article 50 – paragraph 1 – point b

(b) to verify that devices achieve the intended benefits to the patient as specified by the manufacturer;
Amendment 176
Proposal for a regulation
Article 50 - paragraph 1 a (new)

Text proposed by the Commission

1a. For medical devices referred to in Article 43a(1) that are based on a new technology or use a new material, the clinical investigation shall be conducted against a comparator.

Amendment

Amendment 177
Proposal for a regulation
Article 51 – paragraph 2

Text proposed by the Commission

The sponsor of a clinical investigation shall submit an application to the Member State(s) in which the investigation is to be conducted accompanied by the documentation referred to in Chapter II of Annex XIV. Within six days after receipt of the application, the Member State concerned shall notify the sponsor whether the clinical investigation falls within the scope of this Regulation and whether the application is complete.

Amendment

The sponsor of a clinical investigation shall submit an application to the Member State(s) in which the investigation is to be conducted accompanied by the documentation referred to in Chapter II of Annex XIV. Within 14 days after receipt of the application, the Member State concerned shall notify the sponsor whether the clinical performance study falls within the scope of this Regulation and whether the application is complete. In case of more than one Member State concerned, where a Member State disagrees with the coordinating Member State on whether the clinical investigation should be approved, on grounds other than intrinsically national, local or ethical concerns, the Member States concerned shall make an attempt to agree on a conclusion. If no conclusion is found, the Commission shall take a decision after having consulted the Member States concerned, and if appropriate, having taken advice from the MDCG. In case where the concerned Member States object the clinical investigation for
intrinsically national, local or ethical concerns the clinical investigation should not take place in the Member States concerned.

Where the Member State has not notified the sponsor within the time period referred to in the first subparagraph, the clinical investigation shall be considered as falling within the scope of this Regulation and the application shall be considered complete.

Amendment 178

Proposal for a regulation

Article 51 – paragraph 3 – subparagraph 3

Text proposed by the Commission

Where the Member State has not notified the sponsor according to paragraph 2 within three days following receipt of the comments or of the completed application, the clinical investigation shall be considered as falling within the scope of this Regulation and the application shall be considered complete.

Amendment

Where the Member State has not notified the sponsor according to paragraph 2 within six days following receipt of the comments or of the completed application, the clinical investigation shall be considered as falling within the scope of this Regulation and the application shall be considered complete.

Amendment 179

Proposal for a regulation

Article 51 – paragraph 5 – point c

Text proposed by the Commission

(c) after the expiry of 35 days after the validation date referred to in paragraph 4, unless the Member State concerned has notified the sponsor within that period of its refusal based on considerations of public health, patient safety or public policy.

Amendment

(c) after the expiry of 60 days after the validation date referred to in paragraph 4, unless the Member State concerned has notified the sponsor within that period of its refusal based on considerations of public health, patient safety or public policy.
Amendment 180

Proposal for a regulation
Article 51 – paragraph 6

Text proposed by the Commission

6. Member States shall ensure that the persons assessing the application do not have conflicts of interest and that they are independent of the sponsor, the institution of the investigation site(s) and the investigators involved, as well as free of any other undue influence.

Member States shall ensure that the assessment is done jointly by a reasonable number of persons who collectively have the necessary qualifications and experience. In the assessment, the view of at least one person whose primary area of interest is non-scientific shall be taken into account. The view of at least one patient shall be taken into account.

Amendment

6. Member States shall ensure that the persons assessing the application do not have conflicts of interest and that they are independent of the sponsor, the institution of the investigation site(s) and the investigators involved, as well as free of any other undue influence.

Member States shall ensure that the assessment is done jointly by a reasonable number of persons who collectively have the necessary qualifications and experience. In the assessment, the view of at least one person whose primary area of interest is non-scientific shall be taken into account. The view of patients shall be taken into account.

The list of the reviewers should be made available to the sponsor

Amendment 181

Proposal for a regulation
Article 51 – paragraphs 6 a-e (new)

Text proposed by the Commission

6a. Every step in the clinical investigation, from first consideration of the need and justification for the study to the publication of the results, shall be carried out in accordance with recognised ethical principles, such as those laid down in the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects adopted by the 18th World Medical Assembly in Helsinki in 1964 and last amended by the 59th World Medical Association General Assembly in Seoul in

Amendment
6b. Authorisation by the concerned Member State for conducting a clinical investigation under this Article shall be granted only after examination and approval by an independent ethics committee in accordance with the World Medical Association’s Declaration of Helsinki.

6c. The examination of the Ethics Committee shall cover in particular the medical justification for the clinical investigation, the consent of the test subjects participating in the clinical investigation following the provision of full information about the clinical investigation and the suitability of the investigators and investigation facilities.

The ethics committee shall act in accordance with the respective laws and regulations of the country or countries in which the investigation is to be conducted and must abide by all relevant international norms and standards. It shall also work with such efficiency as to enable the Member State concerned to comply with the procedural deadlines set out in this Chapter.

The ethics committee shall be made up of an appropriate number of members, who together are in possession of the relevant qualifications and experience in order to be able to assess the scientific, medical and ethical aspects of the clinical investigation under scrutiny.

The members of the Ethics Committee assessing the application for a clinical investigation shall be independent from the sponsor, the institution of the investigation site, and the investigators involved, as well as free of any other undue influence. Names, qualifications, and declaration of interest of the assessors of the application shall be made publicly available.
6d. Member States shall take the necessary measures to establish Ethics Committees in the field of clinical investigations where such committees do not exist, and to facilitate their work.

6e. The Commission shall facilitate cooperation of ethics committees and the sharing of best practices on ethical issues including the procedures and principles of ethical assessment.

The Commission shall develop guidelines on patient involvement in ethics committees, drawing upon existing good practices.

Amendment 182
Proposal for a regulation
Article 52 – paragraph 1 – point g a (new)

Text proposed by the Commission

Amendment

(ga) the methodology to be used, the number of subjects involved and the intended result of the study.

Amendment 183
Proposal for a regulation
Article 52 – paragraph 2 a (new)

Text proposed by the Commission

Amendment

2a. Upon completion of the clinical investigation, the sponsor shall enter in the electronic system referred to in Article 53a summary of its results drawn up in a way that is easy for a lay person to understand.

Amendment 184
Proposal for a regulation
Article 52 – paragraph 3 – point b

Text proposed by the Commission

(b) protection of commercially sensitive information;

Amendment

(b) protection of commercially sensitive information; data on adverse events and safety data shall not be considered commercially sensitive information;

Amendment 185

Proposal for a regulation

Article 53

Text proposed by the Commission

1. The Commission shall, in collaboration with the Member States, set up and manage an electronic system to create the single identification numbers for on clinical investigations referred to in Article 51(1) and to collate and process the following information:

(a) the registration of on clinical investigations in accordance with Article 52;

(b) the exchange of information between the Member States and between them and the Commission in accordance with Article 56;

(c) the information related to on clinical investigations conducted in more than one Member State in case of a single application in accordance with Article 58;

(d) the reports on serious adverse events and device deficiencies referred to in Article 59(2) in case of single application in accordance with Article 58.

2. When setting up the electronic system referred in paragraph 1, the Commission shall ensure that it is interoperable with the

Amendment

1. The Commission shall, in collaboration with the Member States, set up and manage an electronic system to create the single identification numbers for on clinical investigations referred to in Article 51(1) and to collate and process the following information:

(a) the registration of on clinical investigations in accordance with Article 52;

(b) the exchange of information between the Member States and between them and the Commission in accordance with Article 56;

(c) the information related to on clinical investigations conducted in more than one Member State in case of a single application in accordance with Article 58;

(d) the reports on serious adverse events and device deficiencies referred to in Article 59(2) in case of single application in accordance with Article 58.

(da) the clinical investigation report and summary submitted by the sponsor in accordance with Article 57(3)

2. When setting up the electronic system referred in paragraph 1, the Commission shall ensure that it is interoperable with the
EU database for clinical trials on medicinal products for human use set up in accordance with Article […] of Regulation (EU) No [Ref. of future Regulation on clinical trials]. With the exception of the information referred to in Article 52, the information collated and processed in the electronic system shall be accessible only to the Member States and to the Commission.

3. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 determining which other information regarding clinical investigations collated and processed in the electronic system shall be publicly accessible to allow interoperability with the EU database for clinical trials on medicinal products for human use set up by Regulation (EU) No […]/. Article 52(3) and (4) shall apply.

EU database for clinical trials on medicinal products for human use set up in accordance with Article […] of Regulation (EU) No [Ref. of future Regulation on clinical trials]. With the exception of the information referred to in Article 52 and in points (d) and (da) of Article 53, the information collated and processed in the electronic system shall be accessible only to the Member States and to the Commission. The Commission shall also ensure that healthcare professionals have access to the electronic system.

The information referred to in points (d) and (da) of Article 53 shall be accessible to the public in accordance with Article 52(3) and (4).

2a. Upon a reasoned request, all information on a specific medical device available in the electronic system shall be made accessible to the party requesting it, save where the confidentiality of all or parts of the information is justified in accordance with Article 52(3).

3. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 determining which other information regarding clinical investigations collated and processed in the electronic system shall be publicly accessible to allow interoperability with the EU database for clinical trials on medicinal products for human use set up by Regulation (EU) No […]/. Article 52(3) and (4) shall apply.

Amendment 186

Proposal for a regulation
Article 55 – paragraph 2 a (new)

Text proposed by the Commission

2a. Assessment by the Member State of
the request by the sponsor for a substantial modification to a clinical investigation shall be in accordance with Article 51(6).

Amendment 187
Proposal for a regulation
Article 56 – paragraph 1

Text proposed by the Commission

1. Where a Member State has refused, suspended or terminated a clinical investigation, or has called for a substantial modification or temporary halt of a clinical investigation, or has been notified by the sponsor of the early termination of a clinical investigation on safety grounds, that Member State shall communicate its decision and the grounds therefor to all Member States and the Commission by means of the electronic system referred to in Article 53.

Amendment

1. Where a Member State has refused, suspended or terminated a clinical investigation, or has called for a substantial modification or temporary halt of a clinical investigation, or has been notified by the sponsor of the early termination of a clinical investigation on safety or efficacy grounds, that Member State shall communicate such facts and its decision and the grounds for that decision to all Member States and the Commission by means of the electronic system referred to in Article 53.

Amendment 188
Proposal for a regulation
Article 57 – paragraph 1

Text proposed by the Commission

1. If the sponsor has temporarily halted a clinical investigation on safety grounds, he shall inform the Member States concerned within 15 days of the temporary halt.

Amendment

1. If the sponsor has temporarily halted a clinical investigation on safety or efficacy grounds, he shall inform the Member States concerned within 15 days of the temporary halt.

Amendment 189
Proposal for a regulation  
Article 57 – paragraph 2

Text proposed by the Commission

2. The sponsor shall notify each Member State concerned of the end of a clinical investigation in relation to that Member State, providing a justification in the event of early termination. That notification shall be made within 15 days from the end of the clinical investigation in relation to that Member State.

Amendment

2. The sponsor shall notify each Member State concerned of the end of a clinical investigation in relation to that Member State, providing a justification in the event of early termination, so that all Member States can inform sponsors conducting similar clinical investigations at the same time within the Union of the results of that clinical investigation. That notification shall be made within 15 days from the end of the clinical investigation in relation to that Member State.

If the investigation is conducted in more than one Member State the sponsor shall notify all Member States concerned of the overall end of the clinical investigation. That notification shall be made within 15 days from the overall end of the clinical investigation.

Amendment 190

Proposal for a regulation  
Article 57 - paragraph 3

Text proposed by the Commission

3. Within one year from the end of the clinical investigation, the sponsor shall submit to the Member States concerned a summary of the results of the clinical investigation.

Amendment

3. Irrespective of the outcome of the clinical investigation, within one year from the end of the clinical performance study or from its early termination, the
Where, for scientific reasons, it is not possible to submit the clinical investigation report within one year, it shall be submitted as soon as it is available. In this case, the clinical investigation plan referred to in Section 3 of Chapter II of Annex XIV shall specify when the results of the clinical investigation are going to be submitted, together with an explanation.

Where, for justified scientific reasons, it is not possible to submit the clinical investigation report within one year, it shall be submitted as soon as it is available. In this case, the clinical investigation plan referred to in Section 3 of Chapter II of Annex XIV shall specify when the results of the clinical investigation are going to be submitted, together with a justification.

3a. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 in order to define the content and structure of the layperson's summary.

The Commission shall be empowered to adopt delegated acts in accordance with Article 89 in order to establish rules for the communication of the clinical investigation report.

For cases where the sponsor decides to share raw data on a voluntary basis, the Commission shall produce guidelines for the formatting and sharing of the data.

Amendment 191

Proposal for a regulation
Article 58 – paragraph 1

Text proposed by the Commission

1. By means of the electronic system referred to in Article 53, the sponsor of a

Amendment

1. By means of the electronic system referred to in Article 53, the sponsor of a
clinical investigation to be conducted in more than one Member State may submit, for the purpose of Article 51, the application that, upon receipt, is transmitted electronically to the Member States concerned.

Justification

The possibility to file via the Database should be available in the case of all studies, even when the study is conducted in only one Member State.

Amendment 192

Proposal for a regulation
Article 58 – paragraph 2

Text proposed by the Commission

2. In the single application, the sponsor shall propose one of the Member States concerned as coordinating Member State. If that Member State does not wish to be the coordinating Member State, it shall agree, within six days of submission of the single application, with another Member State concerned that the latter shall be the coordinating Member State. If no other Member State accepts to be the coordinating Member State, the Member State proposed by the sponsor shall be the coordinating Member State. If another Member State than the one proposed by the sponsor becomes coordinating Member State, the deadline referred to in Article 51(2) shall start on the day following the acceptance.

Amendment

2. Concerned Member States shall agree, within six days of submission of the single application, which Member State shall be the coordinating Member State. Member States and the Commission shall agree, in the framework of the attributions of the MDCG, on clear rules for designating the coordinating Member State.

Justification

The solution proposed by the Commission text allows sponsors to cherry pick the competent authorities applying less stringent standards, those less resourced or overburdened with high number of requests which aggravates the proposed tacit approval of clinical investigations. A framework for deciding on the coordinating Member State can be set up by the already proposed MDCG, in line with its tasks described in Article 80.
Amendment 193

Proposal for a regulation
Article 58 – paragraph 3 – subparagraph 2 – point b

Text proposed by the Commission
(b) establish the results of the coordinated assessment in a report to be taken into account by the other Member States concerned when deciding on the sponsor's application in accordance with Article 51(5).

Amendment
(b) establish the results of the coordinated assessment in a report to be approved by the other Member States concerned when deciding on the sponsor's application in accordance with Article 51(5).

Amendment 194

Proposal for a regulation
Article 58 – paragraph 5

Text proposed by the Commission
5. For the purpose of Article 57(3), the sponsor shall submit the clinical performance study report to the Member States concerned by means of the electronic system referred to in Article 53.

Amendment
deleted

Amendment 195

Proposal for a regulation
Article 59 – paragraph 1 – subparagraph 1 a (new)

Text proposed by the Commission
Information regarding incidents that are caused by user errors shall also be collected, as they are a major source of incidents with medical devices. This information shall contribute to improve the safety and knowledge of the device.

Amendment
Amendment 196
Proposal for a regulation
Article 59 – paragraph 1 – subparagraph 1 b (new)

Text proposed by the Commission

Amendment

Member States shall put in place non-electronic formats of reporting to ensure that patients who do not have online access are able to report.

Amendment 197
Proposal for a regulation
Article 59 – paragraph 4 – subparagraph 1

Text proposed by the Commission

Amendment

In the case of a clinical investigation for which the sponsor has used the single application referred to in Article 58, the sponsor shall report any event as referred to in paragraph 2 by means of the electronic system referred to in Article 53. Upon receipt, this report shall be transmitted electronically to all Member States concerned.

In the case of a clinical investigation for which the sponsor has used the single application referred to in Article 58, the sponsor shall report any event as referred to in paragraphs 1 and 2 by means of the electronic system referred to in Article 53. Upon receipt, this report shall be transmitted electronically to all Member States concerned.

Amendment 198
Proposal for a regulation
Article 61

Text proposed by the Commission

Amendment

1. Manufacturers of devices other than custom-made or investigational devices, shall report through the electronic system referred to in Article 62 the following:

(a) any serious incident in respect of devices made available on the Union market;

1. Manufacturers of devices other than custom-made or investigational devices, shall report through the electronic system referred to in Article 62 the following:

(a) any incident, including date and place of incident, with an indication of whether it is serious in accordance with the definition under Article 2, in respect of devices made available on the Union market;
(b) any field safety corrective action in respect of devices made available on the Union market, including any field safety corrective action undertaken in a third country in relation to a device which is also legally made available on the Union market if the reason for the field safety corrective action is not limited to the device made available in the third country.

Manufacturers shall make the report referred to in the first subparagraph without delay, and no later than 15 days after they have become aware of the event and the causal relationship with their device or that such causal relationship is reasonably possible. The time period for reporting shall take account of the severity of the incident. Where necessary to ensure timely reporting, the manufacturer may submit an initial incomplete report followed up by a complete report.

2. For similar serious incidents occurring with the same device or device type and for which the root cause has been identified or the field safety corrective action implemented, manufacturers may provide periodic summary reports instead of individual incident reports, on condition that the competent authorities referred to in points (a), (b) and (c) of Article 62(5) have agreed with the manufacturer on the format, content and frequency of the periodic summary reporting.

3. The Member States shall take all appropriate measures to encourage healthcare professionals, users and patients to report to their competent authorities suspected serious incidents referred to in point (a) of paragraph 1.
They shall record such reports centrally at national level. Where a competent authority of a Member State obtains such reports, it shall *take the necessary steps to ensure that* the manufacturer of the device concerned is informed of the incident. The manufacturer shall ensure the appropriate follow-up.

The Member States shall *coordinate between them the development of* standard *web-based structured* forms for reporting of *serious* incidents by healthcare professionals, users and patients.

4. Manufacturers of custom-made devices shall report any *serious* incidents and field safety corrective actions referred to in paragraph 1 to the competent authority of the Member State in which the device in question has been made available.

*Amendment 199*

**Proposal for a regulation**  
**Article 62**

*Text proposed by the Commission*  
1. The Commission shall, in collaboration with the Member States, set up and manage an electronic system to collate and process the following information:

   (a) the reports by manufacturers on *serious* incidents and field safety corrective actions

*Amendment*  
1. The Commission shall, in collaboration with the Member States, set up and manage an electronic system to collate and process the following information:

   (a) the reports by manufacturers on incidents and field safety corrective actions
referred to in Article 61(1);
(b) the periodic summary reports by manufacturers referred to in Article 61(2);
(c) the reports by competent authorities on serious incidents referred to in the second subparagraph of Article 63(1);
(d) the reports by manufacturers on trends referred to in Article 64;
(e) the field safety notices by manufacturers referred to in Article 63(5);
(f) the information to be exchanged between the competent authorities of the Member States and between them and the Commission in accordance with Article 63(4) and (7).

2. The information collated and processed by the electronic system shall be accessible to the competent authorities of the Member States, to the Commission and to the notified bodies.

3. The Commission shall ensure that healthcare professionals and the public have appropriate levels of access to the electronic system.

4. On the basis of arrangements between the Commission and competent authorities of third countries or international organisations, the Commission may grant those competent authorities or international organisations access to the database at the appropriate level. Those arrangements shall be based on reciprocity and make provision for confidentiality and data protection equivalent to those applicable in the Union.

5. The reports on serious incidents and referred to in Article 61(1);
(b) the periodic summary reports by manufacturers referred to in Article 61(2);
(c) the reports by competent authorities on incidents referred to in the second subparagraph of Article 63(1);
(d) the reports by manufacturers on trends referred to in Article 64;
(e) the field safety notices by manufacturers referred to in Article 63(5);
(f) the information to be exchanged between the competent authorities of the Member States and between them and the Commission in accordance with Article 63(4) and (7).

2. The information collated and processed by the electronic system shall be accessible to the competent authorities of the Member States, to the Commission, to the notified bodies, to healthcare professionals and also to manufacturers where the information pertains to their own product.

3. The Commission shall ensure that the public has an appropriate level of access to the electronic system. In case where information is requested on a specific medical device, that information shall be made available without delay and within 15 days at the latest.

4. On the basis of arrangements between the Commission and competent authorities of third countries or international organisations, the Commission may grant those competent authorities or international organisations access to the database at the appropriate level. Those arrangements shall be based on reciprocity and make provision for confidentiality and data protection equivalent to those applicable in the Union.

5. The reports on serious incidents and
field safety corrective actions referred to in points (a) and (b) of Article 61(1), the periodic summary reports referred to in Article 61(2), the reports on serious incidents referred to in the second subparagraph of Article 63(1) and the trend reports referred to in Article 64 shall be automatically transmitted upon receipt via the electronic system to the competent authorities of the following Member States:

(a) the Member State where the incident occurred;
(b) the Member State where the field safety corrective action is being or is to be undertaken;
(c) the Member State where the manufacturer has his registered place of business;
(d) where applicable, the Member State where the notified body, that issued a certificate in accordance with Article 45 for the device in question, is established.

5 a. The reports and information referred to in Article 62(5), shall also be automatically transmitted for the device in question via the electronic system to the notified body that issued the certificate in accordance with Article 45.

Amendment 200
Proposal for a regulation
Article 63 – paragraph 1 – subparagraph 1

Text proposed by the Commission
Member States shall take the necessary steps to ensure that any information regarding a serious incident that has occurred within their territory or a field safety corrective action that has been or is to be undertaken within their territory, and that is brought to their knowledge in accordance with Article 61 is, at national level,

Amendment
Member States shall take the necessary steps to ensure that any information regarding an incident that has occurred within their territory or a field safety corrective action that has been or is to be undertaken within their territory, and that is brought to their knowledge in accordance with Article 61 is, at national level,
level, evaluated centrally by their competent authority, if possible together with the manufacturer. The competent authority shall take into account the views of all relevant stakeholders, including patient and healthcare professionals' organisations.

Amendment 201
Proposal for a regulation
Article 63 – paragraph 1 – subparagraph 2

Text proposed by the Commission

If in the case of reports received in accordance with Article 61(3) the competent authority ascertains that the reports relate to a serious incident it shall notify without delay those reports to the electronic system referred to in Article 62, unless the same incident has already been reported by the manufacturer.

Amendment

2. The national competent authorities shall carry out a risk assessment with regard to reported serious incidents or field safety corrective actions, taking into account criteria such as causality, detectability and probability of recurrence of the problem, frequency of use of the device, probability of occurrence of harm and severity of harm, clinical benefit of the device, intended and potential users, and population affected. They shall also evaluate the adequacy of the field safety corrective action envisaged or undertaken by the manufacturer and the need for and
kind of any other corrective action. They shall monitor the manufacturer's investigation of the incident. action. They shall monitor the manufacturer's investigation of the incident, as well as they shall take into account patients' opinions.

Amendment 203
Proposal for a regulation
Article 63 – paragraph 3 – subparagraph 1

Text proposed by the Commission

In the case of devices referred to in the first subparagraph of Article 1(4) and where the serious incident or field safety corrective action may be related to a substance which, if used separately, would be considered to be a medicinal product, the evaluating competent authority or the coordinating competent authority referred to in paragraph 6 shall inform the relevant competent authority for medicinal products, or the European Medicines Agency (EMA), that was consulted by the notified body in accordance with the second subparagraph of Article 42(2).

Amendment

In the case of devices referred to in the first subparagraph of Article 1(4) and where the incident or field safety corrective action may be related to a substance which, if used separately, would be considered to be a medicinal product, the evaluating competent authority or the coordinating competent authority referred to in paragraph 6 shall inform the relevant competent authority for medicinal products, or the EMA, that was consulted by the notified body in accordance with the second subparagraph of Article 42(2).

Amendment 204
Proposal for a regulation
Article 63 – paragraph 3 – subparagraph 2

Text proposed by the Commission

In the case of devices covered by this Regulation in accordance with point (e) of Article 1(2) and where the serious incident or field safety corrective action may be related to the tissues or cells of human origin utilised for the manufacture of the device, the competent authority or the coordinating competent authority referred to in paragraph 6 shall inform the relevant competent authority for human tissues and

Amendment

In the case of devices covered by this Regulation in accordance with point (e) of Article 1(2) and where the incident or field safety corrective action may be related to the tissues or cells of human origin utilised for the manufacture of the device, the competent authority or the coordinating competent authority referred to in paragraph 6 shall inform the relevant competent authority for human tissues and
cells that was consulted by the notified body in accordance with the third subparagraph of Article 42(2).

cells that was consulted by the notified body in accordance with the third subparagraph of Article 42(2).

Amendment 205
Proposal for a regulation
Article 63 – paragraph 4

Text proposed by the Commission

4. After carrying out the assessment, the evaluating competent authority shall, through the electronic system referred to in Article 62, inform without delay the other competent authorities of the corrective action taken or envisaged by the manufacturer or imposed on him to minimise the risk of recurrence of a serious incident, including information on the underlying events and the outcome of its assessment.

Amendment

4. After carrying out the assessment, the evaluating competent authority shall, through the electronic system referred to in Article 62, inform without delay the other competent authorities of the corrective action taken or envisaged by the manufacturer or imposed on him to minimise the risk of recurrence, including information on the underlying events and the outcome of its assessment.

Amendment 206
Proposal for a regulation
Article 63 – paragraph 6 – subparagraph 1 – point a

Text proposed by the Commission

(a) where similar serious incidents related to the same device or type of device of the same manufacturer occur in more than one Member State;

Amendment

(a) where similar incidents related to the same device or type of device of the same manufacturer occur in more than one Member State;

Amendment 207
Proposal for a regulation
Article 63 – paragraph 7 – subparagraph 1 – point a
(a) to monitor the investigation of the serious incident by the manufacturer and the corrective action to be taken;

Amendment

(a) to monitor the investigation of the incident by the manufacturer and the corrective action to be taken;

Amendment 208

Proposal for a regulation
Article 63 – paragraph 7 – subparagraph 1 – point b

Text proposed by the Commission

(b) to consult with the notified body that issued a certificate in accordance with Article 45 for the device in question regarding the impact of the serious incident on the certificate;

Amendment

(b) to consult with the notified body that issued a certificate in accordance with Article 45 for the device in question regarding the impact of the incident on the certificate;

Amendment 209

Proposal for a regulation
Article 63 a (new)

Text proposed by the Commission

Article 63 a

Periodic safety update reports

1. Manufacturers of medical devices classified as class III shall report to the electronic system referred to in Article 62:

(a) summaries of data relevant to the benefits and risks of the medical devices, including results of all studies with a consideration of their potential impact on the certification;

(b) a scientific evaluation of the risk-benefit ratio of the medical device;

(c) all data relating to the volume of sales of the medical devices including an estimate of the population exposed to the
2. Manufacturers shall submit periodic safety update reports to the competent authorities immediately upon request or at least once a year during the first 2 years following initial placing on the market of that medical device.

3. The MDCG shall assess the periodic safety update reports to determine whether there are new risks or whether risks have changed, or whether there are changes to the risk-benefit ratio of the medical device.

4. Following the assessment of the periodic safety update reports, the MDCG shall consider whether any action regarding the medical device concerned is necessary. The MDCG shall inform the notified body in case of unfavourable scientific assessment. In this case, the notified body shall maintain, vary, suspend or revoke the authorisation as appropriate.

Amendment 210

Proposal for a regulation
Article 64 – paragraph 1

Text proposed by the Commission

Manufacturers of devices classified in class IIb and III shall report to the electronic system referred to in Article 62 any statistically significant increase in the frequency or severity of incidents that are not serious incidents or of expected undesirable side-effects that have a significant impact on the risk-benefit analysis referred to in Sections 1 and 5 of Annex I and which have led or may lead to unacceptable risks to the health or safety of patients, users or other persons when weighted against the intended benefits. The significant increase shall be established in
significant increase shall be established in comparison to the foreseeable frequency or severity of such incidents or expected undesirable side-effects in respect of the device, or category or group of devices, in question during a specific time period as established in the manufacturer's conformity assessment. Article 63 shall apply.

Amendment 211

Proposal for a regulation
Article 64 a (new)

Text proposed by the Commission

Amendment

Article 64a

Medical devices which fall under legal acts of the European Union concerning the quality and safety of blood

1. This Regulation is without prejudice to existing and implemented provisions at European level relating to the collection, testing, processing, storage and distribution of blood and blood components.

3. This Regulation is without prejudice to national laws and Union legislation in the field of traceability and vigilance in the field of blood and blood components which have a higher standard than this Regulation. They should be retained in the interests of patients.

Amendment 212

Proposal for a regulation
Article 66 – paragraph 1 – point a
(a) typology of serious incidents and field safety corrective actions in relation to specific devices, or categories or groups of devices;

**Amendment 213**

**Proposal for a regulation**
**Article 66 – paragraph 1 – point b**

**Text proposed by the Commission**
(b) harmonised forms for the reporting of serious incidents and field safety corrective actions, periodic summary reports and trend reports by manufacturers as referred to in Articles 61 and 64;

**Amendment**
(b) typology of incidents and field safety corrective actions in relation to specific devices, or categories or groups of devices;

**Amendment 214**

**Proposal for a regulation**
**Article 66 – paragraph 1 – point c**

**Text proposed by the Commission**
(c) timelines for the reporting of serious incidents and field safety corrective actions, periodic summary reports and trend reports by manufacturers, taking into account the severity of the event to be reported as referred to in Articles 61 and 64;

**Amendment**
(c) timelines for the reporting of incidents and field safety corrective actions, periodic summary reports and trend reports by manufacturers, taking into account the severity of the event to be reported as referred to in Articles 61 and 64;

**Amendment 215**

**Proposal for a regulation**
**Article 66 – paragraph 2 – subparagraph 1 a (new)**
In drafting the implementing acts, the Commission shall seek the prior advice of the MDAC.

Amendment 216

Proposal for a regulation
Article 67

1. The competent authorities shall perform appropriate checks on the characteristics and performance of devices including, where appropriate, review of documentation and physical or laboratory checks on the basis of adequate samples. They shall take account of established principles regarding risk assessment and risk management, vigilance data and complaints. The competent authorities may require economic operators to make available the documentation and information necessary for the purpose of carrying out their activities and, where necessary and justified, enter the premises of economic operators and take the necessary samples of devices. They may destroy or otherwise render inoperable devices presenting a serious risk where they deem it necessary.

1a. The competent authorities shall designate inspectors who shall be empowered to carry out the checks referred to in paragraph 1. The checks shall be carried out by the inspectors of the Member State in which the economic operator is located. These inspectors may be assisted by experts appointed by the competent authorities.

1b. Unannounced inspections may also be carried out. The organisation and implementation of such inspections shall
always take account of the principle of proportionality, particularly with reference to the hazard potential of a particular product.

1c. Following each inspection carried out under paragraph 1, the competent authority shall draw up a report on compliance by the economic operator inspected with the legal and technical requirements applicable under this Regulation and any corrective actions needed.

1d. The competent authority which carried out the inspection shall communicate the content of this report to the inspected economic operator. Before adopting the report, the competent authority shall give the inspected economic operator the opportunity to submit comments. The final inspection report as referred to in paragraph 1b shall be entered into the electronic system provided for in Article 68.

1e. Without prejudice to any international agreements concluded between the Union and third countries, checks as referred in paragraph 1 may also take place in the premises of an economic operator located in a third country, if the device is intended to be made available on the Union market.

2. The Member States shall periodically review and assess the functioning of their surveillance activities. Such reviews and assessments shall be carried out at least every four years and the results thereof shall be communicated to the other Member States and the Commission. The Member State concerned shall make a summary of the results accessible to the public.

2. The Member States shall draw up strategic surveillance plans covering their planned surveillance activities, as well as the human and material resources needed to carry these activities out. Member States shall periodically review and assess the implementation of their surveillance plans. Such reviews and assessments shall be carried out at least every two years and the results thereof shall be communicated to the other Member States and the Commission. The Commission may make recommendations for adjustments to the surveillance plans. The Member States shall make a summary of the results and of
the Commission’s recommendations accessible to the public.

Amendment 217

Proposal for a regulation
Article 68 – paragraph 2

Text proposed by the Commission

2. The information mentioned in paragraph 1 shall be immediately transmitted through the electronic system to all competent authorities concerned and be accessible to the Member States and to the Commission.

Amendment

2. The information mentioned in paragraph 1 shall be immediately transmitted through the electronic system to all competent authorities concerned and be accessible to the Member States, to the Commission, to the notified bodies, to the EMA and to healthcare professionals. The Commission shall also ensure that the public has an appropriate level of access to the electronic system. In particular, it shall ensure that, in case information is requested on a specific medical device, it is made available without delay and within 15 days. The Commission, in consultation with the Medical Devices Coordination Group, shall provide an overview of this information, every 6 months, for the public and healthcare professionals. This information shall be accessible through the European databank in Article 27.

Justification

It is important that the Agency and healthcare professionals also have full access to the electronic system for market surveillance since it contains important information on devices presenting risk to health. While the public might have more differentiated access, if there is a legitimate interest in gaining knowledge of serious incidents concerning certain medical devices at an early stage, a comprehensive right to information must therefore be created. The integration of the notified bodies in the exchange of information of the market surveillance authorities must be extended and clearly defined. Particularly, the notified bodies need - within the framework of automated, harmonized communication procedures - consolidated information in order to recognize developments, take new in-formation immediately into account and react promptly and appropriately to occurrences and incidents, for example through post-controls, suspension or withdrawal of a certificate. Healthcare professionals and the public will benefit from an overview of vigilance and market
surveillance information. As this information will require sensitive handling, the MDCG is the appropriate forum for providing this information for the European Databank.

Amendment 218
Proposal for a regulation
Article 68 – paragraph 2 – subparagraph 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The information in to relation to Article 68 paragraph 1, points a, b, c and d shall be made available to the MDCG who shall communicate it at the first meeting of the MDAC after the information becomes available.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 219
Proposal for a regulation
Article 69 – paragraph 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Where the competent authorities of a Member State, based on vigilance data or other information, have sufficient reason to believe that a device presents a risk to the health or safety of patients, users or other persons, they shall carry out an evaluation in relation to the device concerned covering all the requirements laid down in this Regulation that are relevant to the risk presented by the device. The relevant economic operators shall cooperate as necessary with the competent authorities.</td>
<td></td>
</tr>
<tr>
<td>In connection with that evaluation, the competent authorities shall inform the notified assessment bodies, in the case of class IIa, IIb and III devices, and the other competent authorities of the findings of the evaluation and the measures that are to be taken on the basis of those findings.</td>
<td></td>
</tr>
</tbody>
</table>

Where the competent authorities of a Member State, based on vigilance data or other information, have sufficient reason to believe that a device presents a risk to the health or safety of patients, users or other persons, they shall carry out an evaluation in relation to the device concerned covering all the requirements laid down in this Regulation that are relevant to the risk presented by the device. The relevant economic operators shall cooperate as necessary with the competent authorities.
Amendment 220
Proposal for a regulation
Article 69 – paragraph 1 a (new)

Text proposed by the Commission

1a. Where the competent authorities of a Member State, based on vigilance data or other information, have reason to believe that a device presents a risk to the health or safety of patients, users or other persons, they may carry out an evaluation in relation to the device concerned covering all the requirements laid down in this Regulation that are relevant to the risk presented by the device. The relevant economic operators shall cooperate as necessary with the competent authorities.

Amendment 221
Proposal for a regulation
Article 70 – paragraph 1

Text proposed by the Commission

1. Where, having performed an evaluation pursuant to Article 69, the competent authorities find that the device, which presents a risk to the health or safety of patients, users or other persons, does not comply with the requirements laid down in this Regulation, they shall without delay require the relevant economic operator to take all appropriate and duly justified corrective action to bring the device into compliance with those requirements, to prohibit or restrict the making available of the device on the market, to subject the making available of the device to specific requirements, to withdraw the device from the market, or to recall it within a

Amendment

1. Where, having performed an evaluation pursuant to Article 69, the competent authorities find that the device, which presents a risk to the health or safety of patients, users or other persons, does not comply with the requirements laid down in this Regulation, they shall immediately require the relevant economic operator to take all appropriate and duly justified corrective action to bring the device into compliance with those requirements, to prohibit or restrict the making available of the device on the market, to subject the making available of the device to specific requirements, to withdraw the device from the market, or to recall it within a
reasonable period, proportionate to the nature of the risk.

reasonable period that is clearly defined and communicated to the relevant economic operator, proportionate to the nature of the risk.

Amendment 222
Proposal for a regulation
Article 70 – paragraph 2

Text proposed by the Commission

Article 70 – paragraph 2

2. Where the competent authorities consider that non-compliance is not restricted to their national territory, they shall inform the Commission and the other Member States of the results of the evaluation and of the actions which they have required the economic operators to take, by means of the electronic system referred to in Article 68.

Amendment

2. Where the competent authorities consider that non-compliance is not restricted to their national territory, they shall immediately inform the Commission and the other Member States of the results of the evaluation and of the actions which they have required the economic operators to take, by means of the electronic system referred to in Article 68.

Amendment 223
Proposal for a regulation
Article 70 – paragraph 3

Text proposed by the Commission

Article 70 – paragraph 3

3. The economic operators shall ensure that all appropriate corrective action is taken in respect of all the devices concerned that they have made available on the market throughout the Union.

Amendment

3. The economic operators shall without delay ensure that all appropriate corrective action is taken in respect of all the devices concerned that they have made available on the market throughout the Union.

Amendment 224
Proposal for a regulation
Article 70 – paragraph 3 – subparagraph 1 a (new)
Where the concerned devices are to be recalled, the economic operator shall make all reasonable efforts to complete the recall before the end of clearly defined period communicated to it by the competent authority as referred to in paragraph 1,

Amendment 225

Proposal for a regulation
Article 70 – paragraph 4 – subparagraph 2

Text proposed by the Commission
They shall notify the Commission and the other Member States, without delay, of those measures, by means of the electronic system referred to in Article 68.

Amendment
They shall notify the Commission and the other Member States, immediately, of those measures, by means of the electronic system referred to in Article 68.

Amendment 226

Proposal for a regulation
Article 70 – paragraph 6

Text proposed by the Commission
6. Member States other than the Member State initiating the procedure shall without delay inform the Commission and the other Member States of any additional information at their disposal relating to the non-compliance of the device concerned and of any measures adopted by them in relation to the device concerned. In the event of disagreement with the notified national measure, they shall without delay inform the Commission and the other Member States of their objections, by means of the electronic system referred to in Article 68.

Amendment
6. Member States other than the Member State initiating the procedure shall without delay inform the Commission and the other Member States of any additional information at their disposal relating to the non-compliance of the device concerned and of any measures adopted by them in relation to the device concerned. In the event of disagreement with the notified national measure, they shall immediately inform the Commission and the other Member States of their objections, by means of the electronic system referred to in Article 68.
Amendment 227
Proposal for a regulation
Article 70 – paragraph 7

Text proposed by the Commission

7. Where, within two months of receipt of the notification referred to in paragraph 4, no objection has been raised by either a Member State or the Commission in respect of a provisional measure taken by a Member State, that measure shall be deemed justified.

Amendment

7. Where, within one month of receipt of the notification referred to in paragraph 4, no objection has been raised by either a Member State or the Commission in respect of a provisional measure taken by a Member State, that measure shall be deemed justified.

Amendment 228
Proposal for a regulation
Article 70 – paragraph 8

Text proposed by the Commission

8. All Member States shall ensure that appropriate restrictive measures are taken without delay in respect of the device concerned.

Amendment

8. All Member States shall ensure that appropriate restrictive measures are taken immediately in respect of the device concerned.

Amendment 229
Proposal for a regulation
Article 71 – paragraph 1

Text proposed by the Commission

1. Where, within two months of receipt of the notification referred to in Article 70(4), objections are raised by a Member State against a provisional measure taken by another Member State, or where the Commission considers the measure to be contrary to Union legislation, the

Amendment

1. Where, within one month of receipt of the notification referred to in Article 70(4), objections are raised by a Member State against a provisional measure taken by another Member State, or where the Commission considers the measure to be contrary to Union legislation, the
Commission shall evaluate the national measure. On the basis of the results of that evaluation, the Commission shall decide, by means of implementing acts, whether or not the national measure is justified. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 230

Proposal for a regulation
Article 72 – paragraph 1

Text proposed by the Commission

1. Where, having performed an evaluation pursuant to Article 69, a Member State finds that although a device has been legally placed on the market or put into service, it presents a risk to the health or safety of patients, users or other persons or to other aspects of the protection of public health, it shall require the relevant economic operator or operators to take all appropriate provisional measures to ensure that the device concerned, when placed on the market or put into service, no longer presents that risk, to withdraw the device from the market or to recall it within a reasonable period, proportionate to the nature of the risk.

Amendment

1. Where, having performed an evaluation pursuant to Article 69, a Member State finds that although a device has been legally placed on the market or put into service, it presents a risk to the health or safety of patients, users or other persons or to other aspects of the protection of public health, it shall immediately require the relevant economic operator or operators to take all appropriate provisional measures to ensure that the device concerned, when placed on the market or put into service, no longer presents that risk, to withdraw the device from the market or to recall it within a reasonable period, proportionate to the nature of the risk.

Amendment 231

Proposal for a regulation
Article 73 – paragraph 1 – introductory part

Text proposed by the Commission

1. Without prejudice to Article 70, a Member State shall require the relevant economic operator to put an end to the non-compliance concerned within a

Amendment

1. Without prejudice to Article 70, a Member State shall require the relevant economic operator to put an end to the non-compliance concerned within a
reasonable period that is proportionate to the non-compliance where it makes one of the following findings:

reasonable period that is *clearly defined and communicated and that is* proportionate to the non-compliance where it makes one of the following findings:

### Amendment 232

**Proposal for a regulation**  
**Article 73 – paragraph 2**

**Text proposed by the Commission**

2. Where the economic operator does not put an end to the non-compliance within the period referred to in paragraph 1, the Member State concerned shall take all appropriate measures to restrict or prohibit the product being made available on the market or to ensure that it is recalled or withdrawn from the market. That Member State shall inform the Commission and the other Member States *without delay* of those measures, by means of the electronic system referred to in Article 68.

**Amendment**

2. Where the economic operator does not put an end to the non-compliance within the period referred to in paragraph 1, the Member State concerned shall *immediately* take all appropriate measures to restrict or prohibit the product being made available on the market or to ensure that it is recalled or withdrawn from the market. That Member State shall inform the Commission and the other Member States *immediately* of those measures, by means of the electronic system referred to in Article 68.

### Amendment 233

**Proposal for a regulation**  
**Article 74 – paragraph 1**

**Text proposed by the Commission**

1. Where a Member State, after having performed an evaluation which indicates a potential risk related to a device or a specific category or group of devices considers that the making available on the market or putting into service of such device or specific category or group of devices should be prohibited, restricted or made subject to particular requirements or that such device or category or group of devices should be withdrawn from the

**Amendment**

1. Where a Member State, after having performed an evaluation which indicates a potential risk related to a device or a specific category or group of devices considers that the making available on the market or putting into service of such device or specific category or group of devices should be prohibited, restricted or made subject to particular requirements or that such device or category or group of devices should be withdrawn from the
market or recalled in order to protect the health and safety of patients, users or other persons or other aspects of public health, it may take any necessary and justified provisional measures.

market or recalled in order to protect the health and safety of patients, users or other persons or other aspects of public health, it shall take any necessary and justified provisional measures.

Amendment 234
Proposal for a regulation
Article 75 – paragraph 2

Text proposed by the Commission

2. Except in cases where immediate action is necessary for reasons of serious risk to human health or safety, the economic operator concerned shall be given the opportunity to make submissions to the competent authority within an appropriate period of time before any measure is adopted. If action has been taken without the economic operator being heard, he shall be given the opportunity to make submissions as soon as possible and the action taken shall be reviewed promptly thereafter.

Amendment

2. Except in cases where immediate action is necessary for reasons of serious risk to human health or safety, the economic operator concerned shall be given the opportunity to make submissions to the competent authority within an appropriate period of time that is clearly determined before any measure is adopted. If action has been taken without the economic operator being heard, he shall be given the opportunity to make submissions as soon as possible and the action taken shall be reviewed promptly thereafter.

Amendment 235
Proposal for a regulation
Article 75 – paragraph 3

Text proposed by the Commission

3. Any measure adopted shall be immediately withdrawn or amended upon the economic operator's demonstrating that he has taken effective corrective action.

Amendment

3. Any measure adopted shall be immediately withdrawn or amended upon the economic operator's satisfactorily demonstrating that he has taken effective corrective action.
Amendment 236

Proposal for a regulation
Article 76 – paragraph 1

Text proposed by the Commission

1. The Member States shall designate the competent authority or authorities responsible for the implementation of this Regulation. They shall entrust their authorities with the powers, resources, equipment and knowledge necessary for the proper performance of their tasks pursuant to this Regulation. The Member States shall communicate the competent authorities to the Commission which shall publish a list of competent authorities.

Amendment

1. The Member States shall designate the competent authority or authorities responsible for the implementation of this Regulation. They shall entrust their authorities with the powers, resources, equipment and knowledge necessary for the proper performance of their tasks pursuant to this Regulation. The Member States shall communicate the competent authorities to the Commission which shall publish a list of competent authorities and their contact details.

Amendment 237

Proposal for a regulation
Article 77 – paragraph 1

Text proposed by the Commission

1. The competent authorities of the Member States shall cooperate with each other and with the Commission and exchange with each other the information necessary to enable this Regulation to be applied uniformly.

Amendment

1. The competent authorities of the Member States shall cooperate with each other and with the Commission and with the MDCG as appropriate and exchange with each other and the Commission the information necessary to enable this Regulation to be applied uniformly.

Amendment 238

Proposal for a regulation
Article 78 – paragraph 2 – subparagraph 2 a (new)

Text proposed by the Commission

The Commission shall verify the competence of the members of the

Amendment

The Commission shall verify the competence of the members of the
MDCG. The Commission shall make public the results of its verification in each instance and provide information about the competence of the members of the MDCG.

Justification

For the proper working of the regulation, the MDCG should be composed of persons with recognised and relevant competence in medical devices. The Article requires evidence of competence but does not clarify who should verify that competence. Competence needs to be verified and this should be a task of the Commission.

Amendment 239

Proposal for a regulation
Article 78 – paragraph 6

Text proposed by the Commission

Amendment

6. The MDCG may invite, on a case-by-case basis, experts and other third parties to attend meetings or provide written contributions.

deleted

Justification

Rather than on a case by case basis, an advisory committee providing directly specialist advice and expertise should be established to support the work of the Commission, the MDCG and Member States.

Amendment 240

Proposal for a regulation
Article 78 a (new)

Text proposed by the Commission

Amendment

Article 78a

Medical Device Advisory Committee

1. The Commission shall establish a multidisciplinary MDAC composed of experts and representatives of the relevant stakeholders in order to provide support, advice and expertise to the MDCG, the Commission and Member States on
technical, scientific, social and economic aspects of regulating medical devices and in vitro diagnostic medical devices, such as in the field of medical technology, borderline cases involving medicinal products, human tissues and cells, cosmetics, biocides, food and, if necessary, other products, as well as further aspects of the implementation of this Regulation.

2. When establishing the MDAC, the Commission shall ensure a broad, appropriate and balanced representation of the disciplines relevant for medical devices. The MDAC may establish under its responsibility expert panels for specific medical disciplines.

3. The MDAC shall be chaired by a representative of the Commission. The Commission shall provide the logistic support to its operations.

4. The MDAC shall establish its rules of procedure which shall enter into force after receiving a favourable opinion from the Commission.

5. The MDAC shall ensure an appropriate level of consultation of the EMA and the EFSA when deliberating borderline cases involving medicinal and food products.

6. The MDAC shall disclose the declarations of interest of its members.

NB: This AM is horizontal, whenever reference in adopted AMs is made to advisory committee, advisory group, advisory scientific board, it should be understood and replaced by MDAC

Amendment 241

Proposal for a regulation
Article 78b (new)

Text proposed by the Commission

Amendment

Article 78b

Assessment Committee for Medical

RR\1005935EN.doc 159/336 PE507.972v04-00
Devices

1. An ACMD is hereby established, under the principles of highest scientific competence, impartiality, transparency and to avoid potential conflicts of interest.

2. The ACMD shall be composed of sub-groups, in accordance with the medical fields referred to in paragraph 3. A Coordination Group shall be composed of the chairs of each sub-group, one representative of the EMA and three representatives of patients' organisations appointed by the Commission in a transparent manner after a call for interest, for a three-year term which may be renewed.

The Coordination Group shall meet on request from the Commission and its meetings shall be chaired by a Commission representative. The ACMD shall host as one special sub-group the Medical Device Advisory Committee, as referred to in Article 78a. The Commission shall ensure the secretariat of this Committee.

3. Each sub-group of the ACMD shall be composed of:

   a) Where available, each Member State may propose one expert, following a Union-wide call for expression of interest with a clear definition by the Commission of the requested profile. The publication of the call shall be widely advertised. Each expert shall be approved by the Commission and appointed for a three-year term which may be renewed, in the following fields:
      - Anaesthesiology;
      - Blood grouping or tissue typing;
      - Blood transfusion and transplantation;
      - Cardiology;
      - Communicable diseases;
      - Dentistry;
- Dermatology;
- Ear / Nose / Throat (ENT);
- Endocrinology;
- Gastroenterology;
- General/Plastic surgery;
- Medical genetics;
- Nephrology / Urology;
- Neurology;
- Obstetrics/Gynaecology;
- Oncology;
- Ophthalmology;
- Orthopaedics;
- Physical medicine;
- Pulmonology / Pneumology;
- Radiology.

b) One representative of the EMA, for a three-year term which may be renewed.

The Members of the sub-groups shall be chosen for their competence and experience in the corresponding field. They shall perform their tasks with impartiality and objectivity. They shall be completely independent and shall neither seek nor take instructions from any government, notified body or manufacturer. Each member shall draw up declaration of interests which shall be made publicly available.

In the light of technical progress and any information which becomes available, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing the fields referred to in point a of this paragraph.

4. The ACMD shall fulfil the tasks defined in Article 44a. When adopting its opinion, the members of the ACMD shall use their best endeavours to reach consensus. If consensus cannot be reached, the ACMD shall decide by the
majority of their members. In the case of the Coordination Group, the Commission shall not take part in votes. Diverging opinion shall be annexed to the ACMD opinion.

5. The ACMD shall establish its rules of procedure which shall, in particular, lay down procedures for the following:
- the adoption of opinions, including in case of urgency;
- the delegation of tasks to reporting and co-reporting members.

Amendment 242
Proposal for a regulation
Article 80

Text proposed by the Commission

Article 80
Tasks of the MDCG

The MDCG shall have the following tasks:
(a) to contribute to the assessment of applicant conformity assessment bodies and notified bodies pursuant to the provisions set out in Chapter IV;

Amendment

Article 80
Tasks of the MDCG

The MDCG shall have the following tasks:
(a) to contribute to the assessment of applicant conformity assessment bodies and notified bodies pursuant to the provisions set out in Chapter IV;

(ab) to establish and document the high level principles of competence and qualification and procedures for selection and authorisation of persons involved in conformity assessment activities (knowledge, experience and other competence required) and the required training (initial and ongoing). The qualification criteria shall address the various functions within the conformity assessment process as well as the devices, technologies and areas covered by the scope of designation;

(ac) to review and approve the criteria of the competent authorities of Member States in respect of article 80 - paragraph
(b) to contribute to the scrutiny of certain conformity assessments pursuant to Article 44;
(c) to contribute to the development of guidance aimed at ensuring effective and harmonised implementation of this Regulation, in particular regarding the designation and monitoring of notified bodies, application of the general safety and performance requirements and conduct of the clinical evaluation by manufacturers and the assessment by notified bodies;
(d) to assist the competent authorities of the Member States in their coordination activities in the fields of clinical investigations, vigilance and market surveillance;
(e) to provide advice and assist the Commission, at its request, in its assessment of any issue related to the implementation of this Regulation;
(f) to contribute to harmonised administrative practice with regard to medical devices in the Member States.

Amendment 243

Proposal for a regulation
Article 81 – paragraph 2 – point b
<table>
<thead>
<tr>
<th><strong>Text proposed by the Commission</strong></th>
<th><strong>Amendment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) to provide scientific advice regarding the state of the art in relation to specific devices, or a category or group of devices;</td>
<td>(b) to provide scientific advice and technical assistance regarding the definition of the state of the art in relation to specific devices, or a category or group of devices;</td>
</tr>
</tbody>
</table>

**Justification**

*Improved wording and clearer definition of the tasks of the Reference laboratories*

**Amendment 244**

Proposal for a regulation
Article 81 – paragraph 2 – point f

<table>
<thead>
<tr>
<th><strong>Text proposed by the Commission</strong></th>
<th><strong>Amendment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(f) to contribute to the development of standards at international level;</td>
<td>(f) to contribute to the development of CTS as well as of international standards</td>
</tr>
</tbody>
</table>

**Justification**

*Reference Laboratories will have the appropriate knowledge, experience and technical skills to contribute to the development of CTS. Improvement of the wording.*

**Amendment 245**

Proposal for a regulation
Article 81 – paragraph 2 – point ga(new)

<table>
<thead>
<tr>
<th><strong>Text proposed by the Commission</strong></th>
<th><strong>Amendment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(ga) to provide scientific opinions and technical assistance to the Commission in relation to the requalification of single-use devices as reusable devices.</td>
<td></td>
</tr>
</tbody>
</table>

---

**EN**
Amendment 246
Proposal for a regulation
Article 82 – paragraph 1

Text proposed by the Commission

1. Members of the MDCG and staff of the EU reference laboratories shall not have financial or other interests in the medical device industry which could affect their impartiality. They shall undertake to act in the public interest and in an independent manner. They shall declare any direct and indirect interests they may have in the medical device industry and update this declaration whenever a relevant change occurs. Upon request, the declaration of interests shall be accessible to the public. This Article shall not apply to the representatives of stakeholder organisations participating in the sub-groups of the MDCG.

Amendment

1. Members of the MDCG, of the advisory panels to the MDCG and staff of the EU reference laboratories shall not have financial or other interests in the medical device industry or in the supply chain which could affect their impartiality. They shall undertake to act in the public interest and in an independent manner. They shall declare any direct and indirect interests they may have in the medical device industry or in the supply chain and update this declaration whenever a relevant change occurs. The declaration of interests shall be made publicly available on the Commission website.

Amendment 247
Proposal for a regulation
Article 82 – paragraph 2

Text proposed by the Commission

2. Experts and other third parties invited by the MDCG on a case-by-case basis shall be requested to declare their interests in the issue in question.

Amendment

2. Experts participating in the advisory committee referred to in Article 78a shall be requested to declare their interests in the issue in question.

Amendment 248
Proposal for a regulation
Article 83 – paragraph 1

Text proposed by the Commission

The Commission and the Member States

Amendment

The Commission and the Member States
shall take all appropriate measures to encourage the establishment of registers for specific types of devices to gather post-market experience related to the use of such devices. Such registers shall contribute to the independent evaluation of the long-term safety and performance of devices.

shall take all appropriate measures to ensure the establishment of coordinated and harmonised registers for medical devices to gather post-market experience related to the use of such devices. Registers for medical devices in classes IIb and III shall be systematically established. Such registers shall contribute to the independent evaluation of the long-term safety and performance of devices.

Justification

The development of such registries shall be coordinated and harmonised to avoid a burdensome gathering of data of limited use and to ensure that the resources put into the development of registries are efficiently used. Only if registries are organised in a coordinated and harmonised way, they can be analysed together and provide valuable post-market safety information.

Amendment 249

Proposal for a regulation
Article 86

Justification

This Regulation shall be without prejudice to the possibility for Member States to levy fees for the activities set out in this Regulation, provided that the level of the fees is set in a transparent manner and on the basis of cost recovery principles. They shall inform the Commission and the other Member States at least three months before the structure and level of fees is to be adopted.

Amendment

This Regulation shall be without prejudice to the possibility for Member States to levy fees for the activities set out in this Regulation, provided that the level of the fees is set in a transparent manner and on the basis of cost recovery principles. They shall inform the Commission and the other Member States at least three months before the structure and level of fees is to be adopted. The structure and level of fees shall be publicly available on request.
The Member States shall lay down the provisions on penalties applicable for infringement of the provisions of this Regulation and shall take all measures necessary to ensure that they are implemented. The penalties provided for must be effective, proportionate, and dissuasive. The Member States shall notify those provisions to the Commission by [3 months prior to the date of application of the Regulation] and shall notify it without delay of any subsequent amendment affecting them.

Justification

In order to act as a deterrent to fraudulent conduct and ensure its effectiveness, the penalty should be significantly greater than the financial benefit obtained by the producer as a result of the infringement or fraud committed.

Amendment 251

Proposal for a regulation
Article 89 – paragraph 1

Text proposed by the Commission

1. The power to adopt the delegated acts referred to in Articles 2(2) and (3), 4(5), 8(2), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4), 42(11), 45(5), 51(7), 53(3), 74(4) and 81(6) is conferred on the Commission subject to the conditions laid down in this Article.

Amendment 252

Proposal for a regulation
Article 89 – paragraph 2

1. The power to adopt the delegated acts referred to in Articles 2(2) and (3), 15b (1), 16 (1), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4), 44a (2), 44a(9), 45(5), 51(7), 53(3), 57(3a), 74(4), 78b(3) and 81(6) is conferred on the Commission subject to the conditions laid down in this Article.
Text proposed by the Commission

2. The delegation of power referred to in Articles 2(2) and (3), 4(5), 8(2), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4), 42(11), 45(5), 51(7), 53(3), 74(4) and 81(6) shall be conferred on the Commission for an indeterminate period of time from the date of entry into force of this Regulation.

Amendment

2. The delegation of power referred to in Articles 2(2) and (3), 15b (1), 16 (1), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4), 44a (2), 44a(9), 45(5), 51(7), 53(3), 57(3a), 74(4), 78b(3) and 81(6) shall be conferred on the Commission for an indeterminate period of time from the date of entry into force of this Regulation.

Proposal for a regulation

Article 89 – paragraph 3

Text proposed by the Commission

3. The delegation of power referred to in Articles 2(2) and (3), 4(5), 8(2), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4), 42(11), 45(5), 51(7), 53(3), 74(4) and 81(6) may be revoked at any time by the European Parliament or by the Council. A decision of revocation shall put an end to the delegation of the power specified in that decision. It shall take effect the day following its publication in the Official Journal of the European Union or at a later date specified therein. It shall not affect the validity of any delegated acts already in force.

Amendment

3. The delegation of power referred to in Articles 2(2) and (3), 15b (1), 16 (1), 17(4), 24(7), 25(7), 29(2), 40(2), 41(4) 44a (2), 44a(9), 45(5), 51(7), 53(3), 57(3a), 74(4), 78b(3) and 81(6) may be revoked at any time by the European Parliament or by the Council. A decision of revocation shall put an end to the delegation of the power specified in that decision. It shall take effect the day following the publication of the decision in the Official Journal of the European Union or at a later date specified therein. It shall not affect the validity of any delegated acts already in force.

Proposal for a regulation

Article 89 – paragraph 1 – subparagraph 1 a (new)

Text proposed by the Commission

The Commission shall, in drafting delegated acts, seek the advice of the MDCG.

Amendment

The Commission shall, in drafting delegated acts, seek the advice of the MDCG.
Amendment 255
Proposal for a regulation
Article 94 – paragraph 4

**Text proposed by the Commission**

4. By way of derogation from Directives 90/385/EEC and 93/42/EEC, conformity assessment bodies which comply with this Regulation may be designated and notified before its date of application. Notified bodies which are designated and notified in accordance with this Regulation may apply the conformity assessment procedures laid down in this Regulation and issue certificates in accordance with this Regulation before its date of application.

**Amendment**

4. By way of derogation from Directives 90/385/EEC and 93/42/EEC, conformity assessment bodies which comply with this Regulation may be designated and notified before its date of application. Notified bodies which are designated and notified in accordance with this Regulation may apply the conformity assessment procedures laid down in this Regulation and issue certificates in accordance with this Regulation before its date of application if the relevant delegated acts and implementing acts have been implemented.

Amendment 256
Proposal for a regulation
Chapter II - title

**Text proposed by the Commission**

Chapter II
Making available of devices, obligations of economic operators, reprocessing, CE marking, free movement

**Amendment**

Chapter VI
Making available of devices, obligations of economic operators, reprocessing, CE marking, free movement

*Articles under this Chapter: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22*
Amendment 257

Proposal for a regulation
Chapter VI b (new)

Text proposed by the Commission

Amendment

Chapter VIb
Labelling and safe reprocessing of medical devices

Articles under this Chapter: 15a, 15b, 15c, 15d, 15e, 15f

Amendment 258

Proposal for a regulation
Chapter III - title

Text proposed by the Commission

Amendment

Chapter III
Identification and traceability of devices, registration of devices and of economic operators, summary of safety and clinical performance, European databank on medical devices

Chapter VIII
Identification and traceability of devices, registration of devices and of economic operators, European databank on medical devices

Articles under this Chapter: 23, 24, 25, 27

Amendment 259

Proposal for a regulation
Chapter IV - title

Text proposed by the Commission

Amendment

Chapter IV
Notified bodies

Notified bodies

Articles under this Chapter: 28, 29, 29a, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 40a, 43, 43a, 43b, 43c
Amendment 260
Proposal for a regulation
Chapter V - title

Text proposed by the Commission

Chapter V
Classification and conformity assessment

Amendment

Chapter II
Classification of medical devices

Articles under this Chapter: 41

Amendment 261
Proposal for a regulation
Chapter II a (new)

Text proposed by the Commission

Amendment

Chapter III
Conformity assessment

Articles under this Chapter: 26, 42, 44a, 45, 46, 47, 48,

Amendment 262
Proposal for a regulation
Chapter VI - title

Text proposed by the Commission

Amendment

Chapter VI
Clinical evaluation and clinical investigations

Chapter V
Clinical evaluation and clinical investigations

Articles under this Chapter: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
### Amendment 263

**Proposal for a regulation**  
**Chapter VII - title**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter VII</strong></td>
<td><strong>Chapter IX</strong></td>
</tr>
<tr>
<td>Vigilance and market surveillance</td>
<td>Vigilance and market surveillance</td>
</tr>
</tbody>
</table>

*Articles under this Chapter: 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75*

### Amendment 264

**Proposal for a regulation**  
**Chapter VIII - title**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter VIII</strong></td>
<td><strong>Chapter X</strong></td>
</tr>
<tr>
<td>Cooperation between Member States, Medical Device Coordination Group, EU reference laboratories, device registers</td>
<td>Cooperation between Member States, Medical Device Coordination Group, <strong>Medical Device Advisory Committee</strong>, EU reference laboratories, device registers</td>
</tr>
</tbody>
</table>

*Articles under this Chapter: 76, 77, 78, 78a, 78b, 79, 80, 81, 82, 83*

### Amendment 265

**Proposal for a regulation**  
**Chapter IX - title**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter IX</strong></td>
<td><strong>Chapter XI</strong></td>
</tr>
<tr>
<td>Confidentiality, data protection, funding, penalties</td>
<td>Confidentiality, data protection, funding, penalties</td>
</tr>
</tbody>
</table>

*Articles under this Chapter: 84, 85, 86, 87*
Amendment 266
Proposal for a regulation
Annex I – part I – point 2 – point c

Text proposed by the Commission

(c) reduce as far as possible the remaining risks by taking adequate protection measures, including alarms; and

Amendment

(c) reduce as far as possible the remaining risks by taking adequate protection measures, including alarms; hence, it should take into consideration the latest tools and concepts developed in hazard and risk assessment based on human-relevant models, pathways of toxicity, adverse outcome pathways and evidence-based toxicology; and

Justification

- As stated by the EC scientific committees in their discussion paper “Addressing the new challenges for Risk Assessment – Oct 2012: “A shift is foreseen towards using more and more human data on biologically significant perturbations in key toxicity pathways”. Further, the REACH review earlier this year (Feb 2013), commented similarly on these mechanisms to better address the new challenges for hazard and risk assessment.

Amendment 267
Proposal for a regulation
Annex I – part I – point 2 – subparagraph 1 a (new)

Text proposed by the Commission

Points a, b, c and d of this point shall not reduce the necessity for clinical investigation and post-market clinical follow up to adequately address the risks, hazards and performance of devices.

Amendment 268
Proposal for a regulation
Annex I – part II – point 7 – point 7.1 – point b a (new)
Proposal for a regulation
Annex I – part II – point 7 – point 7.4 – paragraph 1

Text proposed by the Commission

7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. Special attention shall be given to substances which are carcinogenic, mutagenic or toxic to reproduction, in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, and to substances having endocrine disrupting properties for which there is scientific evidence of probable serious effects to human health and which are identified in accordance with the procedure set out in Article 59 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).

Amendment

(7a) the physical compatibility between the different manufacturers' parts of the devices which consist of more than one implantable part;

7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. Substances which are carcinogenic, mutagenic or toxic to reproduction, in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, shall be phased out within 8 years from the entry into force of this Regulation, unless no safer alternative substances are available. In the case that no safer alternatives exist, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures. Devices containing substances having endocrine
disrupting properties *that come into contact with the body of patients and* for which there is scientific evidence of probable serious effects to human health and which are identified in accordance with the procedure set out in Article 59 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and in accordance with the endocrine disrupting substances’ criteria set out in the report of the Endocrine Disrupters Expert Advisory Group shall be phased out within 8 years from the entry into force of this Regulation, unless no safer alternative substances are available. In the case that no safer alternatives exist, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures. Special attention shall be given to the recommendations from the EC Scientific committees (SCENIHR, SCCS and SCHER) on their discussion paper "Addressing the new challenges for Risk Assessment – Oct 2012" and REACH Review (COM(2013) 49 final – Feb 2013) which both acknowledged that ‘toxicology is undergoing a transition towards a more mechanistic, pathway- based, cell- and computer-based approach assessing a substance’s toxic mode of action’.

Amendment 270

Proposal for a regulation
Annex I – part II – point 7 – point 7.4 – paragraph 2 – closing part
contain, in a concentration of 0.1% by mass of the plasticised material or above, phthalates which are classified as carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008, these devices shall be labelled on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging as devices containing phthalates. If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures. If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, phthalates should be banned as of 1 January 2020, unless the manufacturer can show that there are no suitable safer substances or devices without these substances. Where the manufacturer can show that there are no suitable safer substances or devices without these substances, these substances shall be labelled on the device itself and/or on the packaging for each unit as devices containing substances which are classified as CMRs 1A or 1B or as EDCs.

Amendment 271

Proposal for a regulation
Annex I – part II – point 8 – point 8.1 – point a a (new)

Text proposed by the Commission

(aa) fully comply with the requirements of applicable Union Directives concerning occupational safety, such as Directive
Amendment 272

Proposal for a regulation
Annex I – part II – point 8 – point 8.1 – point a – paragraph 2

Text proposed by the Commission

Amendment

and, where necessary,
deleted

Amendment 273

Proposal for a regulation
Annex I – part II – point 8 – point 8.7 a (new)

Text proposed by the Commission

Amendment

8.7.a Medical device manufacturers shall notify their users of the levels of disinfection required to ensure patient safety and of all available methods for achieving those levels of disinfection. Manufacturers shall be required to test their devices using all methods designed to ensure patient safety and to substantiate any decision to reject a solution, either by demonstrating that it is ineffective or by demonstrating that it will cause damage impairing the medical usefulness of their devices to a significantly greater degree than other solutions that they themselves recommend.

Justification

Manufacturers recommend protocols, methods and solutions without due regard for the real effectiveness or their availability on the relevant market. In some cases, manufacturers’ recommendations state preferences based on industrial interests rather than patient safety considerations.
Amendment 274
Proposal for a regulation
Annex I – part II – point 9 – introductory part

Text proposed by the Commission

9. Devices incorporating a substance considered to be a medicinal product and devices composed of substances or combination of substances intended to be ingested, inhaled or administered rectally or vaginally.

Amendment

9. Devices incorporating a substance considered to be a medicinal product

Amendment 275
Proposal for a regulation
Annex I – part II – point 9 – point 9.2

Text proposed by the Commission

9.2. Devices that are composed of substances or combination of substances intended to be ingested, inhaled or administered rectally or vaginally and that are absorbed by or dispersed in the human body shall comply, by analogy, with the relevant requirements laid down in Annex I to Directive 2001/83/EC.

Amendment

deleted

Justification

The safety of these devices is ensured by the compliance to recognised harmonised standards or common technical specifications. Therefore, requesting compliance with analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products (Annex I to Directive 2001/83/EC) will not provide any beneficial additional information in terms of patient safety.

Amendment 276
Proposal for a regulation
Annex I – part II – point 10 – point 10.2 – point a a (new)
Text proposed by the Commission

(aa) The use of non-animal methods should be promoted. Animal use should be minimised and tests on vertebrates should be undertaken as a last resort. In accordance with Directive 2010/63/EU, tests on vertebrate animals must be replaced, restricted or refined. Therefore, we call on the Commission to lay down rules to avoid duplicative testing and duplication of tests and studies on vertebrates should be prohibited.

Amendment

Justification

In line with the requirement in the Protocol on the Protection and Welfare of Animals as it has been implemented in Article 13 of the Treaty of the Functioning of the European Union, that the Community and the Member States pay full regard to the welfare requirements of animals in formulating and implementing policies, it should be included that animal testing is kept to an absolute minimum and carried out in line with the requirement in the Protocol on the Protection and Welfare of Animals as it has been implemented in Article 13 of the Treaty of the Functioning of the European Union, that the Community and the Member States pay full regard to the welfare requirements of animals in formulating and implementing policies, it should be included that animal testing is kept to an absolute minimum and carried out only as a last resort, and that the use of alternatives is promoted. This is also in line with the requirements under REACH, plant protection products and the biocides legislations of the EU only as a last resort, and that the use of alternatives is promoted. This is also in line with the requirements under REACH, plant protection products and the biocides legislations of the EU.

Amendment 277

Proposal for a regulation
Annex I – part II – point 10 – point 10.3

Text proposed by the Commission

10.3. For devices manufactured utilising other non-viable biological substances the following applies:

In the case of biological substances other than those referred to in Sections 10.1. and 10.2., the processing, preservation, testing and handling of those substances shall be

Amendment

10.3. For devices manufactured utilising other non-viable biological substances the following applies:

In the case of biological substances other than those referred to in Sections 10.1. and 10.2., the processing, preservation, testing and handling of those substances shall be
carried out so as to provide optimal safety for patients, users and, where applicable, other persons. In particular, safety with regard to viruses and other transmissible agents shall be addressed by implementation of validated methods of elimination or inactivation in the course of the manufacturing process.

carried out so as to provide optimal safety for patients, users and, where applicable, other persons, including in the waste disposal chain. In particular, safety with regard to viruses and other transmissible agents shall be addressed by implementation of validated methods of elimination or inactivation in the course of the manufacturing process.

Amendment 278

Proposal for a regulation
Annex I – part II – point 11 – point 11.2 a (new)

Text proposed by the Commission

11.2.a Devices which can transfer potentially fatal blood-borne infections to healthcare staff, patients or other persons, by unintended cuts and pricks such as needle stick injuries, shall incorporate appropriate safety-engineered protection mechanisms in accordance with Directive 2010/32/EU. However the specificities relating to the dental profession must be respected.

Amendment

11.2.a Devices which can transfer potentially fatal blood-borne infections to healthcare staff, patients or other persons, by unintended cuts and pricks such as needle stick injuries, shall incorporate appropriate safety-engineered protection mechanisms in accordance with Directive 2010/32/EU. However the specificities relating to the dental profession must be respected.

Amendment 279

Proposal for a regulation
Annex I – part II – point 11 – point 11.7

Text proposed by the Commission

11.7. Devices shall be designed and manufactured in such a way as to facilitate the safe disposal of the device and/or of any waste substances by the user, patient or other person.

Amendment

11.7. Devices shall be designed and manufactured in such a way as to facilitate the safe disposal of the device and the substances with which the device has been exposed to and/or of any waste substances by the user, patient or other person and, where possible and appropriate, replace with the use of devices and methods with improved safety features and characteristics to reduce as far as possible
the exposure of patients, users and other persons to potentially harmful substances, such as chemical or nuclear material.

Amendment 280
Proposal for a regulation
Annex I – part II – point 13 – point 13.1 – point a

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Devices shall be designed and manufactured and packaged in such a way that exposure of patients, users and other persons to any emitted radiation shall be reduced as far as possible and appropriate, compatible with the intended purpose, whilst not restricting the application of appropriate specified levels for therapeutic and diagnostic purposes.</td>
<td>(a) Devices shall be designed and manufactured and packaged in such a way that exposure of patients, users and other persons to any emitted radiation shall be reduced as far as possible and appropriate, compatible with the intended purpose, and if possible these applications shall be replaced with applications with a higher safety standard, whilst not restricting the application of appropriate specified levels for therapeutic and diagnostic purposes.</td>
</tr>
</tbody>
</table>

Amendment 281
Proposal for a regulation
Annex I – part II – point 13 – point 13.3 – paragraph 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devices shall be designed and manufactured in such a way that exposure of patients, users and other persons to the emission of unintended, stray or scattered radiation is reduced as far as possible and appropriate.</td>
<td>Devices shall be designed and manufactured in such a way that exposure of patients, users and other persons to the emission of unintended, stray or scattered radiation is reduced as far as possible and appropriate: where possible, methods should be selected which reduce the exposure to radiation of patients, users and other persons who may be affected.</td>
</tr>
</tbody>
</table>
Amendment 282
Proposal for a regulation
Annex I – part II – point 13 – point 13.4 – point a

Text proposed by the Commission

(a) Devices intended to emit ionising radiation shall be designed and manufactured in such a way as to ensure that, where possible, the quantity, geometry and energy distribution (or quality) of radiation emitted can be varied and controlled taking into account the intended use.

Amendment

(a) Devices intended to emit ionising radiation shall be designed and manufactured in such a way as to ensure that, where possible, the quantity, geometry and energy distribution (or quality) of radiation emitted can be varied and controlled taking into account the intended use, and if possible, devices should be used that can at any time during and after treatment monitor the emission of radiation.

Amendment 283
Proposal for a regulation
Annex I – part II – point 18 – point 18.2 – indent 1 a (new)

Text proposed by the Commission

– as laid out in Directive 2010/32/EU, reduce as far as possible the risk of injury and infection to other persons by incorporating safety-engineered protection mechanisms designed to prevent needle stick and other sharp injuries, and

Amendment

Justification

Every year more than 1 million healthcare workers in the EU suffer life-changing and potentially fatal injuries involving medical devices that incorporate needles or other sharps. Not only are healthcare workers at risk of contracting blood-borne infections, they may also act as carrier to increase the risk of transmission to other patients.

Amendment 284
Proposal for a regulation
Annex I – part III – point 19 – point 19.1 – paragraph 1 – point d

Text proposed by the Commission

(d) Labels shall be provided in a human-readable format but may be supplemented by machine-readable forms, such as radio-frequency identification (RFID) or bar codes.

Amendment

(d) Labels shall be provided in a human-readable format and shall be supplemented by machine-readable forms, such as radio-frequency identification (RFID) or bar codes.

Justification

Medical device labels must be in both human-readable and machine-readable format, in order to ensure that there are no difficulties in recording the unique identifier.

Amendment 285

Proposal for a regulation
Annex I – part III – point 19 – point 19.2 – point a a (new)

Text proposed by the Commission

(aa) The mention ‘This product is a medical device’.

Amendment

Justification

It should be clearly stated on the label if a device is of single use only.

Amendment 286

Proposal for a regulation
Annex I – section 19.2 – point b

Text proposed by the Commission

(b) The details strictly necessary for a user to identify the device, the contents of the packaging and, where it is not obvious for the user, the intended purpose of the device.

Amendment

(b) The details strictly necessary for a user to identify the device, the contents of the packaging and, where it is not obvious for the user, the intended purpose of the device and where applicable that the device is only to be used during a single procedure.

Justification

It should be clearly stated on the label if a device is of single use only.
Amendment 287

Proposal for a regulation
Annex I – part III – point 19 – point 19.2 – point o

Text proposed by the Commission

(o) If the device is a single use device that has been reprocessed, an indication of that fact, the number of reprocessing cycles already performed, and any limitation as regards the number of reprocessing cycles.

Amendment

deleted

Amendment 288

Proposal for a regulation
Annex I – part III – point 19 – point 19.3 – point k

Text proposed by the Commission

(k) If the device is reusable, information on the appropriate processes to allow reuse, including cleaning, disinfection, decontamination, packaging and, where appropriate, the validated method of re-sterilisation. Information should be provided to identify when the device should no longer be reused, e.g. signs of material degradation or the maximum number of allowable reuses.

(k) If the device is reusable, information on the appropriate processes to allow reuse, including cleaning, disinfection, decontamination, packaging, the maximum number of allowable reuses and, where appropriate, the validated method of re-sterilisation. Information should be provided to identify when the device should no longer be reused, e.g. signs of material degradation.

Amendment 289

Proposal for a regulation
Annex I – part III – paragraph 19 – point 19.3 – point l

Text proposed by the Commission

(l) If the device bears an indication that the device is for single use, information on known characteristics and technical factors known to the manufacturer that could pose a risk if the device were to be re-used. If in accordance with point c) of Section 19.1 no instructions for use are needed, the

(l) With the exception of devices referred to in Article 15b, if the device bears an indication that it is for single use, the evidence justifying that the device cannot be reprocessed safely referred to in Article 15c(1), and which includes all information on characteristics and technical factors that
information shall be made available to the user upon request. could pose a risk if the device were to be re-used. If in accordance with point c) of Section 19.1 no instructions for use are needed, the information shall be made available to the user upon request.

Amendment 290

Proposal for a regulation
Annex I – part III – point 19 – point 19.3 – paragraph 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The instruction for use shall be lay-friendly and reviewed by the representatives of relevant stakeholders, including patient and healthcare professionals' organisations.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 291

Proposal for a regulation
Annex II – point 5 – paragraph 1 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The documentation shall contain a summary of available information concerning:</td>
<td></td>
</tr>
</tbody>
</table>

Justification

As the primary users of medical devices, and because doctors are responsible for the safety of their patients, members of the health professions must have access to all technical and clinical data available from the manufacturers in order to make a selection among the most suitable devices for their patients and to inform them accordingly.
Amendment 292
Proposal for a regulation
Annex II - point 6.1 - point d

Text proposed by the Commission
(d) the PMCF plan and PMCF evaluation report in accordance with Part B of Annex XIII or any justification why a PMCF is not deemed necessary or appropriate.

Amendment
(d) the PMCF plan and PMCF evaluation report, including a review of the PMCF evaluation report by an independent scientific body for class III medical devices, in accordance with Part B of Annex XIII or any justification why a PMCF is not deemed necessary or appropriate.

Justification

In order to promote transparency, there is a need for an additional review by an independent scientific body of the manufacturer's PMCF evaluation report for the highest risk devices. ...

Amendment 293
Proposal for a regulation
Annex IV – point 1 – introductory part

Text proposed by the Commission
1. The CE marking shall consist of the initials ‘CE’ taking the following form:

Amendment
1. The CE marking shall consist of the initials ‘CE’ accompanied by the term "Medical Device" taking the following form:

Amendment 294
Proposal for a regulation
Annex VI – points 1 and 2

Text proposed by the Commission
1.1. Legal status and organisational structure
1.1.4. The organisational structure, distribution of responsibilities and operation of the notified body shall be such

Amendment
1.1. Legal status and organisational structure
1.1.4. The organisational structure, distribution of responsibilities and operation of the notified body shall be such
that it assures confidence in the performance and results of the conformity assessment activities conducted.

The organisational structure and the functions, responsibilities and authority of its top-level management and of other personnel with influence upon the performance and results of the conformity assessment activities shall be clearly documented. This information shall be made publicly available.

1.2. Independence and impartiality

1.2.1. The notified body shall be a third-party body that is independent of the manufacturer of the product in relation to which it performs conformity assessment activities. The notified body shall also be independent of any other economic operator having an interest in the product as well as of any competitor of the manufacturer.

1.2.3. The notified body, its top-level management and the personnel responsible for carrying out the conformity assessment tasks shall not:

- be the designer, manufacturer, supplier, installer, purchaser, owner, user or maintainer of the products, nor the authorised representative of any of those parties. This shall not preclude the purchase and use of assessed products that are necessary for the operations of the notified body (e.g. measuring equipment), the conduct of the conformity assessment or the use of such products for personal purposes;

- be directly involved in the design, manufacture or construction, the marketing, installation, use or maintenance of the products which they assess, or represent the parties engaged in those
activities. They shall not engage in any activity that may conflict with their independence of judgement or integrity in relation to conformity assessment activities for which they are notified;

- offer or provide any service which may jeopardise the confidence in their independence, impartiality or objectivity. In particular, they shall not offer or provide consultancy services to the manufacturer, his authorised representative, a supplier or a commercial competitor as regards the design, construction, marketing or maintenance of the products or processes under assessment. This does not preclude general training activities relating to medical device regulations or related standards that are not client specific.

The notified body shall make publicly available the declarations of interest of its top-level management and the personnel responsible for carrying out the conformity assessment tasks. The national authority shall verify the compliance of the notified body with the provisions under this point and shall report to the Commission twice a year in full transparency.

1.2.4. The impartiality of the notified bodies, of their top level management and the personnel responsible for carrying out the conformity assessment tasks. The remuneration of the top level management and assessment personnel of a notified body shall not depend on the results of the assessments.

1.2.6. The notified body shall ensure and document that the activities of its subsidiaries or subcontractors, or of any associated body, do not affect its independence, impartiality or objectivity of its conformity assessment activities.

The notified body shall provide evidence to the national authority of compliance with this point.
1.3. Confidentiality

The personnel of a notified body shall observe professional secrecy with regard to all information obtained in carrying out their tasks under this Regulation, except in relation to the national authorities responsible for notified bodies, competent authorities or the Commission. Proprietary rights shall be protected. To this end, the notified body shall have documented procedures in place.

Where information and data are requested from the notified body by the public or healthcare professionals and where such request is declined, the notified body shall justify the reasons for non-disclosure and shall make publicly available its justification.

1.5. Financial requirements

The notified body shall have at its disposal the financial resources required to conduct its conformity assessment activities and related business operations. It shall document and provide evidence of its financial capacity and its sustainable economic viability, taking into account specific circumstances during an initial start-up phase.

1.6. Participation in coordination activities

1.6.1. The notified body shall participate in, or ensure that its assessment personnel is informed of the relevant standardisation activities and the activities of the notified body coordination group and that its assessment and decision making personnel are informed of all relevant legislation, guidance and best practice documents adopted in the framework of this Regulation.

2. QUALITY MANAGEMENT

1.3. Confidentiality

The personnel of a notified body shall observe professional secrecy with regard to information obtained in carrying out their tasks under this Regulation, *only in justified cases and* except in relation to the national authorities responsible for notified bodies, competent authorities or the Commission. Proprietary rights shall be protected. To this end, the notified body shall have documented procedures in place.

The notified body, including its subsidiaries, shall have at its disposal the financial resources required to conduct its conformity assessment activities and related business operations. It shall document and provide evidence of its financial capacity and its sustainable economic viability, taking into account specific circumstances during an initial start-up phase.

1.6.1. The notified body shall participate in, or ensure that its assessment personnel *including subcontractors*, is informed of and trained on the relevant standardisation activities and the activities of the notified body coordination group and that its assessment and decision making personnel are informed of all relevant legislation, *standards*, guidance and best practice documents adopted in the framework of this Regulation. *The notified body shall keep a record of the actions it takes to inform its personnel.*
REQUIREMENTS

2.2. The quality management system of the notified body shall at least address the following:

- policies for assignment of personnel to activities and their responsibilities;
- decision-making process in accordance with the tasks, responsibilities and role of the top-level management and other notified body personnel;
- control of documents;
- control of records;
- management review;
- internal audits;
- corrective and preventive actions;
- complaints and appeals.

REQUIREMENTS

2.2. The quality management system of the notified body and its subcontractors shall at least address the following:

- policies for assignment of personnel to activities and their responsibilities;
- decision-making process in accordance with the tasks, responsibilities and role of the top-level management and other notified body personnel;
- control of documents;
- control of records;
- management review;
- internal audits;
- corrective and preventive actions;
- complaints and appeals;
- continuous training.

Amendment 295

Proposal for a regulation
Annex VI – point 3.1

*Text proposed by the Commission*

3.1.1. A notified body shall be capable of carrying out all the tasks assigned to it by this Regulation with the highest degree of professional integrity and the requisite technical competence in the specific field, whether those tasks are carried out by the notified body itself or on its behalf and under its responsibility.

*Amendment*

3.1.1. A notified body and its subcontractors shall be capable of carrying out all the tasks assigned to it by this Regulation with the highest degree of professional integrity and the requisite technical competence in the specific field, whether those tasks are carried out by the notified body itself or on its behalf and under its responsibility. In accordance with Article 35, this requirement shall be monitored to ensure that it is of the requisite quality.

In particular, it shall have the necessary personnel and shall possess or have access to all equipment and facilities needed to perform properly the technical and administrative tasks entailed in the
conformity assessment activities in relation to which it has been notified.

This presupposes the availability within its organisation of sufficient scientific personnel who possess experience and knowledge sufficient to assess the medical functionality and performance of devices for which it has been notified, having regard to the requirements of this Regulation and, in particular, those set out in Annex I.

Permanent in house staff shall be used. However, in accordance with Article 30, notified bodies may hire external experts on an ad hoc and temporary basis provided they can make publicly available the list of these experts, as well as their declarations of interest and the specific tasks for which they are responsible.

Notified bodies shall conduct unannounced inspections at least once a year of all premises at which the medical devices coming within their remit are manufactured.

The notified body responsible for carrying out the assessment tasks shall notify the other Member States of the findings of the annual inspections carried out. Those findings shall be set out in a report.

It shall also forward a record of the annual inspections carried out to the relevant national authority responsible.

3.1.2. At all times and for each conformity assessment procedure and each kind or category of products in relation to which it has been notified, a notified body shall have within its organisation the necessary administrative, technical and scientific personnel with technical knowledge and sufficient and appropriate experience relating to medical devices and the corresponding technologies to perform the conformity assessment tasks, including the assessment of clinical data.
3.1.3. The notified body shall clearly document the extent and the limits of the duties, responsibilities and authorities in relation of the personnel involved in conformity assessment activities and inform the personnel concerned about it.

3.1.3. The notified body shall clearly document the extent and the limits of the duties, responsibilities and authorities in relation of the personnel, including any subcontractors, subsidiaries and external experts, involved in conformity assessment activities and inform the personnel concerned about it.

3.1.3.a The notified body shall make available the list of its personnel involved in conformity assessment activities and their expertise to the Commission and, upon request, to other parties. That list shall be kept up to date.

Amendment 296

Proposal for a regulation
Annex VI – point 3.2.

Text proposed by the Commission

3.2.1. The Notified Body shall establish and document qualification criteria and procedures for selection and authorisation of persons involved in conformity assessment activities (knowledge, experience and other competence required) and the required training (initial and ongoing training). The qualification criteria shall address the various functions within the conformity assessment process (e.g. auditing, product evaluation/testing, design dossier/file review, decision-making) as well as the devices, technologies and areas

Amendment

3.2.1. The MDCG shall establish and document the principles of high level competence and qualification criteria and procedures for selection and authorisation of persons involved in conformity assessment activities (knowledge, experience and other competence required) and the required training (initial and ongoing training). The qualification criteria shall address the various functions within the conformity assessment process (e.g. auditing, product evaluation/testing, design dossier/file review, decision-making) as
(e.g. biocompatibility, sterilisation, tissues and cells of human and animal origin, clinical evaluation) covered by the scope of designation.

3.2.2. The qualification criteria shall refer to the scope of the notified body's designation in accordance with the scope description used by the Member State for the notification referred to in Article 33, providing sufficient level of detail for the required qualification within the subdivisions of the scope description.

Specific qualification criteria shall be defined for the assessment of biocompatibility aspects, clinical evaluation and the different types of sterilisation processes.

3.2.3. The personnel responsible for authorising other personnel to perform specific conformity assessment activities and the personnel with overall responsibility for the final review and decision-making on certification shall be employed by the notified body itself and shall not be subcontracted. These personnel altogether shall have proven knowledge and experience in the following:

- Union medical devices legislation and relevant guidance documents;
- the conformity assessment procedures in accordance with this Regulation;
- a broad base of medical device technologies, the medical device industry and the design and manufacture of medical devices;
- the notified body’s quality management system and related procedures;
- the types of qualifications (knowledge, experience and other competence) required for carrying out conformity assessments in relation to medical devices as well as the relevant qualification criteria;
- training relevant to personnel involved in

well as the devices, technologies and areas (e.g. biocompatibility, sterilisation, tissues and cells of human and animal origin, clinical evaluation, **risk management**) covered by the scope of designation.

3.2.2. The qualification criteria shall refer to the scope of the notified body's designation in accordance with the scope description used by the Member State for the notification referred to in Article 33, providing sufficient level of detail for the required qualification within the subdivisions of the scope description.

Specific qualification criteria shall be defined for the assessment of biocompatibility aspects, **safety**, clinical evaluation and the different types of sterilisation processes.

3.2.3. The personnel responsible for authorising other personnel to perform specific conformity assessment activities and the personnel with overall responsibility for the final review and decision-making on certification shall be employed by the notified body itself and shall not be subcontracted. These personnel altogether shall have proven knowledge and experience in the following:

- Union medical devices legislation and relevant guidance documents;
- the conformity assessment procedures in accordance with this Regulation;
- a broad base of medical device technologies, the medical device industry and the design and manufacture of medical devices;
- the notified body’s quality management system and related procedures;
- the types of qualifications (knowledge, experience and other competence) required for carrying out conformity assessments in relation to medical devices as well as the relevant qualification criteria;
- training relevant to personnel involved in
conformity assessment activities in relation to medical devices;
- the ability to draw up certificates, records and reports demonstrating that the conformity assessments have been appropriately carried out.

3.2.4. Notified bodies shall have available personnel with *clinical* expertise. This personnel shall be integrated in the notified body's decision-making process in a steady way in order to:

- identify when specialist input is required for the assessment of the clinical evaluation conducted by the manufacturer and identify appropriately qualified experts;
- appropriately train external clinical experts in the relevant requirements of this Regulation, delegated and/or implementing acts, harmonised standards, CTS and guidance documents and ensure that the conformity assessment activities in relation to medical devices;

- at least three years' appropriate experience in the field of conformity assessments within a notified body,
- adequate seniority / experience in conformity assessments under this Regulation or previously applicable directives during a period of at least three years within a notified body. The notified body staff involved in certification decisions shall not have been involved in the conformity assessment on which a certification decision needs to be taken.

3.2.4. **Clinical experts:** notified bodies shall have available personnel with expertise in *clinical investigation design*, *medical statistics*, *clinical patient management*, *Good Clinical Practice in the field of clinical investigations*. Permanent "in house" staff shall be used. However, in accordance with Article 30, notified bodies may hire external experts on an ad hoc and temporary basis provided they can make publicly available the list of these experts, as well as the specific tasks for which they are responsible. This personnel shall be integrated in the notified body's decision-making process in a steady way in order to:

- identify when specialist input is required for the assessment of the clinical investigation plans and the clinical evaluation conducted by the manufacturer and identify appropriately qualified experts;
- appropriately train external clinical experts in the relevant requirements of this Regulation, delegated and/or implementing acts, harmonised standards, CTS and guidance documents and ensure that the
external clinical experts are fully aware of the context and implication of their assessment and advice provided;
- be able to discuss the clinical data contained within the manufacturer's clinical evaluation with the manufacturer and with external clinical experts and to appropriately guide external clinical experts in the assessment of the clinical evaluation;
- be able to discuss the rationale of the planned study design, the clinical investigation plans and the selection of the control intervention with the manufacturer and with external clinical experts and to appropriately guide external clinical experts in the assessment of the clinical evaluation;
- be able to scientifically challenge the clinical data presented, and the results of the external clinical experts' assessment of the manufacturer's clinical evaluation;
- be able to scientifically challenge the clinical investigation plans and the clinical data presented, and the results of the external clinical experts' assessment of the manufacturer's clinical evaluation;
- be able to ascertain the comparability and consistency of the clinical assessments conducted by clinical experts;
- be able to ascertain the comparability and consistency of the clinical assessments conducted by clinical experts;
- be able to make an objective clinical judgement about the assessment of the manufacturer's clinical evaluation and make a recommendation to the notified body's decision maker.
- be able to make an objective clinical judgement about the assessment of the manufacturer's clinical evaluation and make a recommendation to the notified body's decision maker.
- ensure independence and objectivity and disclose potential conflicts of interest.

3.2.5. The personnel responsible for carrying out product related review (e.g. design dossier review, technical documentation review or type examination including aspects such as clinical evaluation, biological safety, sterilisation, software validation) shall have the following proven qualification:

– successful completion of a university or a technical college degree or equivalent qualification in relevant studies, e.g. medicine, natural science or engineering;
- four years professional experience in the field of healthcare products or related sectors (e.g. industry, audit, healthcare, research experience) whilst two years of this experience shall be in the design,
manufacture, testing or use of the device or technology to be assessed or related to the scientific aspects to be assessed;

- appropriate knowledge of the general safety and performance requirements laid down in Annex I as well as related delegated and/or implementing acts, harmonised standards, CTS and guidance documents;

- appropriate knowledge and experience of risk management and related medical device standards and guidance documents;

3.2.6. The personnel responsible for carrying out audits of the manufacturer's quality management system shall have the following proven qualification:

- successful completion of a university or a technical college degree or equivalent qualification in relevant studies, e.g. medicine, natural science or engineering

four years professional experience in the field of healthcare products or related sectors (e.g. industry, audit, healthcare, research experience) whilst two years of this experience shall be in the area of quality management

manufacture, testing or use of the device (as defined within a generic device group) or technology to be assessed or related to the scientific aspects to be assessed;

- appropriate knowledge of the general safety and performance requirements laid down in Annex I as well as related delegated and/or implementing acts, harmonised standards, CTS and guidance documents;

- appropriate knowledge and experience of risk management and related medical device standards and guidance documents;

- appropriate knowledge and experience of clinical evaluation;

3.2.6. Auditor: The personnel responsible for carrying out audits of the manufacturer's quality assurance system shall have specialist qualifications, which should include:

- successful completion of a university or a technical college degree or equivalent qualification in relevant studies, e.g. medicine, natural science or engineering;

four years professional experience in the field of healthcare products or related sectors (e.g. industry, audit, healthcare, research experience) whilst two years of this experience shall be in the area of quality management;

- appropriate knowledge of technologies such as those defined by IAF/EAC coding or equivalent.
Amendment 297

Proposal for a regulation
Annex VI – point 3.4.

Text proposed by the Commission

3.4. Subcontractors and external experts

3.4.1. Without prejudice to the limitations emanating from Section 3.2., notified bodies may subcontract clearly defined parts of the conformity assessment activities. The subcontracting of the auditing of quality management systems or of product related reviews as a whole is not allowed.

3.4.2. Where a notified body subcontracts conformity assessment activities either to an organisation or an individual, it shall have a policy describing the conditions under which subcontracting may take place. Any subcontracting or consultation of external experts shall be properly documented and be subject to a written agreement covering, among others, confidentiality and conflict of interests.

3.4.3. Where subcontractors or external experts are used in the context of the conformity assessment, in particular regarding novel, invasive and implantable medical devices or technologies, the notified body shall have adequate own competence in each product area for which it is designated to lead the conformity assessment, to verify the appropriateness and validity of expert opinions and make the decision on the certification.

Amendment

3.4. Subcontractors and external experts

3.4.1. Without prejudice to the limitations emanating from Section 3.2., notified bodies may subcontract clearly defined parts of the conformity assessment activities in particular where clinical expertise is limited. The subcontracting of the auditing of quality management systems or of product related reviews as a whole is not allowed.

3.4.2. Where a notified body subcontracts conformity assessment activities either to an organisation or an individual, it shall have a policy describing the conditions under which subcontracting may take place. Any subcontracting or consultation of external experts shall be properly documented, be publicly available and be subject to a written agreement covering, among others, confidentiality and conflict of interests.

3.4.3. Where subcontractors or external experts are used in the context of the conformity assessment, in particular regarding novel, invasive and implantable medical devices or technologies, the notified body shall have adequate own competence in each product area, each treatment or medical speciality for which it is designated to lead the conformity assessment, to verify the appropriateness and validity of expert opinions and make the decision on the certification.

3.4.4a. The policy and procedures under points 3.4.2 and 3.4.4 shall be communicated to the national authority before any subcontracting takes place.
### Amendment 298

**Proposal for a regulation**  
**Annex VI – paragraph 3 – point 3.5. – point 3.5.2.**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5.2. It shall review the competence of its personnel and identify training needs in order to maintain the required level of qualification and knowledge.</td>
<td>3.5.2. It shall review the competence of its personnel and identify training needs and ensure that necessary measures are taken accordingly, in order to maintain the required level of qualification and knowledge.</td>
</tr>
</tbody>
</table>

### Amendment 299

**Proposal for a regulation**  
**Annex VI – 3.5 a (new)**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3.5.a Additional requirements for special notified bodies</strong></td>
<td></td>
</tr>
<tr>
<td><strong>3.5 a 1. Clinical experts for special notified bodies</strong></td>
<td></td>
</tr>
<tr>
<td>Special notified bodies shall have available personnel with expertise in clinical investigation design, medical statistics, clinical patient management, good clinical practice in the field of clinical investigations and pharmacology. Permanent in house staff shall be used. However, in accordance with Article 30, notified bodies may hire external experts on an ad hoc and temporary basis provided they can make publicly available the list of these experts, as well as the specific tasks for which they are responsible. This personnel shall be integrated in the notified body's decision-making process in a steady way in order to:</td>
<td></td>
</tr>
<tr>
<td>- identify when specialist input is required for the assessment of the clinical investigation plans and the clinical evaluation conducted by the</td>
<td></td>
</tr>
</tbody>
</table>
manufacturer and identify appropriately qualified experts;

- appropriately train external clinical experts in the relevant requirements of this Regulation, delegated and/or implementing acts, harmonised standards, CTS and guidance documents and ensure that the external clinical experts are fully aware of the context and implication of their assessment and advice provided;

- be able to discuss the rationale of the planned study design, the clinical investigation plans and the selection of the control intervention with the manufacturer and with external clinical experts and to appropriately guide external clinical experts in the assessment of the clinical evaluation;

- be able to scientifically challenge the clinical investigation plans and the clinical data presented, and the results of the external clinical experts' assessment of the manufacturer's clinical evaluation;

- be able to ascertain the comparability and consistency of the clinical assessments conducted by clinical experts;

- be able to make an objective clinical judgement about the assessment of the manufacturer's clinical evaluation and make a recommendation to the notified body's decision maker.

- have an understanding of active substances.

- ensure independence and objectivity and disclose potential conflicts of interest.

3.5 a 2. Product specialists for special notified bodies

The personnel responsible for carrying out product related reviews (for example design dossier review, technical documentation review or type examination) for devices referred to in Article 43a shall have the following
proven product specialist qualification:
- Meet the requirement as stipulated above for product assessors;
- Have an advanced academic degree in field relevant to medical devices, or alternative have six years of relevant experience in medical devices or related sectors;
- Have an ability to identify key risks of products within the specialist’s product categories without prior reference to manufacturer’s specifications or risk analyses;
- Have an ability to assess against the essential requirements in the absence of harmonised or established national standards;
- The professional experience should be gained in the first product category their qualification is based on, relevant to the product category of designation of the notified body, providing sufficient knowledge and experience to thoroughly analyse the design, the validation and verification testing and the clinical use with a sound understanding of the design, manufacture, testing, clinical use and risks associated with such a device;
- Missing professional experience for further product categories closely related to the first product category, may be substituted by internal product specific training programmes;
- For product specialist with qualification in specific technology such as sterilisation, tissues and cells of human and animal origin, combination products, professional experience should be gained in the specific technology area, relevant to the scope of designation of the notified body.

For each designated product category, the Special notify body shall have a minimum of two product specialists of which at least
one in house, to review devices referred to in Art. 43 a (new), first paragraph. For those devices, product specialists shall be available in house for the designated technology fields (for example combination products, sterilisation, tissues and cells of human or animal origin) covered by the scope of notification.

3.5 a 3. Training for product specialists

Product specialists shall receive at minimum 36 hours of training in medical devices, the Medical Device Regulations, and assessment and certification principles, including training in the verification of manufactured product.

The notified body shall ensure that a product specialist to be qualified obtains adequate training in the relevant procedures of the notified body’s quality management system and is taken through a training plan consisting of sufficient design dossier reviews witnessed, performed under supervision and peer reviewed before doing a qualifying full independent review.

For each product category for which qualification is sought, the notified body must show evidence of appropriate knowledge in the product category. A minimum of five design dossiers (at least two of them initial applications or significant extensions of certification) shall be conducted for the first product category. For subsequent qualification in additional product categories evidence of adequate product knowledge and experience needs to be demonstrated.

3.5 a 4. Maintenance qualification for product specialists

Qualifications of product specialists shall be reviewed on an annual basis; a minimum of four design dossier reviews, independent of the number of product categories qualified for shall be
demonstrated as a four-year rolling average. Reviews of significant changes to the approved design (not full design examinations) count for 50%, as do reviews supervised.

On an ongoing basis, the product Specialist needs to show evidence of state-of-art product knowledge, review experience in each product category for which qualification exists. Annual training with regard to latest status of Regulations, harmonised standards, relevant guidance documents, clinical evaluation, performance evaluation, CTS requirements needs to be demonstrated.

If the requirements for renewal of qualification are not met, the qualification shall be suspended. Then the first upcoming design dossier review shall be done under supervision, and re-qualification confirmed based on the outcome of this review.

Amendment 300

Proposal for a regulation
Annex VI point 4.1

Text proposed by the Commission

4.1. The notified body's decision-making process shall be clearly documented, including the process for the issue, suspension, reinstatement, withdrawal or refusal of conformity assessment certificates, their modification or restriction and the issue of supplements.

Amendment

4.1. The notified body's decision-making process shall be transparent and clearly documented and its outcome publicly available, including the issue, suspension, reinstatement, withdrawal or refusal of conformity assessment certificates, their modification or restriction and the issue of supplements.
Amendment 301
Proposal for a regulation
Annex VI point 4.3

Text proposed by the Commission

4.3. The notified body shall have in place documented procedures covering at least:

- the application for conformity assessment by a manufacturer or by an authorised representative,
- the processing of the application, including the verification of the completeness of the documentation, the qualification of the product as device and its classification,

Amendment

4.3. The notified body shall have in place documented procedures that are publicly available covering at least:

- the application for conformity assessment by a manufacturer or by an authorised representative,
- the processing of the application, including the verification of the completeness of the documentation, the qualification of the product as device and its classification, as well as the recommended duration for conducting its conformity assessment,

Amendment 302
Proposal for a regulation
Annex VI – point 4a (new)

Text proposed by the Commission

4a. Recommended duration for conformity assessments conducted by notified bodies

4.1. Notified bodies shall identify the audit duration for the stage 1 and stage 2 initial audits, and surveillance audits for each applicant and certified client

4.2. An audit duration shall be based, inter alia, on the effective number of personnel of the organization, the complexity of the processes within the organization, the nature and the characteristics of the medical devices included in the scope of the audit and the different technologies that are employed to manufacture and control the medical
devices. The audit duration may be adjusted based on any significant factors that uniquely apply to the organization to be audited. The notified body shall ensure that any variation in audit duration does not compromise the effectiveness of audits.

4.3. The duration of any scheduled on site audit shall not be less than one auditor/day.

4.4. Certification of multiple sites under one quality assurance system shall not be based on a sampling system.

Amendment 303
Proposal for a regulation
Annex VII – part III – point 4 – point 4.4 – paragraph 1 – indent 2

**Text proposed by the Commission**

– are intended to be used in direct contact with the heart, the central circulatory system or the central nervous system, in which case they are in class III,

**Amendment**

– are intended to be used in direct contact with the heart, the central circulatory system or the central nervous system, in which case they are in class III, with the exception of sutures and staples.

**Justification**

The classification rule is not fully adapted to some devices like sutures and staples that may be either in class IIb or III depending on the intended use given by the manufacturer. As they are implantable, they would be subject to implant cards requirements, which would represent a high burden without increasing safety, as many sutures or staples might be used during a surgical intervention.

Amendment 304
Proposal for a regulation
Annex VII – part III – point 6 – point 6.7 – paragraph 1

**Text proposed by the Commission**

All devices incorporating or consisting of

**Amendment**

All devices incorporating or consisting of
nanomaterial are in class III unless the nanomaterial is encapsulated or bound in such a manner that it cannot be released into the patient’s or user’s body when the device is used within its intended purpose.

Justification

Many medical devices contain nanomaterials, but do not pose any danger to the patient. In classifying medical devices containing nanomaterials, the intended effect of the nanomaterials should therefore be taken into account.

Amendment 305

Proposal for a regulation
Annex VII – part III – point 6 – point 6.8

Text proposed by the Commission

Amendment

6.8. Rule 20 deleted

All devices intended to be used for aphaeresis, such as aphaeresis machines, sets, connectors and solutions, are in class III.

Justification

Medical devices utilised in the process of aphaeresis are different and wide-ranging and as such it is not appropriate to classify them in a one size fits all manner as Class III. Furthermore, measures on traceability, vigilance, adverse event reporting foreseen for Class III medical devices are already covered by the EU Directives on quality and safety of blood and the EU Pharmaceuticals legislation for these devices alongside national laws and measures.

Amendment 306

Proposal for a regulation
Annex VII – point 6.9 – rule 21

Text proposed by the Commission

Amendment

Devices that are composed of substances or combination of substances intended to be ingested, inhaled or administered rectally or vaginally and that are absorbed deleted
by or dispersed in the human body are in class III.

Amendment 307
Proposal for a regulation
Annex VIII – point 3 – point 3.2 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2. Application of the quality management system shall ensure that the devices conform to the provisions of this Regulation which apply to them at every stage, from design to final inspection. All the elements, requirements and provisions adopted by the manufacturer for his quality management system shall be documented in a systematic and orderly manner in the form of written policies and procedures such as quality programmes, quality plans, quality manuals and quality records.</td>
<td>3.2. Application of the quality management system shall ensure that the devices conform to the provisions of this Regulation which apply to them at every stage, from design to final inspection and delivery. All the elements, requirements and provisions adopted by the manufacturer for his quality management system shall be documented in a systematic and orderly manner in the form of written policies and procedures such as quality programmes, quality plans, quality manuals and quality records.</td>
</tr>
</tbody>
</table>

Justification

The quality assurance system should not only cover the processes up to the final inspection. It should also cover all aspects that are relevant for conformity with the legal requirements and the quality of the product (e.g. proper transport and warehousing).

Amendment 308
Proposal for a regulation
Annex VIII – point 3 – point 3.2 – paragraph 1 – point d – indent 2

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– the product identification procedures drawn up and kept up to date from drawings, specifications or other relevant documents at every stage of manufacture;</td>
<td>– the product identification and traceability procedures drawn up and kept up to date from drawings, specifications or other relevant documents at every stage of manufacture;</td>
</tr>
</tbody>
</table>
Amendment 309
Proposal for a regulation
Annex VIII – point 4 – point 4.1

Text proposed by the Commission

4.1. The aim of surveillance is to ensure that the manufacturer duly fulfils the obligations imposed by the approved quality management system.

Amendment

4.1. The aim of surveillance is to ensure that the manufacturer duly fulfils all the obligations imposed by the approved quality management system.

Amendment 310
Proposal for a regulation
Annex VIII – point 4.4 – paragraph 1

Text proposed by the Commission

The notified body shall randomly perform unannounced factory inspections to the manufacturer and, if appropriate, at the manufacturer's suppliers and/or subcontractors, which may be combined with the periodic surveillance assessment referred to in Section 4.3. or be performed in addition to this surveillance assessment. The notified body shall establish a plan for the unannounced inspections which must not be disclosed to the manufacturer.

Amendment

The notified body shall randomly perform at least once every five years and for each manufacturer and generic device group unannounced inspections at the relevant manufacturing sites and, if appropriate, at the manufacturer's suppliers and/or subcontractors. The notified body shall establish a plan for the unannounced inspections which shall not take a periodicity lower than one inspection per year and must not be disclosed to the manufacturer. At the time of such inspections, the notified body shall carry out the tests or ask to carry them in order to check that the quality management system is working properly. It shall provide the manufacturer with an inspection report and with a test report.

Justification

The number of unannounced inspections in section 4.4 has to be clearly defined in order to strengthen the necessary controls and to guarantee unannounced inspections at the same level and frequency in all member states. Therefore unannounced inspections should be performed at least once in a certification cycle and for each manufacturer and generic device group. Because of the vital importance of this instrument, the scope and procedures of the unannounced inspections should be stated in the Regulation itself instead of in down streamed rules such as an implementing act.
Amendment 311

Proposal for a regulation
Annex VIII – point 4 – point 4.4 – paragraph 3

Text proposed by the Commission

The notified body shall provide the manufacturer with an inspection report which shall include, if applicable, the result of the sample check.

Amendment

The notified body shall provide the manufacturer with an inspection report which shall include, if applicable, the result of the sample check. This report shall be made public.

Justification

One of the key lessons learnt after the PiP scandal is the need for unannounced inspections. In the interests of transparency, the inspection report should be made public.

Amendment 312

Proposal for a regulation
Annex VIII – point 4 – point 4.5 – paragraph 1

Text proposed by the Commission

In the case of devices classified as class III, the surveillance assessment shall also include a check of the approved parts and/or materials that are essential for the integrity of the device, including, where appropriate, the coherence between the quantities of produced or purchased parts and/or materials and the quantities of finished products.

Amendment

deleted

Justification

A check of the coherence between the quantity of produced or purchased raw material or crucial components approved for the type and the quantity of finished products is often not possible. The tasks and competences of the notified bodies are in the field of technical examinations and not business analyses. Checking the coherence is generally the duty of the manufacturer for financial accounting reasons.
Amendment 313
Proposal for a regulation
Annex VIII – point 5.3 – paragraph 1

Text proposed by the Commission
The notified body shall examine the application employing staff with proven knowledge and experience regarding the technology concerned. The notified body may require the application to be completed by further tests or other evidence to allow assessment of conformity with the requirements of the Regulation. The notified body shall carry out adequate physical or laboratory tests in relation to the device or request the manufacturer to carry out such tests.

Amendment
The notified body shall examine the application employing staff with proven knowledge and experience regarding the technology concerned. The notified body shall ensure that the manufacturer’s application adequately describes the design, manufacture and performance of the device, allowing assessment of whether the product conforms with the requirements set out in this Regulation. The notified bodies shall comment on the conformity of the following:

- general description of the product,
- design specifications, including a description of the solutions adopted to fulfil the essential requirements,
- systematic procedures used for the design process and techniques used to control, monitor and verify the design of the device.

The notified body may require the application to be completed by further tests or other evidence to allow assessment of conformity with the requirements of the Regulation. The notified body shall carry out adequate physical or laboratory tests in relation to the device or request the manufacturer to carry out such tests.

Justification
The requirements on the conformity assessment based on design dossier examination should be concretised and amended by taking over the already existing requirements regarding assessment of the application by the manufacturer describe in the voluntary code of conduct of Notify Bodies.
Amendment 314

Proposal for a regulation
Annex VIII – point 5 – point 5.3 a (new)

Text proposed by the Commission

5.3 a. For devices in class III the clinical part of the dossier shall be evaluated by an appropriate clinical expert among those contained in the list developed by the MDCG according to Art. 80 g)

Amendment

Amendment 315

Proposal for a regulation
Annex VIII – point 8 – introductory part

Text proposed by the Commission

8. The manufacturer or his authorised representative shall, for a period ending at least five years, and in the case of implantable devices at least 15 years, after the last device has been placed on the market, keep at the disposal of the competent authorities:

Amendment

8. The manufacturer or his authorised representative shall, for a period at least equivalent to the lifetime of the medical device as defined by the manufacturer, but not less than 10 years from the date of product release by the manufacturer, keep at the disposal of the competent authorities:

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 316

Proposal for a regulation
Annex IX – point 7 – paragraph 1 – introductory part

Text proposed by the Commission

The manufacturer or his authorised representative shall, for a period ending at least five years, and in the case of implantable devices at least 15 years, after

Amendment

The manufacturer or his authorised representative shall, for a period at least equivalent to the lifetime of the medical device as defined by the manufacturer,
the last device has been placed on the market, keep at the disposal of the competent authorities: but not less than 10 years from the date of product release by the manufacturer, keep at the disposal of the competent authorities:

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 317

Proposal for a regulation
Annex X – part A – point 4 – paragraph 2

Text proposed by the Commission

In the case of devices classified as class III, the surveillance shall also include a check of the coherence between the quantity of produced or purchased raw material or crucial components approved for the type and the quantity of finished products.

Amendment

deleted

Justification

A check of the coherence between the quantity of produced or purchased raw material or crucial components approved for the type and the quantity of finished products is often not possible. The tasks and competences of the notified bodies are in the field of technical examinations and not business analyses. Checking the coherence is generally the duty of the manufacturer for financial accounting reasons.

Amendment 318

Proposal for a regulation
Annex X – part A – point 6 – paragraph 1 – introductory part

Text proposed by the Commission

The manufacturer or his authorised representative shall, for a period ending at least five years, and in the case of implantable devices at least 15 years, after the last device has been placed on the

Amendment

The manufacturer or his authorised representative shall, for a period at least equivalent to the lifetime of the medical device as defined by the manufacturer, but not less than 10 years from the date of
market, keep at the disposal of the competent authorities: product release by the manufacturer, keep at the disposal of the competent authorities:

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 319

Proposal for a regulation
Annex X – part A – point 7 – point 7.5 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.5. By way of derogation from Section 6, the manufacturer or his authorised representative shall, for a period ending at least five years after the last device has been placed on the market, keep at the disposal of the competent authorities:</td>
<td>7.5. By way of derogation from Section 6, the manufacturer or his authorised representative shall, for a period at least equivalent to the lifetime of the medical device as defined by the manufacturer, but not less than 10 years from the date of product release by the manufacturer, keep at the disposal of the competent authorities:</td>
</tr>
</tbody>
</table>

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 320

Proposal for a regulation
Annex X – Part B – point 4 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. The notified body shall carry out the appropriate examinations and tests in order to verify the conformity of the device with the requirements of the Regulation by examining and testing every product as specified in Section 5.</td>
<td>4. The notified body shall carry out the appropriate examinations and tests in order to assess the conformity of the device with the requirements of the Regulation by examining and testing every product as specified in Section 5 or by examination and testing of the products on a statistical basis as specified in section 6.</td>
</tr>
</tbody>
</table>
Justification

In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.

Amendment 321

Proposal for a regulation
Annex X – Part B – point 5 a (new) – title

Text proposed by the Commission

5 a. Statistical verification of conformity

Amendment

Justification

In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.

Amendment 322

Proposal for a regulation
Annex X – Part B – point 5 a – part 5.1 (new)

Text proposed by the Commission

5.1. The manufacturer shall present the manufactured products in the form of homogeneous batches. The proof of homogeneity for the presented products shall be part of the batch documentation.

Amendment

Justification

In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.

Amendment 323

Proposal for a regulation
5.2. A random sample is taken from each batch. The products which make up the sample shall be examined individually and the appropriate physical or laboratory tests defined in the relevant standard(s) referred to in Article 6 or equivalent tests shall be carried out in order to verify the conformity of the devices with the type described in the EU type-examination certificate and with the requirements of this Regulation which apply to them.

Justification

In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.

Amendment 324
Proposal for a regulation

5.3. Statistical control of products shall be based on attributes and/or variables, entailing sampling schemes with operational characteristics which ensure a high level of safety and performance according to the state of the art. The sampling schemes will be established by the harmonised standards or equivalent tests referred to in Article 6, taking account of the specific nature of the product categories in question.

Justification

In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.
### Amendment 325

**Proposal for a regulation**  
**Annex X – Part B – point 5 a – part 5.4 (new)**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.4. The notified body shall affix, or have affixed, its identification number to each approved device and shall draw up an EU product verification certificate relating to the tests carried out.</td>
<td></td>
</tr>
<tr>
<td>All products in the batch may be put on the market except any in the sample which failed to conform.</td>
<td></td>
</tr>
<tr>
<td>If a batch is rejected, the competent notified body must take appropriate measures to prevent the batch from being placed on the market.</td>
<td></td>
</tr>
<tr>
<td>In the event of frequent rejection of batches, the notified body may suspend the statistical verification.</td>
<td></td>
</tr>
</tbody>
</table>

**Justification**

*In line with Decision 768/2008/EC, Module F, number 5, the option to conduct statistical verifications should be added, because in particular, products cannot be assessed by means of product verification without the statistical verification processes.*

### Amendment 326

**Proposal for a regulation**  
**Annex X – Part B – point 7 – paragraph 1 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The manufacturer or his authorised representative shall, for a period <em>ending</em> at least <em>five years, and in the case of implantable devices at least 15 years, after the last device has been placed on the market</em>, keep at the disposal of the</td>
<td>The manufacturer or his authorised representative shall, for a period at least <em>equivalent to the lifetime of the medical device as defined by the manufacturer, but not less than 10 years from the date of product release by the manufacturer</em>, keep</td>
</tr>
</tbody>
</table>
competent authorities: at the disposal of the competent authorities:

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 327

Proposal for a regulation
Annex X – Part B – point 8 – point 8.4 – introductory part

Text proposed by the Commission

8.4. By way of derogation from Section 7, the manufacturer or his authorised representative shall, for a period ending at least five years after the last device has been placed on the market, keep at the disposal of the competent authorities:

Amendment

8.4. By way of derogation from Section 7, the manufacturer or his authorised representative shall, for a period at least equivalent to the lifetime of the medical device as defined by the manufacturer, but not less than 10 years from the date of product release by the manufacturer, keep at the disposal of the competent authorities:

Justification

The retention periods for the documents should be adapted in order to fulfil and harmonise with international standards (compare e.g. ISO 13485).

Amendment 328

Proposal for a regulation
Annex XIII – part A – point 2

Text proposed by the Commission

2. Confirmation of conformity with the requirements concerning the characteristics and performances referred to in Section 1 of Annex I, under the normal conditions of use of the device, and the evaluation of the undesirable side-effects and of the acceptability of the benefit/risk ratio referred to in Sections 1 and 5 of Annex I, shall be based on clinical data.

Amendment

2. Confirmation of conformity with the requirements concerning the characteristics and performances referred to in Section 1 of Annex I, under the normal conditions of use of the device, and the evaluation of the undesirable side-effects and of the acceptability of the benefit/risk ratio referred to in Sections 1 and 5 of Annex I, shall be based on clinical data.
Data from independent scientific institutions or medical societies based on their own collections of clinical data shall also be taken into account.

Amendment 329
Proposal for a regulation
Annex XIII - Part A - point 5

**Text proposed by the Commission**

5. In the case of *implantable devices and devices falling within class III*, clinical investigations shall be performed unless it is duly justified to rely on existing clinical data alone. Demonstration of equivalence in accordance with Section 4 shall generally not be considered as sufficient justification within the meaning of the first sentence of this paragraph.

**Amendment**

5. In the case of devices falling within *Article 43a(1), with the exception of those used for a short term*, clinical investigations shall be performed unless it is duly justified to rely on existing clinical data alone. Demonstration of equivalence in accordance with Section 4 shall generally not be considered as sufficient justification within the meaning of the first sentence of this paragraph.

Amendment 330
Proposal for a regulation
Annex XIII – point 5 a (new)

**Text proposed by the Commission**

5 a. All clinical data collected by the manufacturer as part of a PMCF should be made accessible to health professionals.

**Amendment**

5 a. All clinical data collected by the manufacturer as part of a PMCF should be made accessible to health professionals.

Amendment 331
Proposal for a regulation
Annex XIII – part B – point 1

**Text proposed by the Commission**

1. Post-market clinical follow-up,

**Amendment**

1. Post-market clinical follow-up,
hereinafter: PMCF, is a continuous process to update the clinical evaluation referred to in Article 49 and Part A of this Annex and shall be part of the manufacturer’s post-market surveillance plan. To this end, the manufacturer shall proactively collect and evaluate clinical data from the use in or on humans of a device which is authorised to bear the CE marking, within its intended purpose as referred to in the relevant conformity assessment procedure, with the aim of confirming the safety and performance throughout the expected lifetime of the device, the continued acceptability of identified risks and to detect emerging risks on the basis of factual evidence.

3. The manufacturer shall analyse the findings of the PMCF and document the results in a PMCF evaluation report that shall be part of the technical documentation.

For class III medical devices, the manufacturer's PMCF evaluation report shall be reviewed by a third party or external expert under the principles of highest scientific competence and impartiality. In order to conduct its review, the manufacturer shall provide the relevant data to the third party or external expert. Both the manufacturer's PMCF evaluation report and its review by an independent body shall be part of the technical documentation for class III medical devices.
Amendment 333
Proposal for a regulation
Annex XIII – part B – point 4

Text proposed by the Commission

4. The conclusions of the PMCF evaluation report shall be taken into account for the clinical evaluation referred to in Article 49 and Part A of this Annex and in the risk management referred to in Section 2 of Annex I. If through the PMCF the need for corrective measures has been identified, the manufacturer shall implement them.

Amendment

4. The conclusions of the PMCF evaluation report, and where applicable its review by a third party or external experts as referred to in paragraph 3, shall be taken into account for the clinical evaluation referred to in Article 49 and Part A of this Annex and in the risk management referred to in Section 2 of Annex I. If through the PMCF the need for corrective measures has been identified, the manufacturer shall implement them and inform the concerned Member States.

Amendment 334
Proposal for a regulation
Annex XIV – part I – point 1 – paragraph 1

Text proposed by the Commission

Every step in the clinical investigation, from first consideration of the need and justification of the study to the publication of the results, shall be carried out in accordance with recognised ethical principles, as for example those laid down in the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th World Medical Association General Assembly in Helsinki, Finland, in 1964, and last amended by the 59th World Medical Association General Assembly in

Amendment

Every step in the clinical investigation, from first consideration of the need and justification of the study to the publication of the results, shall be carried out in accordance with recognised ethical principles, as for example those laid down in the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th World Medical Association General Assembly in Helsinki, Finland, in 1964, and last amended by the 59th World Medical Association General Assembly in
Seoul, Korea, in 2008. Conformity with the above principles shall be granted after an examination by the concerned Ethics Committee. Regulation of the detailed requirements relating to the participation of subjects in clinical trials shall be the responsibility of the Member States.

Amendment 335

Proposal for a regulation
Annex XIV – Part I – paragraph 2 – point 2.1.

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1. Clinical investigations shall be performed on the basis of an appropriate plan of investigation reflecting the latest scientific and technical knowledge and defined in such a way as to confirm or refute the manufacturer's claims for the device as well as the safety, performance and benefit/risk related aspects referred to in Article 50(1); these investigations shall include an adequate number of observations to guarantee the scientific validity of the conclusions.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1. Clinical investigations shall be performed on the basis of an appropriate plan of investigation reflecting the latest scientific and technical knowledge and defined in such a way as to confirm or refute the technical performance of the device, the clinical safety and efficacy of the device when used for the intended purpose in the target population and in accordance with the instructions of use, and the manufacturer's claims for the device as well as the safety, performance and benefit/risk related aspects referred to in Article 50(1); these investigations shall include an adequate number of observations to guarantee the scientific validity of the conclusions.</td>
</tr>
</tbody>
</table>

Amendment 336

Proposal for a regulation
Annex XIV – Part I – paragraph 2 – point 2.3.

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3. Clinical investigations shall be performed in circumstances similar to the normal conditions of use of the device.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3. Clinical investigations shall be performed in circumstances similar to the normal conditions of use of the device for the intended purpose in the target population.</td>
</tr>
</tbody>
</table>
Amendment 337

Proposal for a regulation
Annex XIV – part I – point 2 – point 2.7

**Text proposed by the Commission**

2.7. The clinical investigation report, signed by the medical practitioner or other authorised person responsible, shall contain a critical evaluation of all the data collected during the clinical investigation, including negative findings.

**Amendment**

2.7. The clinical investigation report, signed by the medical practitioner or other authorised person responsible, shall contain all clinical data collected during the clinical investigation and a critical evaluation of such data, including negative findings.

Amendment 338

Proposal for a regulation
Annex XIV – Part I a (new) – point 1

**Text proposed by the Commission**

1. Incapacitated subjects

In the case of incapacitated subjects who have not given, or who have not refused to give, informed consent before the onset of their incapacity, clinical investigations may be conducted only where, in addition to the general conditions, all of the following conditions are met:

– the informed consent of the legal representative has been obtained; consent shall represent the subject’s presumed will and may be revoked at any time, without detriment to the subject;

– the incapacitated subject has received adequate information in relation to his or her capacity for understanding regarding the clinical investigation and its risks and benefits from the investigator or his/her representative, in accordance with the national law of the Member State
concerned;
– the explicit wish of an incapacitated subject who is capable of forming an opinion and assessing this information to refuse participation in, or to be withdrawn from the clinical investigation at any time without giving a reason and with no liability or prejudice whatsoever being incurred by the subject or their legal representative as a result shall be followed by the investigator;

– no incentives or financial inducements are given except compensation for participation in the clinical investigation;

– such research is essential to validate data obtained in a clinical investigation on persons able to give informed consent or by other research methods;

– such research relates directly to medical condition from which the person concerned suffers;

– the clinical investigation has been designed to minimise pain, discomfort, fear, and any other foreseeable risk in relation to the disease and developmental stage and both the risk threshold and the degree of distress are specially defined and constantly observed;

- the research is necessary to promote the health of the population concerned by the clinical performance study and cannot instead be performed on capacitated subject;

– there are grounds for expecting that participation in the clinical investigation will produce a benefit to the incapacitated subject outweighing the risks or will produce only a minimal risk;

– an ethics committee, with expertise regarding the relevant disease and the patient population concerned, or that has taken advice on clinical, ethical and psychosocial questions in the field of the relevant disease and patient population
concerned, has endorsed the protocol;
The test subject shall as far as possible take part in the consent procedure.

Amendment 339
Proposal for a regulation
Annex XIV – Part I a (new) - point 2

Text proposed by the Commission

Amendment

2. Minors

A clinical investigation may be conducted only where, in addition to the general conditions, all of the following conditions are met:

– the written informed consent of the legal representative or representatives has been obtained, whereby consent shall represent the minor’s presumed will;

- the informed and express consent of the minor has been obtained, where they are able to give consent according to national law,

– the minor has received all relevant information in a way adapted to his or her age and maturity, from a medical doctor (either the investigator or member of the study team) trained or experienced in working with children, regarding the study, the risks and the benefits;

– without prejudice to second indent, the explicit wish of a minor who is capable of forming an opinion and assessing this information to refuse participation in, or to be withdrawn from the clinical investigation at any time, is duly taken into consideration by the investigator;

– no incentives or financial inducements are given except compensation for participation in the clinical investigation;

– such research either relates directly to a
medical condition from which the minor concerned suffers or is of such a nature that it can only be carried out on minors;

– the clinical investigation has been designed to minimise pain, discomfort, fear and any other foreseeable risk in relation to the disease and developmental stage, and both the risk threshold and the degree of distress are specially defined and constantly observed;

– there are grounds to expect that some direct benefit for the category of patients concerned by the study may be obtained from the clinical investigation;

– the corresponding scientific guidelines of the EMA have been followed;

– the interest of the patient shall always prevail over those of science and society;

– the clinical investigation does not replicate other studies based on the same hypothesis and age-appropriate technology are used;

– an ethics committee, with paediatric expertise or after taking advice in clinical, ethical and psychosocial problems in the field of paediatrics, has endorsed the protocol.

The minor shall take part in the consent procedure in a manner adapted to his or her age and maturity. Minors who are able to give consent according to national law shall also give their informed and express consent to participate in the study.

If during a clinical investigation the minor reaches the age of majority as defined in the national law of the Member State concerned, his/her express informed consent shall be obtained before the clinical investigation may continue.
Amendment 340
Proposal for a regulation
Annex XIV – Part II – point 1 – point 1.11

Text proposed by the Commission

1.11. Summary of the clinical investigation plan (objective(s) of the clinical investigation, number and gender of subjects, criteria for subject selection, subjects under 18 years of age, design of the investigation such as controlled and/or randomised studies, planned dates of commencement and of completion of the clinical investigation).

Amendment

1.11. Summary of the clinical investigation plan (objective(s) of the clinical investigation, number and gender of subjects, criteria for subject selection, subjects under 18 years of age, design of the investigation such as controlled and/or randomised studies, planned dates of commencement and of completion of the clinical investigation). As randomised controlled investigations usually generate a higher level of evidence for clinical efficacy and safety, the use of any other design or study has to be justified. Also the choice of the control intervention shall be justified. Both justifications shall be provided by independent experts with the necessary qualifications and expertise.

Amendment 341
Proposal for a regulation
Annex XIV – part II – point 2.4 – first indent

Text proposed by the Commission

2.4 Existing clinical data, in particular - of the relevant scientific literature available relating to the safety, performance, design characteristics and intended purpose of the device, and/or of equivalent or similar devices;

Amendment

2.4 Existing clinical data, in particular - of the relevant scientific literature available relating to the safety, performance, design characteristics and intended purpose of the device and/or of equivalent or similar devices, and of the comparator where applicable;
Amendment 342
Proposal for a regulation
Annex XIV - section II - point 2.5

Text proposed by the Commission

2.5. Summary of the risk/benefit analysis and the risk management, including information regarding known or foreseeable risks, any undesirable effects, contra-indications and warnings.

Amendment

2.5. Summary of the risk/benefit analysis and the risk management, including information regarding known or foreseeable risks, any undesirable effects, contra-indications and warnings of the device, and of the comparator where applicable.

Amendment 343
Proposal for a regulation
Annex XIV – part II – point 3 – point 3.1 – point 3.1.3

Text proposed by the Commission

3.1.3. Information on the principal investigator, coordinating investigator, including their qualifications, and on the investigation site(s).

Amendment

3.1.3. Information on the principal investigator, coordinating investigator, including their qualifications, and on the investigation site(s), as well as information about the contract between the sponsor and the investigating establishment, together with details of the funding.

Justification

It is standard procedure for ethics committees to have access to the contracts between the sponsor and the investigating establishments, and for them to be required to take these into account in evaluating the protocol for the study.

Amendment 344
Proposal for a regulation
Annex XIV – part II – point 3 – point 3.1 – point 3.1.4
3.1.4. Overall synopsis of the clinical investigation.

Justification

To permit an objective evaluation of applicability, a summary of the plan for the investigation in the appropriate national language is vital.

Amendment 345

Proposal for a regulation
Annex XIV - part II - point 3 - point 3.2

3.2 Identification and description of the device, including its intended purpose, its manufacturer, its traceability, the target population, materials coming into contact with the human body, the medical or surgical procedures involved in its use and the necessary training and experience for its use.

Amendment 346

Proposal for a regulation
Annex XIV - part II - point 3.4

3.4 Risks and benefits of the device and of the clinical investigation.

Amendment 347

Proposal for a regulation
Annex XIV – part II – point 3 – point 3.15 a (new)
3.15 a. A plan for the further treatment of subjects after the clinical investigation.

Justification

The Declaration of Helsinki lays down that the protocol must define an agreement on access by subjects, after the study, to interventions which have been identified as useful during the study or access to other care or support.

Amendment 348

Proposal for a regulation
Annex XV

ANNEX XV
List of products covered by the last subparagraph of the definition of ‘medical device’ referred to in number (1) of Article 2(1)
1. Contact lenses;
2. Implants for modification or fixation of body parts;
3. Facial or other dermal or mucous membrane fillers;
4. Equipment for liposuction;
5. Invasive laser equipment intended to be used on the human body;
6. Intense pulsed light equipment.

ANNEX XV
List of products covered by the last subparagraph of the definition of ‘medical device’ referred to in number (1) of Article 2(1)
1. Contact lenses;
2. Implants for modification or fixation of body parts;
3. Facial or other dermal or mucous membrane fillers;
4. Equipment for liposuction and lipolysis;
5. Laser equipment intended to be used on the human body;
6. Intense pulsed light equipment.
7. Tattoo inks;
8. Chemical peels.
EXPLANATORY STATEMENT

Your rapporteur welcomes the Commission proposal to revise the existing regulatory framework on medical devices. Such revision of this twenty years-old framework was particularly needed and many improvements have been brought to the current legislation. However, your rapporteur still believes that many other changes, which you will find described below, should still be introduced in the text.

Order of the text

The Commission proposes a structure for the text which is not entirely satisfactory as it does not mirror the sequence of activities that need to be performed before a medical device can be safely used. The second chapter is already referring to making devices available, free movement, or even reprocessing, before any mention of the classification of the devices or of the selection of the approval procedure. The order used also puts the emphasis on placing the device on the market and on its free movement within the EU, while leaving considerations of patient safety and public health (classification, procedure for approval and clinical investigations) at a second stage.

Your rapporteur believes that the logical sequence of the lifecycle of a device should be better reflected in the structure of the text and therefore proposes to change the chapter sequence of the proposal as follows: section 1 of chapter V on the classification of a device should be taken out and be dealt with in a new chapter II; chapter III should outline the various approval procedures of devices; chapter IV on notified bodies would remain in its place as it is linked with the conformity assessment procedure which is described in the previous chapter; chapter V sets out the provisions on clinical evaluations and clinical investigations which are required to demonstrate conformity with general safety and performance requirements based on clinical data and, consequently, for the approval of a device; following the decision regarding the approval of a device, the placing on the market and free movement of devices are treated in the proposed chapter VI; a separate chapter VII on the labelling of devices as single-use or reusable, and on reprocessing in the case of the latter is established; provisions on the identification and traceability of devices, on the registration of devices and economic operators, as well as the European databank on medical devices are set out in chapter VIII. The last four chapters of the Commission proposal remain at the end of the text.

Classification of devices

Your rapporteur generally agrees with the improvements brought about in the Commission proposal in terms of the classification of medical devices into four classes according to the level of risk they post onto patients. However, rule 21 in annex VII on classification, which stipulates that all devices composed of substances intended to be ingested, inhaled or administered rectally or vaginally and that are absorbed by or dispersed in the human body are classified in class III is disproportionate. It would affect a very high number of medical devices on the market which already fall under rule 5. Your rapporteur suggests the deletion of this new rule.
The approval system of medical devices

The conformity assessment procedure has shown substantial weaknesses over the past years, such as the lack of transparency, swift approval and placing on the market of medical devices despite insufficient investigations on patients and therefore insufficient clinical data, consequently putting patients at risk.

Your rapporteur believes that medical devices presenting the highest potential risks for patients should be subject to a more stringent procedure than a conformity assessment. This category should include medical devices listed in class III, those implanted into the body, incorporating a substance considered to be a medicinal product, intended to administer a medicinal product, or utilising non-viable tissues or cells of human or animal origin, or their derivatives. For such devices, your rapporteur proposes to introduce the possibility to assess on a case-by-case basis the robustness of the clinical data and the evidence that the device can be safely placed on the EU market.

An Assessment Committee for Medical Devices (ACMD) is created in order to provide the case-by-case assessment where its members deemed it necessary to ask for the review of the clinical data. The ACMD is formally hosted by the Commission which ensures its secretariat and ensures its smooth functioning. The ACMD should be composed of the best specialists in various medical fields, as listed in categories or subgroups, which can be subject of modifications, notably in light of technical progress. Patients representatives and a representative from the European Medicines Agency should also take part in the ACMD and contribute to the case-by-case assessments. Three members of the relevant subgroups or Commission may decide to ask for a case-by-case assessment in situations such as the novelty of the device or of an increased rate of incidents reported for a group of devices. In these cases, the Coordination group of the ACMD will ask the relevant sub-group to conduct this review. On the basis of this assessment of the clinical data, the Commission will adopt an opinion which will be binding upon the Special notified body.

Special notified bodies

A category of Special notified bodies is created. These bodies will be in charge of conducting conformity assessments for class III devices, devices implanted into the body, devices incorporating a substance considered to be a medicinal product, or intended to administer a medicinal product, as well as devices utilising non-viable tissues or cells of human or animal origin, or their derivatives. Notified bodies requesting to be designated for the conformity assessment of those devices need to fulfil new additional requirements, notably in terms of qualification of their staff. An EU public health agency, the European Medicines Agency, already has a solid expertise at EU level in the medicines which can be incorporated, administered or removed by an increasing number of medical devices. It will consequently be in charge of designating those Special notified bodies in accordance with the additional requirements listed in the legislation. A network of Special notified bodies is created in order for these Special notified bodies to exchange good practice and to ensure more convergence in their work.

Notified bodies

In addition, both the functioning of notified bodies and their monitoring by national
authorities have shown huge weaknesses over the past years. The issues which were raised notably include: the very large and imprecise number of notified bodies within the EU; substantial disparities concerning the quality of the conformity assessments conducted; the lack of transparency surrounding their organisation, the data used, their activities, and the results of their assessments; the question whether they have personnel available with the required scientific expertise in order to perform assessments of the manufacturers' clinical evaluations appropriately; and the lack of proper and strict monitoring the work of the notified bodies by some national authorities. The proposal of the Commission has addressed some of these weaknesses. This constitutes a substantial improvement as compared to the existing legislation. However, many points in relation to the abovementioned issues still need to be addressed.

Your rapporteur is of the view that the provisions related to the personnel in the national authorities responsible for the designation and monitoring of notified bodies should be reinforced as well to ensure that sufficient qualifications to audit the notified bodies for which they are responsible are available.

Moreover, it should be ensured that notified bodies have permanent "in house" competent personnel and that subcontracting is the exception. Contracts may notably be awarded to cases where clinical expertise is limited, for instance in the event of innovative devices or technologies. Where subcontracting is applied, notified bodies should make publicly available the names of subcontractors and the precise tasks for which they have been awarded a contract. Once a year, notified bodies should be required to send documents to the relevant national authority to enable the verification of the subcontractors' qualifications.

During the designation process of a notify body, the relevant national authority should provide justifications where its decision is not in accordance with the recommendation of the MDCG. The reason why such justifications are needed is that the recommendation will already be based on an opinion of the joint assessment team: this process is consequently providing a series of checks before the recommendation is issued.

As a consequence of the internal market, manufacturers are allowed to apply with a notified body established in another Member State than the one where the manufacturer is registered. However, in the view of improving transparency, if a manufacturer chooses to do so, it should inform the national authority of the Member State where it is registered of such an application.

Your rapporteur supports the Commission proposal to establish a coordination group, which would include all notified bodies. However, in order to guarantee satisfactory coordination and cooperation among notified bodies, and with the overall aim to increase convergence in the quality of the work of notified bodies, it should be ensured that this group meets at least twice a year.

Your rapporteur welcomes the Commission introduction of fees charged by national authorities for their activities related to the designation and monitoring of notified bodies. However, it is important that those fees are made public and comparable across Member States.
Your rapporteur believes that the Commission proposal does not offer sufficient guarantees that the competition among notified bodies on the basis of the fees to perform their conformity assessment activities is not done to the expense of patient safety. Therefore, provisions are included to require Member States to adopt national legislation in this respect, in order to ensure transparency of fees and to facilitate their comparability.

**Labelling of devices as single-use (or reusable) and reprocessing of devices**

Reuse of medical devices was very common until the 1980s, when manufacturers started more systematically to label their devices as single-use. The current situation is that there are too many devices labelled as single-use while they could be reprocessed, as manufacturers want to avoid bearing the responsibility in case the reprocessing of a device would pose a danger to a patient. Sometimes, improper labelling is the result of economic considerations. The Commission has decided to maintain the possibility to reprocess single-use devices. This is not satisfactory. Your rapporteur is of the view that devices labelled as single-use should be real single-use and that there should be only two options: single-use and reusable. Your rapporteur also strongly believes that activities encompassed in the reprocessing of devices should be subject to stricter and more transparent standards.

As a result, only devices labelled as reusable should be reprocessed. To ensure the highest patient safety in the EU, a list of single-use devices unsuitable for reprocessing should be set up by the Commission after consultation of the Medical Device Advisory Committee. In cases where a company specialised in the reprocessing of medical devices, or a hospital or a clinic which already reprocess specific devices, has evidence to challenge the single-use label, it should provide it to one of the EU Reference Laboratories. The latter will assess this evidence and decide whether the device can be safely reprocessed. If the device is removed from the list of single-use devices unsuitable for reprocessing and the manufacturer shall re-label newly produced items as reusable. It should also be made clear that the reprocessing of a device entails an automatic shift of responsibility from the manufacturer to the re-processor, who notably ensures the traceability of the device. Finally, the Commission should adopt implementing acts to set up the highest and most coherent standards for the reprocessing of reusable devices within the EU.

**Clinical investigations**

The Commission has introduced important provisions on clinical investigations and yet some terms such as "performance" or "safety" are not defined although manufacturers should collate data to prove that their devices meet performance and safety requirements.

Performance should notably be understood broadly so as to encompass efficacy and benefit to the patient, which shall be checked in cases where clinical investigations apply. This is crucial to ensure that devices are technically achieving the aim for which they were designed and produced, but also bring benefit to the patient and are efficient when used in real-life. It should also be ensured that, where clinical investigations apply, they shall be designed in a way that the best methodology available is used and randomized controlled clinical investigations are included. The Commission proposal also mirrors the provisions of the proposed regulation on clinical trials in which the reference to ethics committees has disappeared. However, your rapporteur believes that clinical investigations should only start...
after having been granted a positive evaluation result by an independent ethics committee. Member States should take the necessary measures to establish ethics committees where such committees do not exist. Lastly, it should also be ensured that, in case of an early termination of a clinical investigation, information on the reasons for this is provided to all Member States, so that they can inform sponsors conducting similar clinical investigations of the results of that clinical investigation at the same time throughout the EU. This will enable to bring more transparency and to avoid having several studies being run in parallel and successively providing clinical evidence concluding that a device may pose a risk to the patient.

**European databank on medical devices (EUDAMED)**

The use of Eudamed has been obligatory since May 2011, but there has been a lot of criticism regarding its functioning. The Commission has proposed some improvements, but your rapporteur is of the view that some provisions on the transparency of information are still missing.

Consequently, adequate levels of access for the public and healthcare professionals to those parts of Eudamed's electronic systems which provide key information on medical devices that may pose a risk to public health and safety should be ensured.

**Vigilance and market surveillance**

The Commission has introduced important provisions on the reporting of incidents and field safety corrective actions. Some elements are nevertheless still missing to ensure a swift tracing back of all aspects surrounding the incidents. This should help determine whether the incident is linked with the device itself or the way it was used.

Consequently, it should be ensured that the reporting through the electronic system includes date and place of incidents, and where available, information on the patient or user and healthcare professional, in full respect of privacy.

**Coordination between Member States and MDCG**

The Commission has proposed the creation of the MDCG, but it is not sure whether this group will have sufficient expertise to perform its tasks.

Your rapporteur proposes to set up a multidisciplinary advisory committee of experts and representatives of stakeholders and civil society organisations in order to provide scientific advice to the MDCG, but also to the Commission, and the Member States. This group will provide expertise on issues of classification, borderline cases and other aspects of the Regulation's implementation, as necessary.
20.6.2013

OPINION OF THE COMMITTEE ON EMPLOYMENT AND SOCIAL AFFAIRS

for the Committee on the Environment, Public Health and Food Safety

(COM(2012)0542 – C7-0318/2012 – 2012/0266(COD))

Rapporteur: Edite Estrela

SHORT JUSTIFICATION

On 26 September 2012, the Commission adopted a package on innovation in health consisting of a Communication on safe, effective and innovative medical devices and in vitro diagnostic medical devices for the benefit of patients, consumers and healthcare professionals, a Proposal for a Regulation of the EP and of the Council on medical devices, and a Proposal for a Regulation of the EP and of the Council on in vitro diagnostic medical devices. These proposals aim to update the existing European legislation in light of technological and scientific progress and to address recently voiced concerns over certain aspects of patient safety.

The proposal for a Regulation on medical devices, which will replace Directive 90/385/EEC regarding active implantable medical devices, and Directive 93/42/EEC, regarding medical devices, aims to regulate the standards of safety, quality and efficiency of medical devices which can be placed on the market in the European Union.

Under this proposed legislation, the hundreds of thousands of different types of medical devices currently on the market in the European Union, ranging from sticking plasters, syringes, catheters and blood sampling devices to sophisticated implants and life-support technologies, are required to be safe not only for patients but also for the healthcare professionals who use or handle them and for lay persons who come into contact with them.

As laid down in Recital 71 of the proposal, the objective of this Regulation is to ensure high standards of quality and safety for medical devices allowing for a high level of protection of health and safety for patients, users and other persons. The term "user" is defined in the
current proposal as "any healthcare professional or lay person who uses a device” and the Regulation recognises that users are an essential component in providing safe health to patients. Medical devices are used mainly in hospital settings by healthcare professionals but also in other environments, including long-term care homes, patients’ homes and prisons. Those at risk include healthcare workers who use the products, ancillary workers (such as laundry, cleaning and refuse collection staff) as well as patients and the general public. As such, safe medical devices contribute directly to working conditions and need to provide for the safest possible working environment.

"Health and safety" is mentioned throughout the Regulation as an overarching goal. In this spirit, the proposal includes, in Annex I, the general safety and performance requirements for medical devices. Under point 8 of Annex I it explicitly states that "the devices and manufacturing processes shall be designed in such a way as to eliminate or to reduce as far as possible the risk of infection to patients, users and where applicable other persons". Point 11 of the same Annex also underlines the need for devices to avoid risk of injury to patients, users and other persons.

The relationship between safe and high quality medical devices and the overarching goal of ensuring health and safety for users, patients and other persons allows for this proposed Regulation to synergise with applicable EU legislation on occupational health. The Regulation should therefore incorporate explicit references to legislation providing for high levels of safety for users and patients in healthcare settings and take into account design and performance characteristics of medical devices cited in relevant EU Directives on occupational health. This is certainly the case with Directive 2010/32/EU on the prevention from sharp injuries in the hospital and healthcare sector, which aims to improve occupational safety following a Framework Agreement between the social partners at EU level which recognises the need to provide medical devices which incorporate safety-engineered protection mechanisms in order to limit the risk of injuries and infections from medical sharps. Therefore, it is entirely logical for such a provision to be recognised in the general safety and performance requirements of the medical devices Regulation.

It is not only frontline medical staff, such as nurses and doctors, who are at risk, but also caregivers in outpatient and alternative healthcare settings, laboratory staff and support workers such as cleaners, laundry workers, prison staff, etc.

Healthcare institutions need to make sure that their employees receive the necessary training for the correct use of medical devices, tools and practices that help reduce needlestick injuries, the transmission of healthcare associated infections and other adverse effects in order to ensure the safe use of new medical technology and surgical techniques.

All healthcare workers should also receive adequate protection, through vaccination, post-exposure prophylaxis, routine diagnostic screening, provision of personal protective equipment and the use of medical technology that reduces exposure to blood-borne infections.

The proposals put forward in this draft opinion take into account the previous work of the Employment and Social Affairs committee and its resolutions adopted to ensure the safety of workers in the healthcare environment, namely:
• European Parliament resolution on the mid-term review of the European strategy 2007-2012 on health and safety at work adopted on 15 December 2011,

• European Parliament resolution on the proposal for a Council directive implementing the Framework Agreement on prevention from sharp injuries in the hospital and healthcare sector concluded by HOSPEEM and EPSU adopted on 11 February 2010,

• European Parliament resolution on the Community strategy 2007-2012 on health and safety at work adopted on 15 January 2008,

• European Parliament resolution with recommendation to the Commission on protecting European healthcare workers from blood-borne infections due to needlestick injuries adopted on 6 July 2006.
AMENDMENTS

The Committee on Employment and Social Affairs calls on the Committee on the Environment, Public Health and Food Safety, as the committee responsible, to incorporate the following amendments in its report:

Amendment 1
Proposal for a regulation
Recital 2

Text proposed by the Commission

(2) This Regulation aims to ensure the functioning of the internal market as regards medical devices, taking as a base a high level of protection of health. At the same time, this Regulation sets high standards of quality and safety for medical devices to meet common safety concerns as regards these products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market which may then benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for those medical devices by ensuring, among other things, that data generated in clinical investigations is reliable and robust and that the safety of the subjects participating in a clinical investigation is protected.

Amendment

(2) This Regulation aims to ensure the functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients, users and operators. At the same time, this Regulation sets high standards of quality and safety for medical devices to meet common safety concerns as regards these products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market which may then benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for those medical devices by ensuring, among other things, that data generated in clinical investigations is reliable and robust and that the safety of the subjects participating in a clinical investigation is protected.

Amendment 2
Proposal for a regulation
Recital 3
Text proposed by the Commission

(3) Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding devices should be introduced, to improve health and safety.

Amendment

(3) Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding devices should be introduced, to improve health and safety for health professionals, patients, users and operators, including in the waste disposal chain.

Amendment 3

Proposal for a regulation
Recital 13

Text proposed by the Commission

(13) There is scientific uncertainty about the risks and benefits of nanomaterials used for medical devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, with the necessary flexibility to adapt this definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of medical devices, the manufacturers should take special care when using nanoparticles that can be released to the human body and those devices should be subject to the most severe conformity assessment procedure.

Amendment

(13) There is scientific uncertainty about the risks and benefits of nanomaterials used for medical devices. In order to ensure a high level of health and safety protection for health professionals, operators and patients, as well as free movement of goods, legal certainty for manufacturers and responsibility on their part, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, with the necessary flexibility to adapt this definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of medical devices, the manufacturers should take special care when using nanoparticles that can be released to the human body and those devices should be subject to the most severe conformity assessment procedure.
Amendment 4
Proposal for a regulation
Recital 15 a (new)

Text proposed by the Commission

(15a) This Regulation includes requirements regarding the design, safety and performance characteristics of medical devices intended to prevent occupational injuries as laid down in Council Directive 2010/32/EU of 10 May 2010 implementing the Framework Agreement on prevention from sharp injuries in the hospital and healthcare sector concluded by HOSPEEM and EPSU.

1 OJ L 134, 1.6.2010, p. 66.

Amendment 5
Proposal for a regulation
Recital 19

Text proposed by the Commission

(19) To recognise the important role of standardisation in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No […] on European standardisation should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as quality and risk management.

Amendment

(19) To recognise the important role of standardisation and traceability in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU) No […] on European standardisation should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as quality and risk management.

Amendment 6
Proposal for a regulation
Recital 21 a (new)
(21a) The Directive 2013/35/EU of the European Parliament and of the Council of 26 June 2013 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields) (20th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC)\textsuperscript{1} should be the reference text for ensuring that people working in the vicinity of magnetic resonance imaging equipment when it is functioning are properly protected.

\textsuperscript{1} OJ L ..., ..., p. ... (not yet published in the OJ).

Amendment 7

Proposal for a regulation
Recital 32

Text proposed by the Commission

(32) Patients who are implanted with a device should be given essential information related to the implanted device allowing it to be identified and containing any necessary warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.

Amendment

(32) Patients who are implanted with a device must be given clear and easily accessible essential information related to the implanted device allowing it to be identified and containing any necessary warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.

Amendment 8

Proposal for a regulation
Recital 36
(36) One key aspect is the creation of a central database that should integrate different electronic systems, with the UDI as an integral part of it, to collate and process information regarding medical devices on the market and the relevant economic operators, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency, to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member States as well as between Member States among themselves and with the Commission, to avoid multiple reporting requirements and to enhance the coordination between Member States. Within an internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices (Eudamed) set up by Commission Decision 2010/227/EU of 19 April 2010 on the European Databank for Medical Devices.

The database will also facilitate the traceability of medical equipment donated or exported to countries outside the Union. Within an internal market, this can be ensured effectively only at Union level and the Commission should therefore further develop and manage the European databank on medical devices (Eudamed) set up by Commission Decision 2010/227/EU of 19 April 2010 on the European Databank for Medical Devices.

Amendment 9

Proposal for a regulation
Recital 39

(39) For high-risk medical devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available.

(39) For high-risk medical devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available and easily accessible.
Amendment 10
Proposal for a regulation
Recital 40

Text proposed by the Commission

(40) The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection and citizens' confidence in the system. Designation and monitoring of notified bodies by the Member States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.

Amendment

(40) The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection for health professionals, users and operators, including in the waste disposal chain, and for ensuring citizens’ confidence in the system. Designation and monitoring of notified bodies by the Member States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level.

Amendment 11
Proposal for a regulation
Recital 52

Text proposed by the Commission

(52) In order to better protect the health and safety regarding devices on the market, the vigilance system for medical devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions.

Amendment

(52) In order to better protect the health and safety of health professionals, patients, users and operators, including in the waste disposal chain, regarding devices on the market, the vigilance system for medical devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions.

Amendment 12
Proposal for a regulation
Recital 53

Text proposed by the Commission

(53) Healthcare professionals and patients

Amendment

(53) Healthcare professionals and patients
should be empowered to report suspected serious incidents at national level using harmonised formats. The national competent authorities should inform manufacturers and share the information with their peers when they confirm that a serious incident has occurred in order to minimise recurrence of those incidents.

should be empowered to report suspected serious incidents which affect the safety of patients, care givers, healthcare professionals or other persons, at national level using harmonised formats. The national competent authorities should inform manufacturers and share the information with their peers when they confirm that a serious incident has occurred in order to minimise recurrence of those incidents.

Amendment 13

Proposal for a regulation
Article 2 – paragraph 1 – subparagraph 1 – point 45

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(45) ‘corrective action’ means action taken to eliminate the cause of a potential or real non-conformity or other undesirable situation;</td>
<td>(45) ‘corrective action’ means action to eliminate the cause of non-conformities in order to prevent recurrence;</td>
</tr>
</tbody>
</table>

Amendment 14

Proposal for a regulation
Article 2 – paragraph 1 – subparagraph 1 – point 46

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(46) ‘field safety corrective action’ means corrective action taken by the manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market;</td>
<td>(46) Field Safety Corrective Action (FSCA): A field safety corrective action is an action taken by a manufacturer to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device;</td>
</tr>
</tbody>
</table>

Amendment 15

Proposal for a regulation
Article 2 – paragraph 1 – subparagraph 1 – point 47
(47) ‘field safety notice’ means the communication sent by the manufacturer to users or customers in relation to a field safety corrective action;

(47) ‘field safety notice’: a communication sent out by a manufacturer, or its representative to the device users or waste disposal operators in relation to a Field Safety Corrective Action;

Amendment 16
Proposal for a regulation
Article 4 – paragraph 5

Text proposed by the Commission

5. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress and considering the intended users or patients, the general safety and performance requirements set out in Annex I, including the information supplied by the manufacturer.

Amendment

deleted

Justification

The above text should be deleted because the Commission is only allowed to amend or supplement a legal text via delegated acts on non-essential elements. The safety and performance requirements are among the most essential elements of the proposed Regulation and should therefore not be changed via delegated acts.

Amendment 17
Proposal for a regulation
Article 8 – paragraph 2 – subparagraph 2

Text proposed by the Commission

The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress, the elements in the technical documentation set out in Annex II.

Amendment

deleted
Justification

The second part of the above Article should be deleted because the Commission is only allowed to amend or supplement a legal text via delegated acts on non-essential elements. The elements which shall appear in the technical documentation are among the most essential elements of the proposed Regulation.

Amendment 18
Proposal for a regulation
Article 41 – paragraph 4 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. In the light of technical progress and any information which becomes available in the course of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 as regards the following:</td>
<td>4. In the light of technical progress and any information which becomes available in the course of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission, having consulted relevant stakeholders, including healthcare professionals’ organisations, shall be empowered to adopt delegated acts in accordance with Article 89 as regards the following:</td>
</tr>
</tbody>
</table>

Amendment 19
Proposal for a regulation
Article 44 – paragraph 6 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>6a. Throughout the scrutiny process, the views of all relevant stakeholders, including patient, healthcare professionals and caregivers’ organisations, shall be taken into account.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 20
Proposal for a regulation
Article 51 – paragraph 6 a (new)
6a. An ethics review shall be carried out. The Commission shall facilitate the coordination between stakeholders, as well as the sharing of best practices and the development of quality standards for ethics review across the Union.

Amendment 21

Proposal for a regulation
Article 61 – paragraph 3 – subparagraph 2

Text proposed by the Commission

The Member States shall coordinate between them the development of standard web-based structured forms for reporting of serious incidents by healthcare professionals, users and patients.

Amendment

The Member States shall coordinate between them the development of standard web-based structured forms for reporting of serious incidents by healthcare professionals, users and patients. **Member States shall nevertheless maintain other formats for reporting suspected serious incidents to national competent authorities.**

Amendment 22

Proposal for a regulation
Article 63 – paragraph 1 – subparagraph 1

Text proposed by the Commission

1. Member States shall take the necessary steps to ensure that any information regarding a serious incident that has occurred within their territory or a field safety corrective action that has been or is to be undertaken within their territory, and that is brought to their knowledge in accordance with Article 61 is, at national level, evaluated centrally by their competent authority, if possible together with the manufacturer. **The competent**
with the manufacturer.

authority shall take into account the views of all relevant stakeholders, including patient and healthcare professionals' organisations.

Amendment 23
Proposal for a regulation
Article 94 – paragraph 4

Text proposed by the Commission

4. By way of derogation from Directives 90/385/EEC and 93/42/EEC, conformity assessment bodies which comply with this Regulation may be designated and notified before its date of application. Notified bodies which are designated and notified in accordance with this Regulation may apply the conformity assessment procedures laid down in this Regulation and issue certificates in accordance with this Regulation before its date of application.

Amendment

4. By way of derogation from Directives 90/385/EEC and 93/42/EEC, conformity assessment bodies which comply with this Regulation may be designated and notified before its date of application. Notified bodies which are designated and notified in accordance with this Regulation may apply the conformity assessment procedures laid down in this Regulation and issue certificates in accordance with this Regulation before its date of application provided that the relevant delegated and implementing acts have entered into force.

Justification

Implementing and delegated acts which are necessary for the correct implementation of this Regulation shall be ready before this Regulation is applied to any device.

Amendment 24
Proposal for a regulation
Annex 1 – part II – point 7 – point 7.4 – introductory part

Text proposed by the Commission

7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. Special attention shall be given to substances which are

Amendment

7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. Special attention shall be given to substances which are

Amendment 25
Proposal for a regulation
Annex 1 – part II – point 7 – point 7.4 – paragraph 1 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If devices, or parts thereof, that are intended</td>
<td>Devices, or parts thereof, that are intended</td>
</tr>
</tbody>
</table>

Amendment 26
Proposal for a regulation
Annex 1 – part II – point 7 – point 7.4 – paragraph 1 – indent 3 – paragraph 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>contain, in a concentration of 0.1% by mass of the plasticised material or above, phthalates which are classified as</td>
<td>shall not contain, in a concentration of 0.1% or above by mass per homogeneous material, substances which are classified</td>
</tr>
</tbody>
</table>
carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008, these devices shall be labelled on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging as devices containing phthalates. If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures.

Where the manufacturer can show that there are no suitable safer substances or devices without these substances, these devices shall be labelled on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging as devices containing substances which are classified as carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B or substances identified as endocrine disrupters. The manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for patients and, if applicable, on appropriate precautionary measures.

Justification

CMR substances are banned in cosmetic products and CMR phthalates are banned in toys. Similar restrictions should apply for medical devices where exposure is inevitable, unless as carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008, or substances identified as endocrine disrupters pursuant to the first subparagraph, unless the manufacturer can show that there are no suitable safer substances or devices without these substances.
there are no safer alternatives. Where no alternatives exist, manufacturers should label the devices and provide specific justification as to the compliance with the safety provisions of the regulation. The same should also apply for known endocrine disrupters. As the Commission is in the process of adopting a recommendation for the identification of endocrine disrupters, a reference to it should be added.

Amendment 27

Proposal for a regulation
Annex I – part II – point 7 – point 7.6

Text proposed by the Commission
7.6. The devices shall be designed and manufactured in such a way as to reduce to a minimum the risks linked to the size and the properties of particles used. Special care shall be applied when devices contain or consist of nanomaterial that can be released into the patient's or user's body.

Amendment
7.6. The devices shall be designed and manufactured in such a way as to reduce to a minimum the risks linked to the size and the properties of particles used. Special care shall be applied when devices contain or consist of nanomaterials that can be released into the patient's or user's body. The manufacturer shall provide specific evidence that the use of nanomaterials complies with the general safety and performance requirements within the technical documentation and, within the instructions for use, information on residual risks for patients and, if applicable, on appropriate precautionary measures.

Justification
When nanomaterials are being used in medical devices, manufacturers should provide specific evidence that their use complies with the general safety and performance requirements. This would greatly facilitate the application of the most severe conformity assessment as foreseen pursuant to Rule 19 and Recital 13.

Amendment 28

Proposal for a regulation
Annex I – part II – point 8 – point 8.1 – point a a (new)

Text proposed by the Commission
(aa) fully comply with the requirements of applicable Union Directives concerning

Amendment
(aa) fully comply with the requirements of applicable Union Directives concerning
Amendment 29

Proposal for a regulation
Annex 1 – part II – point 8 – point 8.1 – point a – paragraph 1

Text proposed by the Commission Amendment
and, where necessary, deleted

Amendment 30

Proposal for a regulation
Annex 1 – part II – point 10 – point 10.3 – paragraph 1

Text proposed by the Commission Amendment
In the case of biological substances other than those referred to in Sections 10.1 and 10.2., the processing, preservation, testing and handling of those substances shall be carried out so as to provide optimal safety for patients, users and, where applicable, other persons. In particular, safety with regard to viruses and other transmissible agents shall be addressed by implementation of validated methods of elimination or inactivation in the course of the manufacturing process.

Amendment 31

Proposal for a regulation
Annex 1 – part II – point 11 – point 11.2 a (new)

Text proposed by the Commission Amendment
11.2a. Devices which can transfer potentially fatal blood-borne infections to healthcare staff, patients or other persons, by unintended cuts and pricks such as needle stick injuries, shall incorporate appropriate safety-engineered protection
mechanisms in accordance with Directive 2010/32/EU. However the specificities relating to the dental profession must be respected.

Amendment 32

Proposal for a regulation
Annex 1 – part II – point 18 – point 18.2 – indent 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– ensure that the device is easy to use by the intended user at all stages of the procedure, <strong>and</strong></td>
<td>– ensure that the device is easy to use by the intended user at all stages of the procedure,</td>
</tr>
</tbody>
</table>

Amendment 33

Proposal for a regulation
Annex 1 – part II – point 18 – point 18.2 – indent 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– as laid out in Directive 2010/32/EU, reduce as far as possible the risk of injury and infection to other persons by incorporating safety-engineered protection mechanisms designed to prevent needle stick and other sharp injuries, and</td>
<td></td>
</tr>
</tbody>
</table>

Justification

Every year more than 1 million healthcare workers in the EU suffer life-changing and potentially fatal injuries involving medical devices that incorporate needles or other sharps. Not only are healthcare workers at risk of contracting blood-borne infections, they may also act as carrier to increase the risk of transmission to other patients.

Amendment 34

Proposal for a regulation
Annex 1 – part III – point 19 – point 19.3 – paragraph 1 a (new)
The instruction for use shall be lay-friendly and reviewed by the representatives of relevant stakeholders, including patient and healthcare professionals' organisations.
## Title

## References
COM(2012)0542 – C7-0318/2012 – 2012/0266(COD)

## Committee responsible
**Date announced in plenary**
ENVI
22.10.2012

## Opinion by
**Date announced in plenary**
EMPL
22.11.2012

## Rapporteur
**Date appointed**
Edite Estrela
21.11.2012

## Discussed in committee
23.4.2013  29.5.2013

## Date adopted
20.6.2013

## Result of final vote
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>43</td>
</tr>
<tr>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

## Members present for the final vote
Regina Bastos, Edit Bauer, Heinz K. Becker, Jean-Luc Bennahmias, Phil Bennion, Pervenche Berès, Philippe Boulland, Milan Cabrnoch, David Casa, Alejandro Cercas, Ole Christensen, Derek Roland Clark, Marije Cornelissen, Emer Costello, Frédéric Daerden, Karima Delli, Sari Essayah, Richard Falbr, Thomas Hänel, Marian Harkin, Nadja Hirsch, Stephen Hughes, Danuta Jazłowiecka, Martin Kastler, Ádám Kósa, Jean Lambert, Verónica Lope Fontagné, Olle Ludvigsson, Thomas Mann, Elisabeth Morin-Chartier, Csaba Öry, Sylvana Rapti, Licia Ronzulli, Elisabeth Schroedter, Joanna Katarzyna Skrzyteńska, Jutta Steinruck, Traian Ungureanu, Inès Cristina Zuber

## Substitute(s) present for the final vote
Sergio Gutiérrez Prieto, Jelko Kacin, Ria Oomen-Ruijten, Birgit Sippel

## Substitute(s) under Rule 187(2) present for the final vote
Jorgo Chatzimarkakis, Jürgen Klute
08.8.2013

OPINION OF THE COMMITTEE ON THE INTERNAL MARKET AND CONSUMER PROTECTION

for the Committee on the Environment, Public Health and Food Safety

(COM(2012)0542 – C7-0318/2012 – 2012/0266(COD))

Rapporteur: Nora Berra

SHORT JUSTIFICATION

Objectives of the proposal

A number of recent scandals have highlighted the shortcomings in current EU law on medical devices, in particular as regards the designation and functioning of notified bodies, clinical testing, market surveillance and the traceability of devices. Given that improvements were needed which covered all the phases in the life cycle of medical devices, from design to monitoring after they have been placed on the market, your rapporteur welcomes the Commission proposal and endorses the stated aim of introducing a regulation which is directly and immediately applicable and lays down harmonised provisions governing the entire life cycle of such devices. That approach is also consistent with the view expressed by the Committee on the Internal Market and Consumer Protection that wherever possible regulations rather than directives should be chosen as the preferred legal instrument for regulating the single market (see Parliament’s resolution of 7 February 2013 with recommendations to the Commission on the governance of the Single Market).

The revision of the current directive is also designed to bring that legal instrument, for which our committee was responsible during the previous parliamentary term and whose purpose was to eliminate obstacles to the free movement of products, into line with the ‘new approach’.

General comments

Your rapporteur takes the view that although the overriding objective must be the safety of patients and users, steps must also be taken to safeguard the free movement of products. For that reason, her amendments are principally designed to guarantee:

- that the scope of the future regulation covers all products on the market which meet the definition of medical device or have the chief characteristics of medical devices (equivalent aesthetic devices or ‘borderline’ products);
- that the reprocessing of medical devices already on the market does not call their safety and performance into question;
- a clearer definition of the responsibilities of economic operators, in an effort to ensure that monitoring is rigorous and effective;
- the rights of patients in the EU who suffer injury as a result of the use of faulty devices, by imposing more stringent requirements on manufacturers;
- that the same requirements as regards expertise, quality and probity apply to all Union certification bodies, given the vital role they play, and will continue to play, in the procedures governing the placing of medical devices on the market;
- a rapid and uniform response to problems on the part of the authorities and manufacturers, by strengthening the monitoring rules;
- all instances of fraud, default or deficiency can be ruled out by means of clearly defined surveillance rules.
An effective assessment mechanism tailored to high-risk devices

Your rapporteur agrees that a notified body should not have sole responsibility for authorising the placing on the market of innovative medical devices which present the highest levels of risk. If we are serious about strengthening the mechanisms governing the placing of medical devices on the market, it is essential that a given type of device should be required to undergo the same assessments, based on the same requirements, anywhere in the Union. This is difficult at present, however, given that there are few if any common assessment methods (guidelines) which manufacturers and notified bodies can employ. This difficulty is exacerbated by the fact that in many cases it is impossible to carry out exhaustive pre-marketing tests, so that post-marketing observational studies have to be relied upon to some extent instead.

Your rapporteur thus endorses the principle of clinical assessment at EU level for high-risk devices which are not covered by common guidelines.

With a view to establishing an effective system which will guarantee patient safety whilst cutting red tape and shortening lead-in times, your rapporteur is proposing:

- that the mechanism provided for in Article 44 should be applied systematically (in order to rule out discriminatory choices) in the case of class III devices which present the highest level of risk and which are not covered by common technical specifications or guidelines;
- that the opinion of the Medical Devices Coordination Group (MDCG) should be made binding: an opinion may be favourable, favourable but qualified (i.e. favourable for a certain period and subject to certain conditions) or negative, which would rule out final certification by the notified body and the placing of the device on the market;
- the gradual harmonisation of the requirements governing clinical assessments through the setting-up of groups of independent clinical and scientific experts under the authority of the MDCG (Article 81). These experts’ main tasks would be to carry out the scrutiny referred to in Article 44, on the basis of which the MDCG would deliver its opinions, and to draw up guidelines and common technical specifications for manufacturers and notified bodies concerning clinical assessments and post-market follow-up;
- to make provision for the experts to dispense ‘scientific advice’ to manufacturers whose devices are covered by the assessment mechanism, in order to inform them of the latest recommendations concerning clinical assessments, so that they can draw up a suitable development plan.

This assessment mechanism would become increasingly effective, as more and more monitoring information is collated and more and more experience is gained with products placed on the market, clearing the way for the gradual approximation of requirements and practices. The scrutiny provided for in Article 44 would likewise become more and more effective and would increasingly focus on the most innovative devices, which, by their very nature, are not covered by clinical assessment guidelines. Given the wide array of products and the risks involved, we have a duty to establish a dynamic system which enhances patient safety whilst safeguarding the benefits of our internal market.
**AMENDMENTS**

The Committee on the Internal Market and Consumer Protection calls on the Committee on the Environment, Public Health and Food Safety, as the committee responsible, to incorporate the following amendments in its report:

**Amendment 1**

**Proposal for a regulation**

**Recital 8**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>(8) It should be the responsibility of the Member States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. If necessary, the Commission may decide, on a case-by-case basis, whether or not a product falls within the definition of a medical device or of an accessory to a medical device. Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility to take an EU-wide decision regarding the regulatory status of a product should also be introduced in Regulation No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(8) It should be the responsibility of the Member States to decide on a case by case basis whether or not a product falls within the scope of this Regulation. If necessary, the Commission may decide, <em>when necessary, as for example when for a same product the decisions taken at national level vary between Member States</em>, on a case-by-case basis, whether or not a product falls within the definition of a medical device or of an accessory to a medical device. Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility to take an EU-wide decision regarding the regulatory status of a product should also be introduced in Regulation No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.</td>
</tr>
</tbody>
</table>

**Justification**

*It has to be consistent with the provisions of Article 3.1*

**Amendment 2**

**Proposal for a regulation**

**Recital 13**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>(13) There is scientific uncertainty about the risks and benefits of nanomaterials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(13) There is scientific uncertainty about the risks and benefits of nanomaterials</td>
</tr>
</tbody>
</table>
used for medical devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, with the necessary flexibility to adapt this definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of medical devices, the manufacturers should take special care when using nanoparticles that can be released to the human body and those devices should be subject to the most severe conformity assessment procedure.

Justification

The risk of the use of nanomaterials shall be taken into account in the risk assessment process. However, too many products with no serious concern for health may fall under this rule. Therefore, the up-classification in Class III shall be made only when the use of nanomaterials is intentional and part of the intended use of the product.

Amendment 3

Proposal for a regulation
Recital 19 a (new)

Text proposed by the Commission

(19a) With devices that consist of more than one implantable part, such as hip implants, compatibility of the parts of different manufacturers should be ensured in order to avoid the replacement of the functional part of the device and thus unnecessary risks and inconvenience for patients. The Commission should investigate the need for further measures to ensure the compatibility of the equivalent parts of hip implants from different manufacturers, bearing in mind
that the hip operations are most often made on older people for whom the health risks of operations are higher.

Amendment 4
Proposal for a regulation
Recital 20 a (new)

Text proposed by the Commission

(20a) The procedure for identification of common technical specification (CTS) provided for in this Regulation should not undermine the coherence of the European standardisation system as laid down in Regulation (EU) No 1025/2012 on European standardisation. Therefore, this Regulation should also provide for conditions under which it can be considered that a technical specification does not conflict with other European standards. In addition, before identifying CTS, the MDCG established by this Regulation should be used as a forum for consultation of European and national stakeholders, European standardisation organisations and Member States in order to ensure legitimacy of the process.

Justification

This is to ensure consistency with the recent Regulation on European standardisation and in particular to guarantee the best use of the full range of relevant technical specifications.

Amendment 5
Proposal for a regulation
Recital 25 a (new)

Text proposed by the Commission

(25a) To ensure that the risk of damage as well as the risk of the manufacturer’s insolvency are not shifted to patients
harmed by medical devices and that the payers are liable for the cost of treatment, manufacturers shall be obliged to take liability insurance with appropriate minimum coverage.

Justification

Pursuant to Directive 85/374/EEC on product liability, there is yet no obligation to take out insurance coverage for damage events. This unfairly shifts the risk of damage, as well as the risk of the manufacturer’s insolvency, to the patients harmed by defective medical devices and the payers liable for the cost of treatment. In accordance with the rules already in force in the area of medicinal products, the manufacturers of medical devices should also be obliged to take out liability insurance with appropriate minimum sums for the coverage.

Amendment 6

Proposal for a regulation

Recital 31

Text proposed by the Commission


Amendment

modified and the reprocessor should therefore be considered the manufacturer of the reprocessed device.

For more clarity, only 'intended single-use device' should be reprocessed and not 'single-use device'. Therefore, with regard to reprocessing, 'multiple-use device', 'intended single-use device' and 'single-use device' should be defined in this Regulation and those terms should be distinguished one from another.

Justification

Manufacturers should not be able to name their products "single-use devices" without demonstrating objective grounds for the impossibility to reuse the medical device. Without such a demonstration, this device is an "intended single-use device" and can be reprocessed according to the provisions of Article 15.

Amendment 7

Proposal for a regulation
Recital 32

Text proposed by the Commission

(32) Patients who are implanted with a device should be given essential information related to the implanted device allowing it to be identified and containing any necessary warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls.

Amendment

(32) Patients who are going to be implanted with a device should be given beforehand essential information related to the implanted device allowing it to be identified and containing information about the main characteristic of the device, the potential adverse effects, a warning of the potential health risks, post-operative follow-up care measures and any necessary warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls. Member States may introduce national provisions requiring that the implant card also includes information on post-operative follow-up care measures and that it is signed by both the patient and the surgeon responsible for the surgery.
Justification

Information should be provided before the patients are implanted to help them make better informed and more conscious choices.

Amendment 8
Proposal for a regulation
Recital 34

Text proposed by the Commission

(34) The traceability of medical devices by means of a Unique Device Identification (UDI) system based on international guidance should significantly enhance the effectiveness of the post-market safety of medical devices due to improved incident reporting, targeted field safety corrective actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against counterfeit devices. Use of the UDI system should also improve purchase-policy and stock-management by hospitals.

Amendment

(34) The traceability of medical devices by means of a Unique Device Identification (UDI) system based on international guidance should significantly enhance the effectiveness of the post-market safety of medical devices due to improved incident reporting, targeted field safety corrective actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against counterfeit devices. Use of the UDI system should also improve purchase policy and stock management by hospitals, and, where possible, the system should be compatible with the other authentication systems already in place in such environments.

Amendment 9
Proposal for a regulation
Recital 39

Text proposed by the Commission

(39) For high-risk medical devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available.

Amendment

(39) For high-risk medical devices, manufacturers should draft a report of the safety and performance aspects of the device and the outcome of the clinical evaluation. A summary of the safety and performance report should be publicly
Amendment 10
Proposal for a regulation
Recital 42

Text proposed by the Commission

(42) For high risk medical devices, authorities should be informed at an early stage about devices which are subject to conformity assessment and be given the right, on scientifically valid grounds, to scrutinise the preliminary assessment conducted by notified bodies, in particular regarding novel devices, devices for which a novel technology is being used, devices belonging to a category of devices with increased serious incident rates, or devices for which significant discrepancies in the conformity assessments by different notified bodies have been identified in respect of substantially similar devices. The process foreseen in this Regulation does not prevent a manufacturer from informing voluntarily a competent authority of his intention to file an application for conformity assessment for a high risk medical device before submitting the application to the notified body.

Amendment

(42) For innovative high risk medical devices, competent authorities should be informed at an early stage about devices which are subject to conformity assessment and be given the right, in absence of common technical specification or guideline for the conduct of clinical evaluation, to assess clinical data and proceed with a scientific assessment in particular regarding novel devices, devices for which a novel technology is being used, devices belonging to a category of devices with increased serious incident rates, or devices for which significant discrepancies in the conformity assessments by different notified bodies have been identified in respect of substantially similar devices. The process foreseen in this Regulation does not prevent a manufacturer from informing voluntarily a competent authority of his intention to file an application for conformity assessment for a high risk medical device before submitting the application to the notified body.

Justification

A European assessment should be foreseen and made systematic for sensitive and innovating medical devices. The result of that assessment should be binding in order to guarantee that it does not constitute a simple consultation. Thus a negative assessment would prevent devices from being certified and introduced on the market.

Once gained experience, the Commission supported by expert panels should establish guidelines and common technical specifications addressed to manufacturers and notified bodies on clinical evaluation and post-market follow-up; this would progressively reduce this European assessment mechanism to first-in-class and innovative devices.
Amendment 11
Proposal for a regulation
Recital 42 a (new)

Text proposed by the Commission

(42a) High-risk devices manufacturer concerned by the scientific assessment should be provided with an advice for an appropriate assessment of the conformity of their devices, in particular with regard to the clinical data required for the clinical evaluation. This scientific advice could be provided by the Scientific Advisory Board or by an EU reference laboratory and published on a public database.

Justification

This advice should notably help manufacturers to conduct clinical evaluation in accordance with the state of the art and latest recommendations from the European experts group.

Amendment 12
Proposal for a regulation
Recital 54 a (new)

Text proposed by the Commission

(54a) Manufacturers should report periodically on medical devices classified as class III as regards the data relevant to the risk benefit ratio and the exposition of the population in order to evaluate whether any action concerning the medical device concerned is necessary.

Justification

It is important in the framework of the vigilance system to introduce an obligation for the manufacturers to report periodically for medical devices class III on safety data and volume of sales.
Amendment 13
Proposal for a regulation
Recital 56

Text proposed by the Commission

(56) Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures.

Amendment

(56) Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures. The Commission should clearly define the way these inspections should be conducted in order to ensure a full and harmonised implementation within the Union.

Justification

Harmonisation of competent authority's control activities is essential to make the new overarching system efficient. The Regulation shall specify inspection modalities, extra EU inspections, cooperation mechanisms and inspector's appointment supported by Commission’s guidelines.

Amendment 14
Proposal for a regulation
Recital 59

Text proposed by the Commission

(59) An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member States based on their role and expertise in the field of medical devices and in vitro diagnostic medical devices should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) […] on in vitro diagnostic medical devices, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation.

Amendment

(59) An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member States based on their role and expertise in the field of medical devices and in vitro diagnostic medical devices should be established to fulfil the tasks conferred on it by this Regulation and by Regulation (EU) […] on in vitro diagnostic medical devices, to provide advice to the Commission and to assist the Commission and the Member States in ensuring a harmonised implementation of this Regulation. That experts committee should be supported by a Scientific Advisory Board composed of expert
panels for specific medical disciplines in order to proceed with the assessment of high risk device and provide guidelines and common technical specifications for clinical evaluation.

Justification

The MDCG scientific assessment on clinical evaluation foreseen in Article 44 should rely on a board of experts. These experts will contribute to the establishment of guidelines and common technical specifications addressed to manufacturers and accredited bodies for clinical evaluation and post-market follow-up in order to harmonise practices.

Amendment 15

Proposal for a regulation
Recital 64

Text proposed by the Commission

(64) In order to maintain a high level of health and safety, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission in respect of the products subject to this Regulation that are similar to medical devices but do not necessarily have a medical purpose; adaptation of the definition of nanomaterial to technical progress and to developments at Union and international level; adaptation to technical progress of the general safety and performance requirements, of the elements to be addressed in the technical documentation, of the minimum content of the EU declaration of conformity and of the certificates issued by notified bodies, of the minimum requirements to be met by notified bodies, of the classification rules, of the conformity assessment procedures, and of the documentation to be submitted for the approval of clinical investigations; the establishment of the UDI system; the information to be submitted for the registration of medical devices and certain economic operators; the level and structure of fees for the designation and monitoring of notified bodies; the publicly available information in respect of clinical performance studies; the adoption of preventive health protection measures at EU level; and the tasks of and criteria for European Union reference laboratories and the level and structure of fees for scientific opinions delivered by them. However, substantial elements of this Regulation such as general safety and performance requirements, elements to be addressed in clinical evaluation...

Amendment

(64) In order to maintain a high level of health and safety, the power to adopt acts in accordance with Article 290 of the Treaty on the Functioning of the European Union should be delegated to the Commission in respect of the requirements to be met by notified bodies, of the classification rules and of the documentation to be submitted for the approval of clinical performance studies; the establishment of the UDI system; the information to be submitted for the registration of medical devices and certain economic operators; the level and structure of fees for the designation and monitoring of notified bodies; the publicly available information in respect of clinical performance studies; the adoption of preventive health protection measures at EU level; and the tasks of and criteria for European Union reference laboratories and the level and structure of fees for scientific opinions delivered by them. However, substantial elements of this Regulation such as general safety and performance requirements, elements to be addressed in...
the level and structure of fees for the designation and monitoring of notified bodies; the publicly available information in respect of clinical investigations; the adoption of preventive health protection measures at EU level; and the tasks of and criteria for European Union reference laboratories and the level and structure of fees for scientific opinions delivered by them. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. The Commission, when preparing and drawing up delegated acts, should ensure a simultaneous, timely and appropriate transmission of relevant documents to the European Parliament and to the Council.

**Justification**

The mentioned parts are an essential element of the legislation and therefore according to article 290 of the treaty cannot be modified through a delegated act.

**Amendment 16**

**Proposal for a regulation**

**Article 1 – paragraph 1 – subparagraph 1**

*Text proposed by the Commission*

This Regulation establishes rules to be complied with by medical devices and accessories to medical devices that are placed on the market or put into service in the Union for human use.

*Amendment*

This Regulation establishes rules to be complied with by medical devices, accessories to medical devices and aesthetic assimilated devices that are placed on the market or put into service in the Union for human use.

**Justification**

Aesthetic assimilated device should be clearly covered by the scope of this Regulation.

**Amendment 17**

**Proposal for a regulation**

PE507.972v04-00  268/336  RR\1005935EN.doc
Article 2 – paragraph 1 – subparagraph 1 – point 1 – indent 5 – paragraph 2

**Text proposed by the Commission**

The implantable or other invasive products, intended to be used for human beings, which are listed in Annex XV shall be considered medical devices, regardless of whether or not they are intended by the manufacturer to be used for a medical purpose.

**Amendment**

The implantable or other invasive products, as well as products using external physical agents, intended to be used for human beings, which are listed on a non-exhaustive basis in Annex XV, shall be considered medical devices for the purposes of this Regulation, regardless of whether or not they are intended by the manufacturer to be used for a medical purpose.

Amendment 18
Proposal for a regulation
Article 2 – paragraph 1 – point 4

**Text proposed by the Commission**

(4) ‘active device’ means any device, the operation of which depends on a source of electrical energy or any source of power other than that directly generated by gravity and which acts by changing the density of or converting this energy.

**Amendment**

(4) ‘active device’ means any device, the operation of which depends on a source of electrical energy or any source of power other than that directly generated by the human body or by gravity and which acts by changing the density of or converting this energy.

Devices intended to transmit energy, substances or other elements between an active device and the patient, without any significant change, shall not be considered to be active devices.

Stand alone software shall be considered an active device;

**Justification**

The energy generated by the human body can hardly be considered at the same level than electricity. This provision would lead to the up-classification as active devices of syringes, lancets or scalpels.

Amendment 19
Proposal for a regulation
Article 2 – paragraph 1 – subparagraph 1 – point 4 – paragraph 2

**Text proposed by the Commission**

Stand alone software shall be considered an active device;

**Amendment**

deleted

**Justification**

Due to systematic reasons: Move the sentence “Stand alone software shall be considered an active device” from article 2.1 (4) to Annex VII, Rule 9.

Amendment 20
Proposal for a regulation
Article 2 – paragraph 1 – point 8

**Text proposed by the Commission**

(8) ‘single-use device’ means a device that is intended to be used on an individual patient during a single procedure.

**Amendment**

(8) ’single-use device' means a device that is to be used on an individual patient during a single procedure and which has been tested and demonstrated to be impossible to reuse.

The single procedure may involve several uses or prolonged use on the same patient;

**Justification**

Manufacturers have to provide detailed information justifying why a medical device cannot be reused or why its reuse would endanger the safety of patients/users. If on objective grounds the impossibility of reuse has been demonstrated, the medical device shall not be reprocessed. This specific provision should avoid medical devices being excessively labelled as "single-use" and allow a better supervision of reprocessing.

Amendment 21
Proposal for a regulation
Article 2 – paragraph 1 – point 8 a (new)

**Text proposed by the Commission**

(8a) "intended for single-use device" means a device that is to be used on an individual patient during a single procedure for which impossibility of reuse has not been demonstrated;

**Amendment**
Justification

By extension of the definition of 'single-use device', if impossibility of reusing the single-use device has not been demonstrated, the possibility of reprocessing shall be left open to the reprocessor if such a reprocessing is proven to be safe and in accordance with the provisions of Art 15. Information on the label and information in the instructions for use (as laid down in section 19.2 and 19.3 of Annex I) should be modified accordingly to reflect the distinction introduced between a "single-use" device and an "intended single-use" device.

Amendment 22
Proposal for a regulation
Article 2 – paragraph 1 – point 8 b (new)

Text proposed by the Commission

(8b) 'multiple-use device' means a device which is reusable and must be provided with information on the appropriate processes to allow reuse, including cleaning, disinfection, packaging and, where appropriate, the method of sterilization of the device to be re-sterilised, and any restriction on the number of reuses;

Amendment

(8b) 'multiple-use device' means a device which is reusable and must be provided with information on the appropriate processes to allow reuse, including cleaning, disinfection, packaging and, where appropriate, the method of sterilization of the device to be re-sterilised, and any restriction on the number of reuses;

Justification

For more clarity and contrary to devices "intended for single-use", devices which have been demonstrated as reusable should be defined as "multiple-use" devices.

Amendment 23
Proposal for a regulation
Article 2 – paragraph 1 – subparagraph 1 – point 32

Text proposed by the Commission

(32) ‘clinical evaluation’ means the assessment and analysis of clinical data pertaining to a device in order to verify the safety and performance of the device when used as intended by the manufacturer;

Amendment

(32) ‘clinical evaluation’ means the assessment and analysis of clinical data pertaining to a device in order to verify the safety, performance and clinical benefits of the device when used as intended by the manufacturer;
**Amendment 24**

Proposal for a regulation  
Article 2 – paragraph 1 – subparagraph 1 – point 36 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(36a) ‘performance’ means the ability of a device to produce the effect intended by the manufacturer relative to the medical condition, including attainment of technical capabilities and clinical claims;</td>
<td></td>
</tr>
</tbody>
</table>

**Amendment 25**

Proposal for a regulation  
Article 2 – paragraph 1 – subparagraph 1 – point 37

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(37) ‘sponsor’ means an individual, company, institution or organisation which takes responsibility for the initiation and management of a clinical investigation;</td>
<td></td>
</tr>
<tr>
<td>(37) ‘sponsor’ means an individual, company, institution or organisation which takes responsibility for the initiation, management or funding of a clinical investigation;</td>
<td></td>
</tr>
</tbody>
</table>

**Amendment 26**

Proposal for a regulation  
Article 2 – paragraph 1 – subparagraph 1 – point 40

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(40) ‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer;</td>
<td></td>
</tr>
<tr>
<td>(40) ‘device deficiency’ means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, or inadequacy in the information supplied by the manufacturer;</td>
<td></td>
</tr>
</tbody>
</table>
Amendment 27
Proposal for a regulation
Article 3 – paragraph 1

Text proposed by the Commission

1. The Commission may at the request of a Member State or on its own initiative by means of implementing acts, determine whether or not a specific product, or category or group of products, falls within the definitions of 'medical device' or 'accessory to a medical device'. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment

1. The Commission may on its own initiative or shall at the request of a Member State by means of implementing acts, determine whether or not a specific product, or category or group of products, falls within the definitions of 'medical device' or 'accessory to a medical device'. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 28
Proposal for a regulation
Article 3 – paragraph 2

Text proposed by the Commission

2. The Commission shall ensure the sharing of expertise between Member States in the fields of medical devices, in vitro diagnostic medical devices, medicinal products, human tissues and cells, cosmetics, biocides, food and, if necessary, other products in order to determine the appropriate regulatory status of a product, or category or group of products.

Amendment

2. The Commission shall, by means of implementing act determine the regulatory status of border line products on the basis of the opinion of the EU multidisciplinary experts group composed of experts in the fields of medical devices, in vitro diagnostic medical devices, medicinal products, human tissues and cells, cosmetics, biocides and food. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 29
Proposal for a regulation
Article 3 – paragraph 2 a (new)
2 a. For products or groups of products composed of substances or combination of substances that are intended to penetrate inside the body, either through a body orifice or through the surface of the body, which have been considered as medical devices by the multidisciplinary expert group, the Commission shall, by means of implementing acts, determine the risk classification on the basis of the actual risks and on the ground of valid scientific evidence. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 30

Proposal for a regulation
Article 4 – paragraph 5

Text proposed by the Commission

5. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress and considering the intended users or patients, the general safety and performance requirements set out in Annex I, including the information supplied by the manufacturer.

Amendment

deleted

Justification

The general safety and performance requirement constitute an essential element of the legislation and therefore according to article 290 of the treaty cannot be modified through a delegated act.

Amendment 31
Proposal for a regulation
Article 7 – paragraph 1

Justification
1. **Where no harmonised standards exist or where relevant harmonised standards are not sufficient**, the Commission shall be empowered to adopt common technical specifications (CTS) in respect of the general safety and performance requirements set out in Annex I, the technical documentation set out in Annex II or the clinical evaluation and post-market clinical follow-up set out in Annex XIII. The CTS shall be adopted by means of implementing acts in accordance with the examination procedure referred to in Article 88(3).

**Justification**

This is in order to ensure consistency with the recent Regulation on European standardisation and in particular to guarantee the best use of the full range of relevant technical specifications. See also amendment introducing in that regard a new subparagraph 1 a (new).

**Amendment 32**

Proposal for a regulation

**Article 7 – paragraph 1 – subparagraph 1 a (new)**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>When adopting CTS referred to in paragraph 1, the Commission shall not undermine the coherence of the European standardisation system. CTS are coherent if they do not conflict with European standards, that is to say they cover areas where no harmonised standards exist, the adoption of new European standards is not foreseen within a reasonable period, where existing standards have not gained market uptake or where those standards have become obsolete or have been demonstrated as clearly insufficient according to vigilance or surveillance data, and where the transposition of the technical specifications into European standardisation deliverables is not</td>
<td>The Commission shall be empowered to adopt common technical specifications (CTS) in respect of the general safety and performance requirements set out in Annex I, the technical documentation set out in Annex II or the clinical evaluation and post-market clinical follow-up set out in Annex XIII. The CTS shall be adopted by means of implementing acts in accordance with the examination procedure referred to in Article 88(3).</td>
</tr>
</tbody>
</table>
foreseen within a reasonable period.

Justification

This is to ensure consistency with the recent Regulation on European standardisation and in particular to guarantee the best use of the full range of relevant technical specifications.

Amendment 33
Proposal for a regulation
Article 7 – paragraph 1 – subparagraph 1 b (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commission shall adopt CTS referred to in paragraph 1 after consulting the MDCG, which shall also include a representative of the European standardisation organisations.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 34
Proposal for a regulation
Article 8 – paragraph 2 – subparagraph 2

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing, in the light of technical progress, the elements in the technical documentation set out in Annex II.</td>
<td>deleted</td>
</tr>
</tbody>
</table>

Justification

The general safety and performance requirement constitute an essential element of the legislation and therefore according to article 290 of the treaty cannot be modified through a delegated act.

Amendment 35
Proposal for a regulation
Article 8 – paragraph 6 – subparagraph 1
Proportionate to the risk class and the type of device, manufacturers of devices, other than custom-made devices, shall institute and keep up to date a systematic procedure to collect and review experience gained from their devices placed on the market or put into service and to apply any necessary corrective action, hereinafter referred to as ‘post-market surveillance plan’. The post-market surveillance plan shall set out the process for collecting, recording and investigating complaints and reports from healthcare professionals, patients or users on suspected incidents related to a device, keeping a register of non-conforming products and product recalls or withdrawals, and if deemed appropriate due to the nature of the device, sample testing of marketed devices. Part of the post-market surveillance plan shall be a plan for post-market clinical follow-up in accordance with Part B of Annex XIII.
Where post-market clinical follow-up is not deemed necessary, this shall be duly justified and documented in the post-market surveillance plan.

Justification

All manufacturers of marketed class III devices should communicate incidents to electronic system to improve the surveillance of medical devices. For devices that support or sustain life, this is essential for early detection of adverse events and device defects before large patient populations have been exposed. The centralised reporting is also important to enhance automated surveillance systems of clinical experience, to accumulate the data needed to guide patient care as well as for comparison of new devices with established products.
Amendment 36
Proposal for a regulation
Article 8 – paragraph 7

Text proposed by the Commission

Manufacturers shall ensure that the device is accompanied by the information to be supplied in accordance with Section 19 of Annex I in an official Union language which can be easily understood by the intended user or patient. The language(s) of the information to be supplied by the manufacturer may be determined by the law of the Member State where the device is made available to the user or patient.

Amendment

Manufacturers shall ensure that the device is accompanied by the instructions and safety information to be supplied in accordance with Section 19 of Annex I in a language which can be easily understood by the intended user or patient, as determined by the Member-State concerned.

Justification

Patients and users have to be provided with information in their own language.

Amendment 37
Proposal for a regulation
Article 8 – paragraph 9

Text proposed by the Commission

9. Manufacturers shall, in response to a reasoned request from a competent authority, provide it with all the information and documentation necessary to demonstrate the conformity of the device, in an official Union language which can be easily understood by that authority. They shall cooperate with that authority, at its request, on any corrective action taken to eliminate the risks posed by devices which they have placed on the market or put into service.

Amendment

9. Manufacturers shall, in response to a reasoned request from a competent authority, provide it with all the information and documentation necessary to demonstrate the conformity of the device, in an official Union language which can be easily understood by that authority. They shall cooperate with that authority, at its request, on any corrective action taken to eliminate the risks posed by devices which they have placed on the market or put into service.

If a competent authority considers or has reason to believe that a device has caused damages, it shall ensure that the potentially harmed user, the user's successor in title, the user's health insurance company or other third parties affected by the damage caused to the user may request the information referred to in
the first subparagraph from the manufacturer, while ensuring due respect to the intellectual property rights.

Justification

A reinforced right to information eliminates the risk of lack of relevant information in case of damage.

Amendment 38
Proposal for a regulation
Article 8 – paragraph 10 – subparagraph 1 a (new)

Text proposed by the Commission

Amendment

1a. Manufacturers shall have an appropriate liability insurance covering any damages that may be caused by their medical devices to patients or users in the event of the death of or injury to patient or user or in the event of the death of or injury to multiple patients or users due to the use of the same medical device.

Justification

Pursuant to Directive 85/374/EEC on product liability, there is yet no obligation to take insurance coverage for damage events. This unfairly shifts the risk of damage, as well as the risk of the manufacturer’s insolvency, to the patients harmed by defective medical devices and the payers liable for the cost of treatment. In accordance with the rules already in force in the area of medicinal products, the manufacturers of medical devices should also be obliged to take out liability insurance with appropriate minimum sums for the coverage.

Amendment 39
Proposal for a regulation
Article 11 – paragraph 2 – point b

Text proposed by the Commission

Amendment

(b) that an authorised representative in accordance with Article 9 has been designated by the manufacturer;

(b) that the manufacturer is identified and that an authorised representative in accordance with Article 9 has been designated by the manufacturer.
Justification

It is important to ensure that the importer has identified the manufacturer.

Amendment 40
Proposal for a regulation
Article 11 – paragraph 2 – point f a (new)

Text proposed by the Commission

(fa) that the manufacturer has taken out appropriate liability insurance coverage pursuant to Article 8(10) unless the importer himself can ensure sufficient coverage corresponding to the same requirements.

Justification

Importers should make sure that manufacturers fulfil their obligations regarding insurance.

Amendment 41
Proposal for a regulation
Article 11 – paragraph 7

Text proposed by the Commission

7. Importers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately inform the manufacturer and his authorised representative and, if appropriate, take the necessary corrective action to bring that device into conformity, withdraw or recall it. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available and, if applicable, the notified body that issued a certificate in accordance with Article 45 for the device in question, giving details, in particular, of the non-compliance and of any corrective action taken.

Amendment

7. Importers who consider or have reason to believe that a device which they have placed on the market is not in conformity with this Regulation shall immediately inform the manufacturer, and where applicable his authorised representative and, if appropriate, ensure that the necessary corrective action to bring that device into conformity, withdraw or recall it, is taken and, implement that action. Where the device presents a risk, they shall also immediately inform the competent authorities of the Member States in which they made the device available and, if applicable, the notified body that issued a certificate in accordance with Article 45 for the device in question, giving details, in particular, of the non-compliance and of any corrective action they have
implemented.

Justification

To avoid any dilution of information and responsibility, the manufacturer or where appropriate its authorised representative shall be the only one responsible for taking corrective actions on the product. Importers should not take any corrective actions by themselves but only implement those actions in accordance with manufacturers' decisions.

Amendment 42
Proposal for a regulation
Article 15 – title

Text proposed by the Commission
Single-use devices and their reprocessing

Amendment
Intended single-use devices and their reprocessing

Justification

Only devices for which the impossibility of reprocessing has not been demonstrated should be reprocessed in accordance with the provisions laid down in this article.

Amendment 43
Proposal for a regulation
Article 15 – paragraph 1

Text proposed by the Commission
1. Any natural or legal person who reprocesses a single-use device to make it suitable for further use within the Union shall be considered to be the manufacturer of the reprocessed device and shall assume the obligations incumbent on manufacturers laid down in this Regulation.

Amendment
1. Any natural or legal person who reprocesses an intended single-use device to make it suitable for further use within the Union shall be considered to be the manufacturer of the reprocessed device and shall assume the obligations incumbent on manufacturers laid down in this Regulation.

Amendment 44
Proposal for a regulation
Article 15 – paragraph 2

Text proposed by the Commission
2. Only single-use devices that have been

Amendment
2. Only intended single-use devices that
Amendment 45
Proposal for a regulation
Article 15 – paragraph 3

Text proposed by the Commission

3. In the case of reprocessing of single-use devices for critical use, only reprocessing that is considered safe according to the latest scientific evidence may be carried out.

Amendment

3. In the case of reprocessing of intended single-use devices for critical use, only reprocessing that is considered safe according to the latest scientific evidence may be carried out.

Amendment 46
Proposal for a regulation
Article 15 – paragraph 4

Text proposed by the Commission

4. The Commission, by means of implementing acts, shall establish and regularly update a list of categories or groups of single-use devices for critical use which may be reprocessed in accordance with paragraph 3. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment

4. The Commission, by means of delegated acts, shall establish and regularly update a list of categories or groups of intended single-use devices for critical use which may be reprocessed in accordance with paragraph 3. Those delegated acts shall be adopted in accordance Article 89.

Amendment 47
Proposal for a regulation
Article 15 – paragraph 4 a (new)

Text proposed by the Commission

4a. The Commission shall, by means of implementing acts, establish practical guidelines and EU standards to ensure
the safe reprocessing of intended for single use medical devices that guarantee at least the same level of safety and performance as compared to the original device. In doing so, the Commission shall ensure that such standards are consistent with the latest scientific evidence, the relevant ISO standards or other international technical standards adopted by recognised international standard-setting organizations, provided that they guarantee at least the same level of safety and performance as ISO standards.

Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 48
Proposal for a regulation
Article 15 – paragraph 5 – subparagraph 2

Text proposed by the Commission
The name and address of the manufacturer of the original single-use device shall no longer appear on the label, but shall be mentioned in the instructions for use of the reprocessed device.

Amendment
The name and address of the manufacturer of the original intended single-use device shall no longer appear on the label, but shall be mentioned in the instructions for use of the reprocessed device.

Amendment 49
Proposal for a regulation
Article 15 – paragraph 6 – point a

Text proposed by the Commission
(a) the reprocessing of single-use devices and the transfer of single-use devices to another Member State or to a third country with a view to their reprocessing;

Amendment
(a) the reprocessing of intended single-use devices and the transfer of intended single-use devices to another Member State or to a third country with a view to their reprocessing;
Amendment 50
Proposal for a regulation
Article 15 – paragraph 6 – point b

Text proposed by the Commission
(b) the making available of reprocessed single-use devices.

Amendment
(b) the making available of reprocessed intended single-use devices.

Amendment 51
Proposal for a regulation
Article 16 – paragraph 1

Text proposed by the Commission
1. The manufacturer of an implantable device shall provide together with the device an implant card which shall be made available to the particular patient who has been implanted with the device.

Amendment
1. The manufacturer of an implantable, sterile-packaged device shall make available in advance to the healthcare professional or where relevant, to the particular patient who is going to be implanted with the device, the information to be included in an implant passport or in an implant card.

Amendment 52
Proposal for a regulation
Article 16 – paragraph 1 – subparagraph 1 a (new)

Text proposed by the Commission

Amendment
The following implants are excluded from this obligation: sutures, staples, dental implants, screws and plates.

Amendment 53
Proposal for a regulation
Article 16 – paragraph 1 – subparagraph 1 b (new)
The Commission shall, by means of implementing acts, regularly update the list of implantable devices which do not have to fulfil this obligation. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 54

Proposal for a regulation
Article 16 – paragraph 2 – subparagraph 1 – point c a (new)

(ca) a short description of the characteristics of the devices, including the materials used;

Amendment 55

Proposal for a regulation
Article 16 – paragraph 2 – subparagraph 1 – point c b (new)

(cb) the potential adverse events that might occur on the basis of the data from the clinical evaluation and investigation.

Amendment 56

Proposal for a regulation
Article 17 – paragraph 4

4. The Commission shall be empowered to adopt delegated acts in accordance with
Article 89 amending or supplementing the minimum content of the EU declaration of conformity set out in Annex III in the light of technical progress.

Justification

As the main means of showing compliance to the legislation, the declaration of conformity is an essential element of the legislation and therefore according to article 290 of the treaty cannot be modified through a delegated act.

Amendment 57
Proposal for a regulation
Article 21 – paragraph 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Any natural or legal person who makes available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without significantly changing its performance or safety characteristics, shall ensure that the article does not adversely affect the safety and performance of the device. Substantiating evidence shall be kept available to the competent authorities of the Member States.</td>
<td>1. Any natural or legal person who makes available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without changing its performance or safety characteristics, shall ensure that the article does not adversely affect the safety and performance of the device. Substantiating evidence shall be kept available to the competent authorities of the Member States.</td>
</tr>
</tbody>
</table>

Justification

The term 'significant' can lead to differing interpretations of the facts and, because of its indeterminacy, to incoherent implementation of the requirements. Changes to or in the performance and security features should under all circumstances lead to a classification of the article as a new medical device.

Amendment 58
Proposal for a regulation
Article 21 – paragraph 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Any natural or legal person who makes</td>
<td>1. Any natural or legal person who makes</td>
</tr>
</tbody>
</table>
available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without significantly changing its performance or safety characteristics, shall ensure that the article does not adversely affect the safety and performance of the device. Substantiating evidence shall be kept available to the competent authorities of the Member States.

Amendment 59
Proposal for a regulation
Article 21 – paragraph 2

Text proposed by the Commission

2. An article that is intended specifically to replace a part or component of a device and that significantly changes the performance or safety characteristics of the device shall be considered a device.

Amendment

2. An article that is intended specifically to replace a part or component of a device and that changes the performance or safety characteristics of the device shall be considered as a device and shall meet the requirements laid down in this Regulation.

Justification

The term 'significant' can lead to differing interpretations of the facts and, because of its indeterminacy, to incoherent implementation of the requirements. Changes to or in the performance and security features should under all circumstances lead to a classification of the article as a new medical device.

Amendment 60
Proposal for a regulation
Article 21 – paragraph 2 a (new)

Text proposed by the Commission

Amendment

2a. Any natural or legal person who refurbishes a device according to the provisions formally laid down by the manufacturer of the device shall ensure that the refurbishment does not adversely affect the safety and performance.

Amendment 61

Proposal for a regulation

Article 21 – paragraph 2 b (new)

Text proposed by the Commission

Amendment

2b. Any natural or legal person who refurbishes a device either in the absence of provisions formally laid down by the manufacturer of the device or disregarding or violating such provisions to make it suitable for further use within the Union shall be considered to be the manufacturer of the refurbished device and shall assume the obligations incumbent on manufacturers as laid down in this Regulation.

Amendment 62

Proposal for a regulation

Article 24 – paragraph 1 a (new)

Text proposed by the Commission

Amendment

1a. It shall be updated with the results of the post-market clinical follow-up evaluation report referred to in Section 3 of Part B of Annex XIII.
Amendment 63
Proposal for a regulation
Article 24 – paragraph 8 – point b

Text proposed by the Commission
(b) the legitimate interest in protecting commercially sensitive information;

Amendment
(b) the legitimate interest in protecting commercially sensitive information, providing that it does not conflict with public health protection;

Amendment 64
Proposal for a regulation
Article 24 – paragraph 8 – point e a (new)

Text proposed by the Commission
(ea) compatibility with the other traceability systems used by medical device stakeholders.

Amendment

Amendment 65
Proposal for a regulation
Article 25 – paragraph 2

Text proposed by the Commission
2. Before a device, other than a custom-made or investigational device, is placed on the market the manufacturer or his authorised representative shall submit to the electronic system the information referred to in paragraph 1.

Amendment
2. Before a device, other than a custom-made or investigational device, is placed on the market the manufacturer or his authorised representative shall submit to the electronic system the information referred to in paragraph 1. It shall be ensured that besides the European registration no national registrations in individual Member States can additionally be required.

Justification
It needs to be made sure that, beside the European registration, no national registrations in...
individual EU-countries can be required.

Amendment 66  Proposal for a regulation  Article 26 – paragraph 1

Text proposed by the Commission

1. In the case of devices classified as class III and implantable devices, other than custom-made or investigational devices, the manufacturer shall draw up a summary of safety and clinical performance. It shall be written in a way that is clear to the intended user. The draft of this summary shall be part of the documentation to be submitted to the notified body involved in the conformity assessment in accordance with Article 42 and shall be validated by that body.

Amendment

1. In the case of devices classified as class III and implantable devices, other than custom-made or investigational devices, the manufacturer shall draw up a summary of safety and clinical performance and shall update it with the conclusions of the post market clinical follow-up evaluation report referred to in point 3 of Part B of Annex XIII. It shall be written in a way that is clear to the intended use and in the language of the country where the medical device is made available on the market. The draft of this summary shall be part of the documentation to be submitted to the notified body involved in the conformity assessment in accordance with Article 42 and shall be validated by that body.

Justification

Manufacturer's post market clinical follow-up should be transparent for health professionals and patients in order to be able to scrutinise. Results from this follow-up could be fed into the public summaries of safety and performance information.

This document should be publicly available and written in a language easily understandable by user/patients and healthcare professionals.

Amendment 67  Proposal for a regulation  Article 28 – paragraph 7

Text proposed by the Commission

7. Member States shall provide the Commission and the other Member States

Amendment

7. Member States shall provide the Commission and the other Member States
with information on their procedures for the assessment, designation and notification of conformity assessment bodies and for the monitoring of notified bodies, and of any changes thereto. Based on this exchange of information and on best practices established across Member States, the Commission shall define, within two years after the entry into force of this Regulation, guidelines for the procedures for the assessment, designation and notification of conformity assessment bodies and for the monitoring of notified bodies to be carried out by national authorities concerned.

Amendment 68
Proposal for a regulation
Article 29 – paragraph 1

Text proposed by the Commission
1. Notified bodies shall satisfy the organisational and general requirements and the quality management, resource and process requirements that are necessary to fulfil their tasks for which they are designated in accordance with this Regulation. Minimum requirements to be met by notified bodies are set out in Annex VI.

Amendment
1. Notified bodies shall satisfy the organisational and general requirements and the quality management, resource and process requirements that are necessary to fulfil their tasks for which they are designated in accordance with this Regulation. Requirements to be met by notified bodies are set out in Annex VI.

Justification
In order to establish equal requirements for notified bodies in all European Member States and to ensure fair and uniform conditions, the term 'minimum' should be deleted.

Amendment 69
Proposal for a regulation
Article 29 – paragraph 2

Text proposed by the Commission
2. The Commission shall be empowered to adopt delegated acts in accordance with

Amendment
deleted

2. The Commission shall be empowered to adopt delegated acts in accordance with
Article 89 amending or supplementing the minimum requirements in Annex VI, in the light of technical progress and considering the minimum requirements needed for the assessment of specific devices, or categories or groups of devices.

Amendment 70
Proposal for a regulation
Article 30 – paragraph 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 a. Subcontracting shall be limited to only specific tasks connected with the conformity assessment and the need to subcontract such tasks shall be duly justified to the national authority.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 71
Proposal for a regulation
Article 31 – paragraph 1 b (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1b. Any subsidiaries of the applicant conformity assessment body which are involved in the conformity assessment process, in particular those located in third countries, shall be subject to the application for notification mechanism and its assessment as described in Article 32.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 72
Proposal for a regulation
Article 33 – paragraph 2
2. Member States may notify only conformity assessment bodies which satisfy the requirements set out in Annex VI and which have successfully passed an initial assessment performed by the joint assessment team according to Article 32(3).

Amendment 73
Proposal for a regulation
Article 33 – paragraph 4 – subparagraph 1

The notification shall clearly specify the scope of the designation indicating the conformity assessment activities, the conformity assessment procedures and the type of devices which the notified body is authorised to assess.

Amendment

The notification shall clearly specify the scope of the designation indicating the conformity assessment activities, the conformity assessment procedures, the risk-class and the type of devices which the notified body is authorised to assess.

Justification

Notification should, if necessary specify which class of medical devices the notified bodies is allowed to assess. Some high risk medical devices should only be assessed by notified bodies fulfilling specific requirements laid down by EC through implementing act.

Amendment 74
Proposal for a regulation
Article 33 – paragraph 4 – subparagraph 2

The Commission may, by means of implementing acts, set up a list of codes and the corresponding types of devices to define the scope of the designation of notified bodies which the Member States shall indicate in their notification. Those implementing acts shall be adopted in accordance with the advisory procedure referred to in Article 88(2).

Amendment

The Commission may, by means of implementing acts, set up a list of codes and the corresponding risk-classes and types of devices to define the scope of the designation of notified bodies which the Member States shall indicate in their notification. Those implementing acts shall be adopted in accordance with the advisory procedure referred to in Article 88(2).
**Amendment 75**

Proposal for a regulation  
Article 35 – paragraph 4

*Text proposed by the Commission*

4. **Three** years after notification of a notified body, and again every **third** year thereafter, the assessment to determine whether the notified body still satisfies the requirements set out in Annex VI shall be conducted by the national authority responsible for notified bodies of the Member State in which the body is established and a joint assessment team designated in accordance with the procedure described in Article 32(3) and (4). At the request of the Commission or of a Member State, the MDCG may initiate the assessment process described in this paragraph at any time when there is reasonable concern about the ongoing compliance of a notified body with the requirements set out in Annex VI.

*Amendment*

4. **Two** years after notification of a notified body, and again every **second** year thereafter, the assessment to determine whether the notified body still satisfies the requirements set out in Annex VI shall be conducted by the national authority responsible for notified bodies of the Member State in which the body is established and a joint assessment team designated in accordance with the procedure described in Article 32(3) and (4). At the request of the Commission or of a Member State, the MDCG may initiate the assessment process described in this paragraph at any time when there is reasonable concern about the ongoing compliance of a notified body with the requirements set out in Annex VI.

**Amendment 76**

Proposal for a regulation  
Article 37 – paragraph 1

*Text proposed by the Commission*

1. The Commission shall investigate all cases where concerns have been brought to its attention regarding the continued fulfilment by a notified body of the requirements set out in Annex VI or the obligations to which it is subject. It may also commence such investigations on its own initiative.

*Amendment*

1. The Commission shall investigate all cases where concerns have been brought to its attention regarding the continued fulfilment by a notified body of the requirements set out in Annex VI or the obligations to which it is subject. It may also commence such investigations on its own initiative, *including the unannounced inspection of the notified body by a joint assessment team whose composition meets*
Amendment 77

Proposal for a regulation
Article 41 – paragraph 2 – subparagraph 2

**Text proposed by the Commission**

At least 14 days prior to any decision, the competent authority shall notify the MDCG and the Commission of its envisaged decision.

**Amendment**

At least 14 days prior to any decision, the competent authority shall notify the MDCG and the Commission of its envisaged decision. *The final decision shall be made publically available in the Eudamed.*

Amendment 78

Proposal for a regulation
Article 41 – paragraph 3 – subparagraph 1

**Text proposed by the Commission**

The Commission may, at the request of a Member State, on its own initiative, by means of implementing acts, decide on the application of the classification criteria set out in Annex VII to a given device, or category or group of devices, with a view to determining their classification.

**Amendment**

The Commission may, at the request of a Member State or on its own initiative, by means of implementing acts, decide on the application of the classification criteria set out in Annex VII to a given device, or category or group of devices, with a view to determining their classification. *Such decision should in particular be taken in order to resolve diverging decisions between Member States.*

**Justification**

*The current version of Article 41 does not contain a clear procedure for cases of a different assessment of medical devices by different competent authorities. In such cases the commission shall finally decide on the application of a specific rule related to a given device in order to ensure a uniform European wide implementation.*

Amendment 79

Proposal for a regulation
Article 42 – paragraph 2 – subparagraph 1
Text proposed by the Commission

Manufacturers of devices classified as class III, other than custom-made or investigational devices, shall be subject to a conformity assessment based on full quality assurance and design dossier examination as specified in Annex VIII. Alternatively, the manufacturer may choose to apply a conformity assessment based on type examination as specified in Annex IX coupled with a conformity assessment based on product conformity verification as specified in Annex X.

Amendment

Manufacturers of devices classified as class III, other than custom-made or investigational devices, shall be subject to a conformity assessment based on type examination as specified in Annex IX coupled with a conformity assessment based on product conformity verification as specified in Annex X.

Justification

For class III devices, conformity assessment based on full quality assurance and design examination may not be enough. Through the introduction of EU type-examination as an obligatory procedure the approach of product-related testing of medical devices ('hands-on-product') is strengthened.

Amendment 80

Proposal for a regulation

Article 42 – paragraph 10 – subparagraph 1 – introductory part

Text proposed by the Commission

The Commission may, by means of implementing acts, specify the modalities and the procedural aspects with a view to ensuring harmonised application of the conformity assessment procedures by the notified bodies for any of the following aspects:

Amendment

The Commission shall, by means of implementing acts, specify the modalities and the procedural aspects with a view to ensuring harmonised application of the conformity assessment procedures by the notified bodies for any of the following aspects:

Amendment 81

Proposal for a regulation

Article 42 – paragraph 10 – indent 2

Text proposed by the Commission

- the minimum frequency of

Amendment

deleted
unannounced factory inspections and sample checks to be conducted by notified bodies in accordance with Section 4.4 of Annex VIII, taking into account the risk-class and the type of device;

Justification

The number of unannounced inspections in section 4.4 of Annex VIII has to be clearly defined in order to strengthen the necessary controls and to guarantee unannounced inspections at the same level and frequency in all Member States. Therefore unannounced inspections should be performed at least once in a certification cycle and for each manufacturer and generic device group. Because of the vital importance of this instrument, the scope and procedures of the unannounced inspections should be stated in the Regulation itself instead of in down streamed rules such as an implementing act.

Amendment 82

Proposal for a regulation
Article 42 – paragraph 10 a (new)

Text proposed by the Commission

Amendment

10a. Unannounced inspections, in terms of their nature and extent, may be counted as regular inspections, with offsetting of economic operators’ costs resulting from unannounced inspections, provided that no significant non-conformities are recorded during unannounced inspections. Account must be taken at all times, when ordering unannounced inspections and carrying them out, of the proportionality principle, with due regard, in particular, for the risk potential of each individual product.

Amendment 83

Proposal for a regulation
Article 42 – paragraph 11
11. In the light of technical progress and any information which becomes available in the course of the designation or monitoring of notified bodies set out in Articles 28 to 40, or of the vigilance and market surveillance activities described in Articles 61 to 75, the Commission shall be empowered to adopt delegated acts in accordance with Article 89 amending or supplementing the conformity assessment procedures set out in Annexes VIII to XI.

Justification

The description of the conformity assessment procedures constitutes an essential element of the legislation and therefore according to article 290 of the treaty cannot be modified through a delegated act.

Amendment 84
Proposal for a regulation
Article 43 – paragraph 1

Text proposed by the Commission

1. Where the conformity assessment procedure requires the involvement of a notified body, the manufacturer may apply to a notified body of his choice, provided that the body is notified for the conformity assessment activities, the conformity assessment procedures and the devices concerned. An application may not be lodged in parallel with more than one notified body for the same conformity assessment activity

Amendment

1. Where the conformity assessment procedure requires the involvement of a notified body, the manufacturer may apply to a notified body of his choice, provided that the body is notified for the conformity assessment activities, the conformity assessment procedures and the devices concerned. An application shall not be lodged in parallel with more than one notified body for the same conformity assessment activity

Justification

To avoid any divergent interpretation, this provision should be made clear.
Amendment 85
Proposal for a regulation
Article 44 – title

Text proposed by the Commission

Mechanism for scrutiny of certain conformity assessments

Amendment

Scientific assessment provided by MDCG

Justification

A European assessment should be foreseen and made systematic for sensitive and innovating medical devices. The result of that assessment should be binding in order to guarantee that it does not constitute a simple consultation. Thus a negative assessment would prevent devices from being certified and introduced on the market.

Once gained experience, the Commission supported by expert panels should establish guidelines and common technical specifications addressed to manufacturers and notified bodies on clinical evaluation and post-market follow-up; this would progressively reduce this European assessment mechanism to first class and innovative devices.

Amendment 86
Proposal for a regulation
Article 44 – paragraph 1

Text proposed by the Commission

1. Notified bodies shall notify the Commission of applications for conformity assessments for devices classified as class III, with the exception of applications to supplement or renew existing certificates. The notification shall be accompanied by the draft instructions for use referred to in Section 19.3 of Annex I and the draft summary of safety and clinical performance referred to in Article 26. In its notification the notified body shall indicate the estimated date by which the conformity assessment is to be completed. The Commission shall immediately transmit the notification and the accompanying documents to the MDCG.

Amendment

1. For implantable devices, classified as class III, the notified body, before delivering the certificate of conformity, shall request a scientific assessment provided by MDCG on the clinical evaluation and the post-market clinical follow-up.

Notwithstanding first subparagraph of Article 44(1), this requirement shall not apply to devices for which specifications
referred to in Articles 6 and 7 have been published for the clinical evaluation and the post-market clinical follow-up and devices for which the application for certification only aims at supplementing or renewing existing certificates.

Amendment 87
Proposal for a regulation
Article 44 – paragraph 2 – subparagraph 1

Text proposed by the Commission

Within 28 days of receipt of the information referred to in paragraph 1, the MDCG may request the notified body to submit a summary of the preliminary conformity assessment prior to issuing a certificate. Upon suggestion by any of its members or by the Commission, the MDCG shall decide on making such request in accordance with the procedure set out in Article 78(4). In its request the MDCG shall indicate the scientifically valid health reason for having selected the specific file for submission of a summary of the preliminary conformity assessment. When selecting a specific file for submission, the principle of equal treatment shall be duly taken into account.

Amendment

The MDCG shall communicate the result of its scientific assessment at the latest 45 days after submission of the clinical evaluation report as referred to in Part A of Annex XIII, including the results of clinical investigations as referred to in Annex XIV; the post-market clinical follow-up referred to in Part B of Annex XIII; the draft instructions for use referred to in Section 19.3 of Annex I and the draft summary of safety and clinical performance referred to in Article 26 and the technical documentation related to annex XIII. Within that time period and at the latest 45 days after submission of those documents, the MDCG may request the submission of additional information necessary for the scientific assessment. Until the submission of additional information, that time period of 45 days shall be suspended. Subsequent requests of MDGC for additional information shall not suspend the period for MDCG scientific assessment.

Amendment 88
Proposal for a regulation
Article 44 – paragraph 2 – subparagraph 2

Text proposed by the Commission

Within 5 days after receipt of the request

Amendment

deleted
by the MDCG, the notified body shall inform the manufacturer thereof.

Amendment 89
Proposal for a regulation
Article 44 – paragraph 3

Text proposed by the Commission

3. The MDCG may submit comments on the summary of the preliminary conformity assessment at the latest 60 days after submission of this summary. Within that period and at the latest 30 days after submission, the MDCG may request the submission of additional information that for scientifically valid grounds are necessary for the analysis of the notified body's preliminary conformity assessment. This may include a request for samples or an on-site visit to the manufacturer's premises. Until submission of the additional information requested, the period for comments referred to in the first sentence of this subparagraph shall be suspended. Subsequent requests for additional information from the MDCG shall not suspend the period for the submission of comments.

Amendment

3. The MDCG scientific assessment is based on an assessment of the dossier by the Scientific Advisory Board referred to in Article 80a. If for a device concerned, the manufacturer requested a scientific advice following the procedure referred to in Article 82a, the outcome of that procedure shall be submitted together with the notification or as soon as that procedure is completed. The scientific advice shall be duly taken into account by the MDCG and the Commission in the course of the implementation of this Article.

Amendment 90
Proposal for a regulation
Article 44 – paragraph 4

Text proposed by the Commission

4. The notified body shall give due consideration to any comments received in accordance with paragraph 3. It shall convey to the Commission an explanation of how they have been taken into consideration, including any due justification for not following the comments received, and its final decision

Amendment

4. In case of a favourable scientific assessment, the notified body may proceed with the certification. However, if the favourable scientific assessment is dependant on the application of specific measures (e.g. adaptation of the post-market clinical follow-up plan, certification with a time limit), the notified
regarding the conformity assessment in question. The Commission shall immediately transmit this information to the MDCG.

body shall issue the certificate of conformity only on the condition that those measures are implemented.

In case of unfavourable scientific assessment, the notified body shall not deliver the certificate of conformity. Nevertheless, the notified body may submit new information in response to the explanation included in the MDCG scientific assessment.

At the request of the manufacturer, the Commission shall organise a hearing allowing discussion on the scientific grounds for the unfavourable scientific assessment and any action that the manufacturer may take or data that may be submitted to address the MDCG concerns.

Amendment 91
Proposal for a regulation
Article 44 – paragraph 5 – subparagraph 1

Text proposed by the Commission

Where deemed necessary for the protection of patient safety and public health, the Commission, may determine, by means of implementing acts, specific categories or groups of devices, other than devices of class III, to which paragraphs 1 to 4 shall apply during a predefined period of time. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment

Where deemed necessary for the protection of patient safety and public health, the Commission, may determine, by means of implementing acts, specific devices, categories or groups of devices, other than devices referred to in paragraph 1 to which paragraphs 1 to 4 shall apply during a predefined period of time. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(3).

Amendment 92
Proposal for a regulation
Article 44 – paragraph 5 – subparagraph 2 – point a

Text proposed by the Commission

a) the novelty of the device or of the

Amendment

a) technological novelty or new

PE507.972v04-00 302/336 RR\1005935EN.doc


Technology on which it is based and the significant clinical or public health impact thereof;

Therapeutic use, which can have significant clinical or public health impact;

Amendment 93
Proposal for a regulation
Article 44 a (new)

Text proposed by the Commission

Amendment

Article 44a

Notification before placing on the market

1. Notified bodies shall notify the Commission of applications for conformity assessments for devices classified as class III, except applications to supplement or renew existing certificates. Those notifications shall be accompanied by the draft instructions for use referred to in Section 19.3 of Annex I and the draft summary of safety and clinical performance referred to in Article 26. In its notifications the notified body shall indicate the estimated date by which the conformity assessment is to be completed. The Commission shall immediately transmit the notification and the accompanying documents to the MDCG.

2. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 to extend the scope of devices which must be notified before placing on the market as referred to in paragraph 1.

Justification

The pre-market notification as foreseen in Article 44 paragraph 1 and 5 first sub-paragraph of the proposal of the Commission should be maintained in a new Article in order to allow the Commission to have market knowledge and surveillance.
Amendment 94

Proposal for a regulation
Article 49 – paragraph 3

Text proposed by the Commission

3. Where demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be given based on the results of the manufacturer’s risk management and on consideration of the specifics of the interaction between the device and the human body, the clinical performances intended and the claims of the manufacturer. The adequacy of demonstration of conformity with the general safety and performance requirements based on the results of non-clinical testing methods alone, including performance evaluation, bench testing and pre-clinical evaluation, has to be duly substantiated in the technical documentation referred to in Annex II.

Amendment

3. Except for class III devices, where demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be given based on the results of the manufacturer’s risk management and on consideration of the specifics of the interaction between the device and the human body, the clinical performances intended and the claims of the manufacturer. The adequacy of demonstration of conformity with the general safety and performance requirements based on the results of non-clinical testing methods alone, including performance evaluation, bench testing and pre-clinical evaluation, has to be duly substantiated in the technical documentation referred to in Annex II.

Exemption from demonstration of conformity with general safety and performance requirements based on clinical data under the first subparagraph shall be subject to prior approval by the competent authority.

Justification

To avoid a loop hole risking an easy opt-out from clinical evaluations, namely in what concerns high-risk devices.

Amendment 95

Proposal for a regulation
Article 49 – paragraph 5 – subparagraph 1 a (new)
Proposed by the Commission

For devices classified as class III and implantable devices, the summary of safety and clinical performance referred to in Article 26(1) shall be updated at least annually with clinical evaluation reports.

Amendment 96
Proposal for a regulation
Article 50 – paragraph 1 – introductory part

Text proposed by the Commission

1. Clinical investigations shall be subject to Articles 50-60 and Annex XIV if they are conducted for one or more of the following purposes:

Amendment

1. Clinical investigations whether they are carried out with the purpose of placing on the market of a medical device or its post-marketing study shall be subject to Articles 50-60 and Annex XIV if they are conducted for one or more of the following purposes:

Justification

The same level of quality standards and ethical principles need to be ensured.

Amendment 97
Proposal for a regulation
Article 51 – paragraph 6 – subparagraph 1

Text proposed by the Commission

Member States shall ensure that the persons assessing the application do not have conflicts of interest and that they are independent of the sponsor, the institution of the investigation site(s) and the investigators involved, as well as free of any other undue influence.

Amendment

Member States shall ensure that the persons assessing the application do not have conflicts of interest and that they are independent of the sponsor, the institution of the investigation site(s) and the investigators involved, as well as free of any other undue influence. Member States shall ensure that the assessment is done jointly by a reasonable number of persons.
who collectively have the necessary qualifications and experience. In the assessment, the view of at least one person whose primary area of interest is non-scientific shall be taken into account. The view of at least one patient shall be taken into account. Realization of the clinical investigation shall be subject to an examination by the concerned Ethics Committee.

**Amendment 98**

**Proposal for a regulation**  
**Article 52 – paragraph 3 – point b**

Text proposed by the Commission

(b) protection of commercially sensitive information;

Amendment

(b) protection of commercially sensitive information; data on adverse events and safety data shall not be considered commercially sensitive information;

**Amendment 99**

**Proposal for a regulation**  
**Article 53 – paragraph 1 – point da (new)**

Text proposed by the Commission

(da) the clinical investigation report referred to in Annex XIV.

**Amendment 100**

**Proposal for a regulation**  
**Article 53 – paragraph 2**

Text proposed by the Commission

2. When setting up the electronic system referred in paragraph 1, the Commission shall ensure that it is interoperable with the

Amendment

2. When setting up the electronic system referred in paragraph 1, the Commission shall ensure that it is interoperable with the
EU database for clinical trials on medicinal products for human use set up in accordance with Article [...] of Regulation (EU) No [.../...]. With the exception of the information referred to in Article 52, the information collated and processed in the electronic system shall be accessible only to the Member States and to the Commission.

The clinical data collected during the investigation referred to in Annex XIV point (2.7) shall be made accessible, upon request and within 20 days, to healthcare professionals and to independent medical societies. A non-disclosure agreement covering the clinical data may be requested.

Justification

For transparency and public health reasons. There is no reason to prevent access by the public and independent academics to data on clinical adverse events.

Amendment 101

Proposal for a regulation

Article 53 – paragraph 3

Text proposed by the Commission

3. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 determining which other information regarding clinical investigations collated and processed in the electronic system shall be publicly accessible to allow interoperability with the EU database for clinical trials on medicinal products for human use set up by Regulation (EU) No [.../...]. Article 52(3) and (4) shall apply.

Amendment

3. The Commission shall be empowered to adopt delegated acts in accordance with Article 89 for determining the technical requirements and parameters to allow interoperability with the EU database for clinical trials on medicinal products for human use set up by Regulation (EU) No [.../...].
Amendment 102
Proposal for a regulation
Article 55 – paragraph 2

**Text proposed by the Commission**

2. The sponsor may implement the modifications referred to in paragraph 1 at the earliest 30 days after notification, unless the Member State concerned has notified the sponsor of its refusal based on considerations of public health, patient safety or public policy.

**Amendment**

2. The sponsor may implement the modifications referred to in paragraph 1 at the earliest 30 days after notification, unless the Member State concerned has notified the sponsor of its *duly justified* refusal.

**Justification**

Restricting the grounds for refusal as proposed in the original text would wrongly exclude aspects such as insufficiently relevant or robust data and other ethical considerations. Modifications to clinical investigations proposed by sponsors should not allow any reduction in scientific or ethical standards motivated by commercial interests.

Amendment 103
Proposal for a regulation
Article 55 – paragraph 2 a (new)

**Text proposed by the Commission**

2a. Assessment by the Member State of the request by the sponsor for a substantial modification to a clinical investigation shall be in accordance with Article 51(6).

**Amendment**


Amendment 104
Proposal for a regulation
Article 56 – paragraph 1

**Text proposed by the Commission**

1. Where a Member State has refused, suspended or terminated a clinical

**Amendment**

1. Where a Member State has refused, suspended or terminated a clinical
investigation, or has called for a substantial modification or temporary halt of a clinical investigation, or has been notified by the sponsor of the early termination of a clinical investigation on safety grounds, that Member State shall communicate its decision and the grounds therefor to all Member States and the Commission by means of the electronic system referred to in Article 53.

Amendment 105
Proposal for a regulation
Article 57 – paragraph 2 – subparagraph 2

Text proposed by the Commission

If the investigation is conducted in more than one Member State the sponsor shall notify all Member States concerned of the overall end of the clinical investigation. That notification shall be made within 15 days from the overall end of the clinical investigation.

Amendment

If the investigation is conducted in more than one Member State the sponsor shall notify all Member States concerned of the early termination in one Member State and of the overall end of the clinical investigation. That notification shall be made within 15 days from the end of the clinical investigation in one or more Member States.

Amendment 106
Proposal for a regulation
Article 57 – paragraph 3

Text proposed by the Commission

3. Within one year from the end of the clinical investigation, the sponsor shall submit to the Member States concerned a summary of the results of the clinical investigation in form of a clinical investigation report referred to in Section 2.7 of Chapter I of Annex XIV. Where, for scientific reasons, it is not possible to submit the clinical investigation report

Amendment

3. Within one year from the end of the clinical investigation, the sponsor shall submit to the Member States concerned a summary of the results of the clinical investigation in form of a clinical investigation report referred to in Section 2.7 of Chapter I of Annex XIV, together with all the data collected during the clinical investigation, including negative
within one year, it shall be submitted as soon as it is available. In this case, the clinical investigation plan referred to in Section 3 of Chapter II of Annex XIV shall specify when the results of the clinical investigation are going to be submitted, together with an explanation.

findings. Where, for scientific reasons, it is not possible to submit the clinical investigation report within one year, it shall be submitted as soon as it is available. In this case, the clinical investigation plan referred to in Section 3 of Chapter II of Annex XIV shall specify when the results of the clinical investigation are going to be submitted, together with an explanation.

Justification

Such data is already available to the sponsor and shall be communicated to the Member State for adequate statistical scrutiny.

Amendment 107

Proposal for a regulation
Article 58 – paragraph 2

Text proposed by the Commission

2. In the single application, the sponsor shall propose one of the Member States concerned as coordinating Member State. If that Member State does not wish to be the coordinating Member State, it shall agree, within six days of submission of the single application, with another Member State concerned that the latter shall be the coordinating Member State. If no other Member State accepts to be the coordinating Member State, the Member State proposed by the sponsor shall be the coordinating Member State. If another Member State than the one proposed by the sponsor becomes coordinating Member State, the deadline referred to in Article 51(2) shall start on the day following the acceptance.

Amendment

2. Concerned Member States shall agree, within six days of submission of the single application, which Member State shall be the coordinating Member State. Member States and the Commission shall agree, in the framework of the attributions of the MDCG, on clear rules for designating the coordinating Member State.

Justification

The solution proposed by the Commission text allows sponsors to cherry pick the competent authorities applying less stringent standards, those less resourced or overburdened with high number of requests which aggravates the proposed tacit approval of clinical investigations. A
framework for deciding on the coordinating Member State can be set up by the already proposed MDCG, in line with its tasks described in Article 80.

Amendment 108
Proposal for a regulation
Article 59 – paragraph 4 – subparagraph 1

Text proposed by the Commission
In the case of a clinical investigation for which the sponsor has used the single application referred to in Article 58, the sponsor shall report any event as referred to in paragraph 2 by means of the electronic system referred to in Article 53. Upon receipt, this report shall be transmitted electronically to all Member States concerned.

Amendment
In the case of a clinical investigation for which the sponsor has used the single application referred to in Article 58, the sponsor shall report any event as referred to in paragraphs 1 and 2 by means of the electronic system referred to in Article 53. Upon receipt, this report shall be transmitted electronically to all Member States concerned.

Amendment 109
Proposal for a regulation
Article 61 – paragraph 1 – subparagraph 1 – point a

Text proposed by the Commission
(a) any serious incident in respect of devices made available on the Union market;

Amendment
(a) any incident in respect of devices made available on the Union market;

Justification
Reporting of incidents and field safety corrective actions should not only mention serious incidents but all incidents and, by extension regarding definition of incident Art 2 (43), include undesirable side-effects.

Amendment 110
Proposal for a regulation
Article 61 – paragraph 3 – subparagraph 1
The Member States shall take all appropriate measures to encourage healthcare professionals, users and patients to report to their competent authorities suspected serious incidents referred to in point (a) of paragraph 1. They shall record such reports centrally at national level. Where a competent authority of a Member State obtains such reports, it shall take the necessary steps to ensure that the manufacturer of the device concerned is informed of the incident. The manufacturer shall ensure the appropriate follow-up.

**Amendment 111**

**Proposal for a regulation**

**Article 61 – paragraph 3 – subparagraph 2**

**Text proposed by the Commission**

The Member States shall coordinate between them the development of standard web-based structured forms for reporting of serious incidents by healthcare professionals, users and patients.

**Amendment**

The Member States shall coordinate between them the development of standard web-based structured forms for reporting of serious incidents by healthcare professionals, users and patients. The Member States shall also provide healthcare professionals, users and patients with another forms for reporting of suspected incidents to national competent authorities.

**Justification**

This could represent a limit for some patients and users that may not have access to the web or necessary experience in using such tools. Hence, another format for reporting should be foreseen by the national authorities.
Article 61 – paragraph 3 a (new)

Text proposed by the Commission
3a. Member States and the Commission shall develop and guarantee the interoperability between national records and the electronic system on vigilance referred to in Article 62, to ensure the automated export of data to this system, while avoiding duplication of registries.

Justification
High quality registries for broad populations will avoid fragmentation of registries and will enable a more adequate picture of safety and efficacy of medical devices.

Amendment 113
Proposal for a regulation
Article 62 – paragraph 1 – point d a (new)

Text proposed by the Commission
(da) the periodic safety update reports drawn by manufacturers, as referred to in Article 63a;

Amendment 114
Proposal for a regulation
Article 62 – paragraph 2

Text proposed by the Commission
2. The information collated and processed by the electronic system shall be accessible to the competent authorities of the Member States, to the Commission and to the notified bodies.

Amendment
2. The information collated and processed by the electronic system shall be accessible to the competent authorities of the Member States, to the Commission, and without prejudice to the preservation of intellectual property and commercially sensitive information to the notified bodies healthcare professionals and independent medical societies and to manufacturers relating to information about their own
devices. The data referred to in points (a) to (e) of Article 62(1) shall not be considered commercially confidential information unless the MDCG issues a contrary opinion.

Justification

Access to clinical data is essential to preserve system’s transparency and for analysis by independent academics and professional medical organizations. No intellectual property or commercially sensitive information is implicated in such clinical data.

Amendment 115
Proposal for a regulation
Article 62 – paragraph 5 a (new)

Text proposed by the Commission

Amendment

5a. The reports and information referred to in Article 62(5), shall also be automatically transmitted as regards the device in question via the electronic system to the notified body that issued the certificate in accordance with Article 45.

Justification

The integration of the notified bodies in the exchange of information of the market surveillance authorities must be extended and clearly defined. Particularly, the notified bodies need - within the framework of automated, harmonised communication procedures - consolidated information in order to recognise developments, take new information immediately into account and react promptly and appropriately to occurrences and incidents.

Amendment 116
Proposal for a regulation
Article 62 – paragraph 5 a (new)

Text proposed by the Commission

Amendment

5a. It shall be ensured that besides the European reporting no national reporting in individual Members States can additionally be required.
Amendment 117
Proposal for a regulation
Article 63 – paragraph 1 – subparagraph 2

Text proposed by the Commission
If in the case of reports received in accordance with Article 61(3) the competent authority ascertains that the reports relate to a serious incident it shall notify without delay those reports to the electronic system referred to in Article 62, unless the same incident has already been reported by the manufacturer.

Amendment
If in the case of reports received in accordance with Article 61(3) the competent authority ascertains that the reports relate to an incident it shall notify without delay those reports to the electronic system referred to in Article 62,

Justification
Reports should be notified to the electronic system in any case, especially to ensure the circulation of all information.

Amendment 118
Proposal for a regulation
Article 63 a (new)

Text proposed by the Commission

Amendment
Article 63a
Periodic safety update reports
1. Manufacturers of medical devices classified as class III shall report to the electronic system referred to in Article 62:

(a) summaries of data relevant to the benefits and risks of the medical devices, including results of all studies with a consideration of their potential impact on the certification;

(b) a scientific evaluation of the risk-benefit ratio of the medical device;

(c) all data relating to the volume of sales of the medical devices including an estimate of the population exposed to the medical device.
2. The frequency with which the manufacturers shall make the report referred to in the paragraph 1 shall be specified in the MDCG scientific assessment referred to in Article 44.

Manufacturers shall submit periodic safety update reports to the competent authorities immediately upon request or at least once a year during the first 2 years following initial placing on the market of that medical device.

3. The MDCG shall assess periodic safety update reports to determine whether there are new risks or whether risks have changed, or whether there are changes to the risk-benefit ratio of the medical device.

4. Following the assessment of periodic safety update reports, the MDCG shall consider whether any action regarding the medical device concerned is necessary. The MDCG shall inform the notified body in case of unfavourable scientific assessment. In this case, the notified body shall maintain, vary, suspend or revoke the authorisation as appropriate.

Justification

It is important in the framework of the vigilance system to introduce an obligation for the manufacturers to report periodically for medical devices class III on safety data and volume of sales.

Amendment 119
Proposal for a regulation
Article 67 – paragraph 1

Text proposed by the Commission
1. The competent authorities shall perform appropriate checks on the characteristics and performance of devices including, where appropriate, review of documentation and physical or laboratory checks on the basis of adequate samples. They shall take account of established

Amendment
1. The competent authorities shall perform appropriate checks on the characteristics and performance of devices including, where appropriate, review of documentation and physical or laboratory checks on the basis of adequate samples. They shall take account of established
principles regarding risk assessment and risk management, vigilance data and complaints. The competent authorities may require economic operators to make available the documentation and information necessary for the purpose of carrying out their activities and, where necessary and justified, enter the premises of economic operators and take the necessary samples of devices. They may destroy or otherwise render inoperable devices presenting a serious risk where they deem it necessary.

Justification

Competent authorities should not have to justify any inspection

Amendment 120

Proposal for a regulation
Article 67 – paragraph 1 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a. Unannounced inspections, in terms of their nature and extent, may be counted as regular inspections, with offsetting of economic operators’ costs resulting from unannounced inspections, provided that no significant non-conformities are recorded during unannounced inspections. Account must be taken at all times, when ordering unannounced inspections and carrying them out, of the proportionality principle, with due regard, in particular, for the risk potential of each individual product.</td>
<td></td>
</tr>
</tbody>
</table>

Amendment 121
Proposal for a regulation
Article 67 – paragraph 5 a (new)
5a. Without prejudice to any international agreements concluded between the Union and third countries, checks as referred in paragraph 1 can also take place in the premises of an economic operator located in a third country, if the device is intended to be made available on the Union market.

**Justification**

*Inspections by the competent authorities of the Member States should be possible in premises established in third countries when placing devices on the EU market.*

**Amendment 122**

Proposal for a regulation

**Article 67 – paragraph 5 b (new)**

5b. After every check, as referred in paragraph 1, the concerned competent authority shall report to the inspected economic operator on the level of compliance with this Regulation. Before adopting the report, the competent authority shall give the inspected economic operator the possibility to submit comments.

**Justification**

*It is important that the inspected entity is informed on the outcome of the inspection and has the possibility to make comments.*

**Amendment 123**

Proposal for a regulation

**Article 67 – paragraph 5 c (new)**

5c. The Commission shall establish detailed guidelines on the principles for carrying out the checks referred to in this
Article including in particular on the qualifications of inspectors, and on inspection arrangements and access to data and information held by economic operators.

Justification

Establishment of guidelines should create a harmonised approach of control activities in the Union

Amendment 124
Proposal for a regulation
Article 78 – paragraph 7 a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7a. The MDCG shall establish a stakeholder dialogue group made up of stakeholders representatives organised at Union level. Such group shall act in parallel and work with the Medical Device Coordination Group (MDCG), advising the Commission and Member States on various aspects of medical technology and implementation of the Regulation.</td>
<td></td>
</tr>
</tbody>
</table>

Justification

It is important to maintain a stakeholder dialogue group allowing patients, healthcare professionals and industry to communicate with regulators.

Amendment 125
Proposal for a regulation
Article 80 – point b

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) to contribute to the scrutiny of certain conformity assessments pursuant to Article 44;</td>
<td>(b) to provide a scientific assessment on certain types of medical devices pursuant to Article 44;</td>
</tr>
</tbody>
</table>

Justification

In accordance with Article 44.
Amendment 126
Proposal for a regulation
Article 80a (new)

Text proposed by the Commission

Amendment

Article 80a

Scientific Advisory Board

1. The Commission shall set up and provide the logistic support for a Scientific Advisory Board made up of not more than 15 scientific and/or clinical experts in the field of medical devices, appointed in their personal capacity by the MDCG.

2. When appointing these experts, the Commission shall ensure a broad, appropriate and balanced coverage of the medical disciplines relevant for medical devices, the publication of any interests which might affect the conduct of their work and the signature of a confidentiality clause. The Scientific Advisory Board may establish under its responsibility expert panels for specific medical disciplines. The Commission or the MDCG may request the Scientific Advisory Board to provide scientific advice on any issue related to the implementation of this Regulation.

3. The Scientific Advisory Board shall appoint one chairperson and one vice chairperson from among its members for a term of three years, renewable once. In duly justified situations, the majority of its members may request the chairperson and/or vice-chairperson to resign.

4. The Scientific Advisory Board shall establish its rules of procedure which shall, in particular, lay down procedures for:

a) the functioning of expert panel;

b) the appointment and replacement of its
chairperson and vice-chairperson,
c) the scientific assessment foreseen in Article 44, including in cases of urgency,
The rules of procedure shall enter into force after receiving a favourable opinion from the Commission.

Justification

The MDCG scientific assessment on clinical evaluation foreseen in art 44 should relies on an experts board. These experts will contribute to establish guidelines and common technical specifications addressed to manufacturers and accredited bodies for clinical evaluation and post-market follow-up in order to harmonise practices.

Amendment 127
Proposal for a regulation
Article 82 – paragraph 1

Text proposed by the Commission
1. Members of the MDCG and staff of the EU reference laboratories shall not have financial or other interests in the medical device industry which could affect their impartiality. They shall undertake to act in the public interest and in an independent manner. They shall declare any direct and indirect interests they may have in the medical device industry and update this declaration whenever a relevant change occurs. Upon request, the declaration of interests shall be accessible to the public. This Article shall not apply to the representatives of stakeholder organisations participating in the sub-groups of the MDCG.

Amendment
1. Members of the MDCG, of the advisory panels to the MDCG and staff of the EU reference laboratories shall not have financial or other interests in the medical device industry which could affect their impartiality. They shall undertake to act in the public interest and in an independent manner. They shall declare any direct and indirect interests they may have in the medical device industry and update this declaration whenever a relevant change occurs. The declaration of interests shall be made publicly available on the European Commission web site.

Amendment 128
Proposal for a regulation
Article 82 – paragraph 2
2. **Experts and other third parties invited by the MDCG on a case-by-case basis shall be requested to declare their interests in the issue in question.**

2. **Representative of stakeholder organizations participating in the subgroups of the MDCG shall declare any direct and indirect interests they may have in the medical device industry and update this declaration whenever a relevant change occurs. The declaration of interests shall be made publicly available on the European Commission web site. This shall not apply to representatives of the medical devices industry.**

---

**Amendment 129**

Proposal for a regulation

**Article 82 a (new)**

---

**Text proposed by the Commission**

**Article 82a**

**Scientific advice**

1. The Commission shall facilitate the access of manufacturers of innovative devices concerned by the scientific assessment laid down in Article 44 to scientific advice provided by the Scientific Advisory Board or by an EU reference laboratory to information concerning the criteria for an appropriate assessment of the conformity of a device, in particular with regard to the clinical data required for the clinical evaluation.

2. The scientific advice provided by the Scientific Advisory Board or by an EU reference laboratory shall not be binding.

3. The Commission shall publish summaries of the scientific advice referred to in paragraph 1, providing that all information of commercial confidential nature have been deleted.
**Justification**

*This advice should notably help manufacturers to conduct clinical evaluation in accordance with the state of the art and latest recommendations from the European experts group.*

---

**Amendment 130**

**Proposal for a regulation**

Annex I – part II – point 7 – point 7.1 – point b a (new)

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(ba) the physical compatibility where appropriate, between equivalent articles of the devices which consist of more than one implantable part;</em></td>
<td></td>
</tr>
</tbody>
</table>

---

**Amendment 131**

**Proposal for a regulation**

Annex I – part II – point 7 – point 7.4 – introductory part

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. <em>Special attention shall be given to</em> substances which are carcinogenic, mutagenic or toxic to reproduction, in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, <em>and to</em> substances having endocrine disrupting properties for which there is scientific evidence of probable serious effects to human health and which are identified in accordance...</td>
<td></td>
</tr>
</tbody>
</table>

7.4. The devices shall be designed and manufactured in such a way as to reduce as far as possible and appropriate the risks posed by substances that may leach or leak from the device. Substances which are carcinogenic, mutagenic or toxic to reproduction, in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, **shall be phased out within 8 years from the entry into force of this Regulation, unless no safer alternative substances are available. In the case that no safer alternatives exist, the manufacturer shall provide a specific**
justification for the use of these substances with regard to compliance with the general safety and performance requirements, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures. Devices containing substances having endocrine disrupting properties that come into contact with the body of patients and for which there is scientific evidence of probable serious effects to human health and which are identified in accordance with the procedure set out in Article 59 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and in accordance with the endocrine disrupting substances’ criteria set out in the report of the Endocrine Disrupters Expert Advisory Group shall be phased out within 8 years from the entry into force of this Regulation, unless no safer alternative substances are available. In the case that no safer alternatives exist, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures.

Amendment 132
Proposal for a regulation
Annex I – part II – point 7 – point 7.4 – paragraph 1 – indent 3 – paragraph 1
contain, in a concentration of 0.1% by mass of the plasticised material or above, phthalates which are classified as carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008, these devices shall be labelled on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging as devices containing phthalates. If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures.

Amendment
contain, in a concentration of 0.1% by mass of the plasticised material or above, phthalates, these substances shall be phased out within 8 years from the entry into force of this Regulation, unless no safer alternatives are available. In the case that no safer alternatives exist, the manufacturer shall provide a specific justification for the use of these substances with regard to compliance with the general safety and performance requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures. If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, phthalates should be banned as of 1st January 2020, unless the manufacturer can show that there are no suitable safer substances or devices without these substances. Where the manufacturer can show that there are no suitable safer substances or devices without these substances, these substances shall be labelled on the device itself and/or on the packaging for each unit as devices containing substances which are classified as CMRs 1A or 1B or as EDCs.

Amendment 133
Proposal for a regulation
Annex I – section 19.2 – point a a (new)

Text proposed by the Commission
(aa) the mention "This product is a medical device".
### Justification

*A medical product should be clearly identified as such on its label.*

### Amendment 134

**Proposal for a regulation**  
**Annex I – section 19.2 – point b**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) The details strictly necessary for a user to identify the device, the contents of the packaging and, where it is not obvious for the user, the intended purpose of the device.</td>
<td>(b) The details strictly necessary for a user to identify the device, the contents of the packaging and, where it is not obvious for the user, the intended purpose of the device and <em>where applicable that the device is only to be used during a single procedure.</em></td>
</tr>
</tbody>
</table>

### Justification

*It should be clearly stated on the label if a device is of single use only.*

### Amendment 135

**Proposal for a regulation**  
**Annex IV – point 1 – introductory part**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The CE marking shall consist of the initials ‘<em>CE</em>’ taking the following form:</td>
<td>1. The CE marking shall consist of the initials ‘<em>CE</em>’ accompanied by the term &quot;<em>Medical Device</em>&quot; taking the following form:</td>
</tr>
</tbody>
</table>

### Amendment 136

**Proposal for a regulation**  
**Annex VI – Title**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>MINIMUM REQUIREMENTS TO BE MET BY NOTIFIED BODIES</em></td>
<td>REQUIREMENTS TO BE MET BY NOTIFIED BODIES</td>
</tr>
</tbody>
</table>
### Amendment 137

**Proposal for a regulation**  
Annex VII – part III – point 4 – point 4.2 – paragraph 1 – indent 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– are intended to control, diagnose, monitor or correct a defect of the heart or of the central circulatory system through direct contact with these parts of the body, in which case they are in class III,</td>
<td>– are <strong>active devices</strong> intended specifically to control, diagnose, monitor or correct a defect of the heart or of the central circulatory system through direct contact with these parts of the body, in which case they are in class III,</td>
</tr>
</tbody>
</table>

### Amendment 138

**Proposal for a regulation**  
Annex VII – part III – point 4 – point 4.2 – paragraph 1 – indent 3

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– are intended specifically <strong>for use in direct contact with</strong> the central nervous system, in which case they are in class III,</td>
<td>– are <strong>active devices</strong> intended specifically to control, diagnose, monitor or correct a defect of the central nervous system through direct contact with these parts of the body, in which case they are in class III,</td>
</tr>
</tbody>
</table>

### Amendment 139

**Proposal for a regulation**  
Annex VII – part III – point 4 – point 4.3 – paragraph 1 – indent 1

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– are intended specifically to control, diagnose, monitor or correct a defect of the heart or of the central circulatory system through direct contact with these parts of the body, in which case they are in class III,</td>
<td>– are <strong>active devices</strong> intended specifically to control, diagnose, monitor or correct a defect of the heart or of the central circulatory system through direct contact with these parts of the body, in which case they are in class III,</td>
</tr>
</tbody>
</table>
## Amendment 140
Proposal for a regulation
Annex VII – part III – point 4 – point 4.3 – paragraph 1 – indent 2

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– are intended specifically for use in direct contact with the central nervous system, in which case they are in class III,</td>
<td>– are active devices intended specifically for use in direct contact with the central nervous system, in which case they are in class III,</td>
</tr>
</tbody>
</table>

## Amendment 141
Proposal for a regulation
Annex VII – part III – point 4 – point 4.4 – paragraph 1 – indent 8

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>– are spinal disc replacement implants and implantable devices that come into contact with the spinal column, in which case they are in class III.</td>
<td>– are spinal disc replacement implants, in which case they are in class III.</td>
</tr>
</tbody>
</table>

## Amendment 142
Proposal for a regulation
Annex VII – section 6.7

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>All devices incorporating or consisting of nanomaterial are in class III unless the nanomaterial is encapsulated or bound in such a manner that it cannot be released into the patient’s or user's body when the device is used within its intended purpose.</td>
<td>All devices incorporating or consisting of nanomaterial intended to be intentionally released in the human body are classified as class III.</td>
</tr>
</tbody>
</table>

### Justification

The risk of the use of nanomaterials shall be taken into account in the risk assessment process. However, too many products with no serious concern for health may fall under this rule. Then the up-classification in Class III shall be made only when the use of nanomaterials is intentional and part of the intended use of the product.
Amendment 143
Proposal for a regulation
Annex VII – part III – point 6 – point 6.9 – paragraph 1

Text proposed by the Commission
Devices that are composed of substances or combination of substances intended to be ingested, inhaled or administered rectally or vaginally and that are absorbed by or dispersed in the human body are in class III.

Amendment
Devices that are composed of substances or combination of substances primarily intended to be ingested, inhaled or administered rectally or vaginally and that are absorbed by and dispersed in the human body in order to achieve their intended purpose are in class III.

Amendment 144
Proposal for a regulation
Annex VIII – section 3.2 - point d – indent 2

Text proposed by the Commission
- the product identification procedures drawn up and kept up to date from drawings, specifications or other relevant documents at every stage of manufacture;

Amendment
- the product identification and traceability procedures drawn up and kept up to date from drawings, specifications or other relevant documents at every stage of manufacture;

Justification
The traceability of the product and parts or components thereof within the development and production process is an integral part of the functioning of the quality assurance system and therefore of its evaluation.

Amendment 145
Proposal for a regulation
Annex VIII – section 4.4 – paragraph 1

Text proposed by the Commission
The notified body shall randomly perform unannounced factory inspections to the manufacturer and, if appropriate, at the manufacturer's suppliers and/or

Amendment
The notified body shall randomly perform at least once every five years and for each manufacturer and generic device group unannounced inspections at the relevant
subcontractors, **which may be combined with the periodic surveillance assessment referred to in Section 4.3. or be performed in addition to this surveillance assessment.** The notified body shall establish a plan for the unannounced inspections which must not be disclosed to the manufacturer.

**Justification**

*The number of unannounced inspections in section 4.4 has to be clearly defined in order to strengthen the necessary controls and to guarantee unannounced inspections at the same level and frequency in all member states. Therefore unannounced inspections should be performed at least once in a certification cycle and for each manufacturer and generic device group. Because of the vital importance of this instrument, the scope and procedures of the unannounced inspections should be stated in the Regulation itself instead of in down streamed rules such as an implementing act.*

---

**Amendment 146**

**Proposal for a regulation**

**Annex VIII – section 5.3 – paragraph 1**

**Text proposed by the Commission**

The notified body shall examine the application employing staff with proven knowledge and experience regarding the technology concerned. The notified body may require the application to be completed by further tests or other evidence to allow assessment of conformity with the requirements of the Regulation. The notified body shall carry out adequate physical or laboratory tests in relation to the device or request the manufacturer to carry out such tests.

**Amendment**

The notified body shall examine the application employing staff with proven knowledge and experience regarding the technology concerned. **The notified body shall ensure that the manufacturer’s application adequately describes the design, manufacture and performance of the device, allowing assessment of whether the product conforms with the requirements set out in this Regulation. The notified bodies shall comment on the conformity of the following:**

- **general description of the product,**
- design specifications, including a description of the solutions adopted to fulfil the essential requirements,
- systematic procedures used for the design process and techniques used to control, monitor and verify the design of the device.

The notified body may require the application to be completed by further tests or other evidence to allow assessment of conformity with the requirements of the Regulation. The notified body shall carry out adequate physical or laboratory tests in relation to the device or request the manufacturer to carry out such tests.

**Justification**

*The requirements on the conformity assessment based on design dossier examination should be concretised and amended by taking over the already existing requirements regarding assessment of the application by the manufacturer describe in the voluntary code of conduct of Notify Bodies.*

**Amendment 147**

**Proposal for a regulation**

**Annex XIII – part A – point 5**

*Text proposed by the Commission*

5. In the case of implantable devices and devices falling within class III, clinical investigations shall be performed unless it is duly justified to rely on existing clinical data alone. Demonstration of equivalence in accordance with Section 4 shall generally not be considered as sufficient justification within the meaning of the first sentence of this paragraph.

*Amendment*

5. In the case of implantable devices and devices falling within class III, clinical investigations shall be performed unless it is duly justified to rely on existing clinical data alone. *For novel products*, demonstration of equivalence in accordance with Section 4 shall not be considered as sufficient justification within the meaning of the first sentence of this paragraph. *However, for iteration of devices already on the market and for which clinical data are available and for which the data from the post-market surveillance are not indicating any safety concerns, demonstration of equivalence may be considered as a sufficient justification. For devices submitted to the*
Justification

The formulation "shall generally" is too vague. Cases where equivalence could be justified should be clarified in the text. However with the introduction in Article 44 of a systematic assessment on clinical data, it will be the responsibility of European experts to determine if equivalence is demonstrated or if clinical investigation is necessary.

Amendment 148

Proposal for a regulation
Annex XIII – part B – point 1

Text proposed by the Commission

1. Post-market clinical follow-up, hereinafter: PMCF, is a continuous process to update the clinical evaluation referred to in Article 49 and Part A of this Annex and shall be part of the manufacturer’s post-market surveillance plan. To this end, the manufacturer shall proactively collect and evaluate clinical data from the use in or on humans of a device which is authorised to bear the CE marking, within its intended purpose as referred to in the relevant conformity assessment procedure, with the aim of confirming the safety and performance throughout the expected lifetime of the device, the continued acceptability of identified risks and to detect emerging risks on the basis of factual evidence.

Amendment

1. Post-market clinical follow-up, hereinafter: PMCF, is a continuous process to update the clinical evaluation referred to in Article 49 and Part A of this Annex and shall be part of the manufacturer’s post-market surveillance plan. To this end, the manufacturer shall proactively collect, register in the electronic system on vigilance referred to in Article 62 and evaluate clinical data from the use in or on humans of a device which is authorised to bear the CE marking, within its intended purpose as referred to in the relevant conformity assessment procedure, with the aim of confirming the safety and performance throughout the expected lifetime of the device, the continued acceptability of identified risks and to detect emerging risks on the basis of factual evidence.

Amendment 149

Proposal for a regulation
Annex XIII – part B – point 3
3. The manufacturer shall analyse the findings of the PMCF and document the results in a PMCF evaluation report that shall be part of the technical documentation. and be sent periodically to the concerned Member States.

Amendment 150

Proposal for a regulation
Annex XIII – part B – point 4

Text proposed by the Commission

4. The conclusions of the PMCF evaluation report shall be taken into account for the clinical evaluation referred to in Article 49 and Part A of this Annex and in the risk management referred to in Section 2 of Annex I. If through the PMCF the need for corrective measures has been identified, the manufacturer shall implement them.

Amendment

4. The conclusions of the PMCF evaluation report shall be taken into account for the clinical evaluation referred to in Article 49 and Part A of this Annex and in the risk management referred to in Section 2 of Annex I. If through the PMCF the need for corrective measures has been identified, the manufacturer shall implement them and inform the concerned Member States.

Amendment 151

Proposal for a regulation
Annex XIV – part I – point 1 – paragraph 1

Text proposed by the Commission

Every step in the clinical investigation, from first consideration of the need and justification of the study to the publication of the results, shall be carried out in accordance with recognised ethical principles, as for example those laid down in the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th

Amendment

Every step in the clinical investigation, from first consideration of the need and justification of the study to the publication of the results, shall be carried out in accordance with recognised ethical principles, as for example those laid down in the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th
Amendment 152

Proposal for a regulation
Annex XIV – part I – point 2 – point 2.7

Text proposed by the Commission

2.7. The clinical investigation report, signed by the medical practitioner or other authorised person responsible, shall contain a critical evaluation of all the data collected during the clinical investigation, including negative findings.

Amendment

2.7. The clinical investigation report, signed by the medical practitioner or other authorised person responsible, shall contain all clinical data collected during the clinical investigation and a critical evaluation of such data, including negative findings.

Amendment 153

Proposal for a regulation
Annex XV – point 4

Text proposed by the Commission

4. Equipment for liposuction;

Amendment

4. Equipment for liposuction and lipolysis;
### PROCEDURE

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>References</strong></td>
<td>COM(2012)0542 – C7-0318/2012 – 2012/0266(COD)</td>
</tr>
<tr>
<td><strong>Committee responsible</strong></td>
<td>ENVI</td>
</tr>
<tr>
<td>Date announced in plenary</td>
<td>22.10.2012</td>
</tr>
<tr>
<td><strong>Opinion by</strong></td>
<td>IMCO</td>
</tr>
<tr>
<td>Date announced in plenary</td>
<td>22.10.2012</td>
</tr>
<tr>
<td><strong>Rapporteur</strong></td>
<td>Nora Berra</td>
</tr>
<tr>
<td>Date appointed</td>
<td>10.10.2012</td>
</tr>
<tr>
<td><strong>Discussed in committee</strong></td>
<td>20.3.2013</td>
</tr>
<tr>
<td></td>
<td>25.4.2013</td>
</tr>
<tr>
<td></td>
<td>29.5.2013</td>
</tr>
<tr>
<td><strong>Date adopted</strong></td>
<td>18.6.2013</td>
</tr>
<tr>
<td><strong>Result of final vote</strong></td>
<td>+: 32</td>
</tr>
<tr>
<td></td>
<td>-: 0</td>
</tr>
<tr>
<td></td>
<td>0: 4</td>
</tr>
<tr>
<td><strong>Members present for the final vote</strong></td>
<td>Claudette Abela Baldacchino, Pablo Arias Echeverría, Preslav Borissov, Jorgo Chatzimarkakis, Sergio Gaetano Cofferati, Birgit Collin-Langen, Lara Comi, Anna Maria Corazza Bildt, António Fernando Correia de Campos, Christian Engström, Evelyne Gebhardt, Małgorzata Handzlik, Malcolm Harbour, Toine Manders, Sirpa Pietikäinen, Phil Prendergast, Zuzana Roithová, Heide Rühle, Matteo Salvini, Christel Schaldemose, Andreas Schwab, Catherine Stihler, Róža Gräfin von Thun und Hohenstein, Gino Trematerra, Emilie Turunen, Bernadette Vergnaud, Barbara Weiler</td>
</tr>
<tr>
<td><strong>Substitute(s) present for the final vote</strong></td>
<td>Raffaele Baldassarre, Nora Berra, Jürgen Creutzmann, María Irigoyen Pérez, Roberta Metsola, Olle Schmidt, Marc Tarabella, Sabine Verheyen</td>
</tr>
<tr>
<td><strong>Substitute(s) under Rule 187(2) present for the final vote</strong></td>
<td>Marek Józef Gróbarczyk</td>
</tr>
</tbody>
</table>
# PROCEDURE

| References | COM(2012)0542 – C7-0318/2012 – 2012/0266(COD) |
| Date submitted to Parliament | 26.9.2012 |
| Committee responsible | ENV1 |
| Date announced in plenary | 22.10.2012 |
| Committee(s) asked for opinion(s) | INTA 22.10.2012, EMPL 22.11.2012, ITRE 22.10.2012, IMCO 22.10.2012 |
| Date announced in plenary | INTA 22.10.2012, ITRE 22.10.2012 |
| Date of decision | INTA 10.10.2012, ITRE 9.10.2012 |
| Rapporteur(s) | Dagmar Roth-Behrendt |
| Date appointed | 16.10.2012 |
| Discussed in committee | 20.3.2013, 24.4.2013, 29.5.2013 |
| Date adopted | 25.9.2013 |
| Result of final vote | +: 52, -: 12, 0: 3 |
| Substitute(s) present for the final vote | Margrete Aukén, Mark Demesmaeker, Gaston Franco, Julie Girling, Jutta Haug, Miroslav Mikolášík, Vittorio Prodi, Christel Schaldemose, Renate Sommer, Bart Staes, Rebecca Taylor, Vladimir Urutchev, Anna Záborská |
| Substitute(s) under Rule 187(2) present for the final vote | Ioan Enciu, Sabine Lössing, Kerstin Westphal, Dubravka Šuica |
| Date tabled | 9.10.2013 |